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INTRODUCTION 
1. STATEMEN! OF .PROBLEM 
- . : ,~ ... - . ,..,: .. 
Although the formal study of neuroendocrinology is a relatively 
new discipline, historical writings have long shown an awareness of 
interactions between the nervous and endocrine systems. The writings of 
Aristotle on pseudo-pregnancy described a relationship between hormones 
and emotional states, and the practice of primitive husbandmen to cas-
trate bulls, thus altering aggressive behavior, are two such examples. 
It was mainly the results of Geoffrey Harris's work in the late 
1940 's which ushered in the new era of neuroendocrinology. The anatomi-
cal studies of Green and Harris (1949) demonstrated that a direct 
connection between the central nervous system (CNS) and the endocrine 
pituitary gland existed in the form of the portal venous system. The 
portal veins were shown to drain capillaries that have traversed the 
median eminence region of the hypothalamus, an area of the central 
nervous system having complex neural connections with other brain areas. 
The veins themselves then break up into a capillary plexus in the pitui-
tary which, in its tum, is drained by veins into the general venous 
circulation. Thus virtually all the afferent blood supply of the an-
terior pituitary was shown to have first been in contact with the 
hypothalamus. 
Specific examples of the interaction between the central nervous 
and endocrine systems have been revealed by clinical observations 
1 
2 
demonstrating that lesions of the hypothalamus can induce malftmction of 
the pituitary gland, such as suppression of the release. of pituitary 
growth hormone, as observed by Frohman et al (1968). Other fi.mctions 
attributed to the pituitary gland which are modified by such lesions 
include the regulation of endocrine systems manufacturing steroids in 
the adrenals and thyroxine in the thyroid gland, a5 well as the regula-
tion of other key metabolic processes more directly regulated through 
the pituitary gland's output of growth hormone and thyroid stimulating 
hormone. 
The importance of the portal venous connection between hypothalamus 
and pituitary was shown by the subsequent work of Schally et al (1966), 
and Guillemin (1966) who demonstrated the existence of hypothalamic 
peptidergic hormones that act to control the release of pituitary hor-
mones. These peptides are produced in the hypothalamus and are trans-
ported via the portal vascular system to the pituitary cells on which 
they exert their action. Gonadotropin releasing hormone (GnRH) appears 
to modulate the synthesis and release of two pituitary hormones, follicle 
stimulating hormone and luteinizing hormone; and thyroid releasing 
hormone (TRH), the secretion of two other pituitary hormones, prolactin 
and thyroid stimulating hormone (TSH). Both GnRH and TRH have been 
characterized chemically and synthesized by Enzmann et al (1971) and 
Matsuo et al (1971), respectively. The hypothalamus was also found to 
contain peptides that inhibited the release of pituitary hormones. The 
first of these to be isolated by Brazeau et al (1973), was the tetra-
decapeptide, somatostatin, which was shown to inhibit the secretion 
3 
of pituitary growth hormone (GH), TSH, and prolactin as well as the 
secretion of glucagon and insulin from the pancreas. 
It appears from studies such as those of Krulich et al (1977), 
II Schneider et al (1969), and Muller (1973) that the hypothalamic secre-
tory cells producing such regulatory factors are themselves activated by 
neurotransmitters of CNS origin such as dopamine and norepinephrine, which 
are released at synaptic connections from the various afferent neurons 
known to converge on the hypothalamic region from brain areas such as 
the hippocampus, amygdala, cortex and thalamus (Szentagothai et al, 1968). 
A somewhat simplified picture of the neuroendocrine system can 
therefore be summarized as involving the stimulation of hypothalamic 
neurosecretory cells by neurotransmitters, produced in other higher 
centers of the brain, to produce releasing or inhibitory factors, which 
regulate pituitary hormone secretion, which in turn largely controls 
growth and development and functions connected with the adrenals, thy-
raid, and reproductive glands. On the other hand, the hypothalamic 
inhibitory and releasing factors have been shown to have roles which are 
not restricted to the control of pituitary function. As reviewed by 
Prange et al (19 75) in the article'. "Brain Behavioral Effects of Hypo-
thalamic Releasing Hormones," peptides identical to hypophysiotropic 
hormones have been found in extrahypothalamic areas of the brain; TRH 
has been demonstrated in the cerebellum, thalamus, brain stem and cere-
bral cortex (Winokur et al, 1974, and Oliver et al, 1974); somatostatin 
has been found widespread throughout the CNS (Brown et al, 1975), and 
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GnRH appears to be present in the mammillary body, thalamus, amygdala, 
and hippocampus (Kubek et al, 1979). These findings have led to the 
suggestion by Krieger et al (1980) that these peptides may also act as 
synaptic transmitters, i.e., convey information between adjacent nerve 
cells or neuromodulators, which amplify or dampen neuronal activity. 
Such a neuromodulator role may include functions in relation to sensory 
conduction (Renaud et al, 1975), pain mechanisms (Segal et al, 1975), 
and behavioral responses (Moss, 1979) in various brain regions. 
Schaeffer et al (1977) and Arimura et al (1975) have reported the 
presence of hypophysiotropic hormones outside the central nervous system, 
most notably in the gastrointestinal tract where, for example, the 
finding of TRH has led to the speculation that this peptide may modulate 
the responses of feeding and drinking behavior (Moss, 1979). There is 
growing evidence that the reverse situation is also true. In addition 
to the presence of brain peptides outside the CNS, other hormones, 
classically thought to have a site of origin in, for example, the kidney, 
such as renin (Haulica et al, 1975), and in the gastrointestinal tract, 
such as glucagon (Conlon et al, 1979), gastrin (Vanderhaeglin et al, 1975), 
or vasoactive intestinal protein (Said et al, 1976) and Substance P 
(Hokfelt et al, 1975), have now also been isolated from the CNS. 
More recently there have been reports giving evidence for the 
presence of the classical anterior pituitary hormones in discrete regions 
of the CNS. Krieger et al (1977~have reported the finding of adreno-
corticotrophin (ACTH) in extrapituitary locations such as the arcuate 
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nucleus of the hypothalamus and the amygdala. Fuxe et al (1977) have 
shown prolactin containing cells in the hypothalamus, and Vaudry et al 
(1978) have demonstrated melanocyte stimulating hormone (o<.. MSH) in cells 
of the arcuate nucleus. 
Once thought only to contain monoaminergic neurotransmitters or 
their precursors, the isolation of more than 20 different peptides in 
the brain in the last ten years has led to a new concept of the function-
ing of the CNS. Speculation, such as that of Krieger (1980), has led to 
the hypothesis that peptides, such as those of pituitary origin, exist 
in the brain as part of a peptidergic neural system, present in addi-
tion to the classically described motor, sensory, and autonomic systems. 
During this time when ectopic sites of origin for many peptide 
hormones were being described, Lawrence et al (1974) reported the pre-
sence of a factor in human cerebrospinal fluid which actively promotes 
the in-vitro and in-vivo release of pituitary growth hormone. 
In the course of seeking to identify the origin of this growth hormone 
releasing factor, Pacold et al (1976) fotmd pituitary growth hormone-
like immtmoreactive material in dispersed rat brain cell cultures. 
It is the further characterization of this anterior pituitary-like 
growth hormone in the CNS that will be the subject of this dissertation. 
Similar studies will also aim to characterize a pituitary TSH-like 
material which was also found during the course of this work in rat 
brain cell tissue cultures. The purpose of this dissertation will 
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therefore first be to review data drawn from classical studies of the 
two pituitary hormones, GH and TSH, with a view to characterizing their 
presence in the rat brain. An attempt will be made using biochemical, 
anatomical, and physiological methodology to determine whether these 
particular peptides correspond to their pituitary counterparts or not. 
The significance of these findings and the findings of other "brain 
peptides" will be reviewed and discussed. 
2. RELEVANT LITERATURE REVIEW 
A. THE PITUITARY-HYPOTHA,LA;."lIC LINK 
An understanding of the anatomy of the pituitary gland and its 
hypothalamic connections is crucial to the analysis of its physiological 
functions. 
These functions include the secretion of at least 6 well-charac-
terized hormones from the anterior lobe of the gland. Growth hormone 
(GH) and thyroid stimulating hormone (TSH) have important modulatory 
effects on carbohydrate, lipid, and protein metabolism, whereas ACTH, 
a linear polypeptide, once released from the pituitary, exerts its most 
potent effect on the adrenal cortex, where it stimulates the conversion 
of cholesterol to pregnenolone, a precursor of steroid hormones such as 
cortisol. Follicle stimulating hormone (FSH) and luteinizing hormone 
(LH) are glycoproteins produced in the pituitary and which act on the 
Leydig cells of the testis to stimulate androgen secretion and on the 
tubules to induce spermatogenesis in the male. In the female they 
regulate the ovulatory cycle. In addition, the anterior pituitary 
cells secrete prolactin, a polypeptide exhibiting a diversity of physio-
logic actions, including an effect on growth of-mammary duct tissue and 
the maintenance of progesterone output by the corpus luteum of the ovary. 
Another group of pituitary peptides consists of a and S melanocyte stim-
ulating hormones (a and S MSH), Sandy lipotropins (Sandy LPH), and 
the endorphins which, together with ACTH, originate from a common pre-
cursor molecule and exhibit a variety of physiological effects. 
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Two hormones, vasopressin and oxytocin, are released from the 
posterior lobe of the pituitary gland and are concerned with the main-
tenance of volume and tonicity of body fluids, and influence pregnant 
uterine contractions and post partum milk ejection, respectively. 
The pituitary gland, itself long considered the "master gland" 
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for reasons obvious from the preceding discussion, is located at the 
base of the skull, covered by a tough connective tissue diaphragm and 
lies in a bony cup, the sella turcica. It is connected by the pituitary 
stalk, containing vascular and neural elements, to the floor of the 
hypothalamic region of the diencephalic brain. Fig. 1. 
This intimate relationship between the pituitary gland and the 
hypothalamus develops during embryonic life. The origins of the pitui-
tary can be traced to Rathke's pouch, which begins as a cul-de-sac 
protruding from the roof of the stomoderm, the posterior nasopharynx. 
During development, Rathke's pouch loses its connection to the stomoderm 
and becomes a hollow spheroid collection of cells forming the primitive 
anterior pituitary. The posterior pituitary evaginates downward from 
the base of the primitive brain diencephalon as the anterior lobe grows 
upward from the buccal endoderm, forming the mature pituitary gland 
linked to the diencephalon by the pituitary stalk. The distinct origins 
of posterior and anterior pituitary lobes are reflected in their cellular 
anatomy, the posterior lobe consisting of up to 42% nerve axons and axon 
terminals whereas the anterior lobe contains a variety of hormone secre-
tory cells and an apparent absence of neural - ·imput from the brain. 
ANTERIOR 
HYPOTHALAMIC AREA 
MEDIAL PREOPTIC 
NUCLEUS 
SUPRAOPTIC 
NUCLEUS 
PRIMARY PLEXUS 
IN MEDIAN 
EMINENCE 
PARAVENTRICULAR 
NUCLEUS 
I 
DORSAL 
HYPOTHALAMIC AREA 
POSTERIOR 
HYPOTHALAMIC 
AREA 
DORSOMEDIAL 
NUCLEUS \ 
I \_ VENTROMEDIAL "j NUCLEUS 
' 1'_PITUITARY STALK I 
I 
. I 
'k-POSTERIOR PITUITARY 
I 
I 
I 
LONG HYPOPHYSEAL I PLANE OF FRONTAL SECTION. FIG-:-2) 
PORTAL VEINS . 
Figure 1. The major centers of the hypothalamus and 
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The origin of the nerve terminals in the posterior pituitary are 
the supraoptic and paraventricular nuclei in the hypothalamus (Figs. 1 
and 2). Nerve tracts descend from these hypothalamic nuclei via the 
pituitary stalk and the severance of this hypothalamic-pituitary con-
nection causes atrophy and irreversible damage to posterior lobe function. 
This intimate anatomical link influencing the functioning of the posterior 
pituitary was defined by Scharrer in 1954, who showed that the two pitui-
tary hormones, oxytocin and vasopressin, originate in the supraoptico-
and paraventriculohypophyseal nuclei of the hypothalamus. Experiments in 
which the neurons of these nuclei were pulse-labeled with radioactive 
amino acids indicated that the two posterior pituitary hormones and their 
respective neurophysin-carrier proteins are synthesized as part of sep-
arate precursor proteins which are processed into the smaller biologically 
active molecules while being transported along the axons within the pitui-
tary stalk (Sachs et al. 1969). A study of the development of this neural 
link by Diakoku in 1971 revealed that by the 18th day of fetal life, a 
rat already possesses some nerve fibers containing dense core, precursor-
filled vesicles in the hypothalamus. 
The link between the rat hypothalamus and the anterior lobe of the 
pituitary is vascular in nature. These connections via the pituitary 
stalk were first observed by Popa and Fielding in 1930. Although these 
early studies postulated that the flow of blood in the stalk vessel sys-
tem was from pituitary to brain, Wislocki et al in 1936 demonstrated that 
the flow of blood was toward the pituitary. Green and Harris, in 1949, 
u THIRD VENTRICLE 
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Figure 2. Frontal section showing relationshLps of 
nuclear centers of the hypothalamus. 
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confirmed this observation and their classic anatomical studies identi-
fied the vascular connections as the long portal vessels, which were 
independent from the blood supply to the brain and upper hypothalamus 
and which divided into capillary tufts within the floor of the third 
ventricle of the diencephalon. The embryonic development of such a 
hypothalamic-pituitary vascular link was examined in the rat by Glydon 
in 1957, who showed that although the portal veins could be identified 
in the pituitary stalk at the time of birth, the primary capillary plex-
us in the hypothalamus did not actually attain full development until 
5 days after birth. 
In adult animals, loss of this vascular connection leads to a 
marked decrease in some of the anterior pituitary's functions such as 
the secretion of the hormone TSH. Transsection of the rat pituitary 
stalk by Cahane in 1936 led to a degenerative change in the histologi-
cal appearance of both the pituitary and thyroid, the latter being a 
target organ for pituitary TSH. As already reviewed, the, finding of 
hypothalamic inhibitory and releasing factors controlling anterior pi-
tuitary hormone secretion by Schally (1966), Guillemin (1966), and 
Brazeau (1973) supports this idea that the brain, particularly the 
hypothalamus, is intimately involved in the functioning of the anterior 
pituitary. 
Mechanisms controlling anterior pituitary secretion, other than 
those of hypothalamic origin, are those exerted by the target gland hor-
mones such as thyroid, adrenal, and gonadal hormones. Changes in circu-
lating levels of target organ hormones may either inhibit or encourage 
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the synthesis of pituitary hormones, and in this way an optimum level of 
hormone is maintained in the general circulation. These "feedback loops", 
as they are known, are also thought to affect the levels of hypothalamic-
hypophysiotropic hormones on exposure of the hypothalamus to changing 
levels in circulating hormones such as T4 and the steroids. 
This section has dealt with the hypothalamic-pituitary link and 
its role in the control of pituitary hormone release. The two anterior 
pituitary hormones, growth hormone, and thyroid stimulating hormone will 
be discussed in greater depth in the sections which follow, with respect 
to their molecular structure, normal levels found in the pituitary and 
serum, mechanism of action on target tissues or metabolic systems, and 
the regulation of their release from the normal pituitary gland. 
B. PITUITARY GROWTH HORMONE 
Synthesized and secreted by the eosinophylic somatotroph cells of 
the anterior pituitary, growth hormone cells account for 4% - 10% of the 
wet weight of the adult anterior pituitary. The hormone is produced in 
the Golgi area of the somatotroph, and the cell's microtubular system is 
involved in the movement of hormone-containing granules from this area 
to the plasma membrane, whose release into the circulation is associated 
with fusion of the secretory granules with the plasma membrane. 
Circulating GH is needed for longitudinal growth of the skeleton, 
has both insulin-like and anti-insulin like effects on the metabolism of 
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glucose and enhances the incorporation of amino acid into protein. The 
hormone also induces lipolysis of stored fats as shown by Raben in 1959, 
who observed a rise in plasma-free fatty acids after administration of 
growth. hormone intravenously to man. 
a. Molecular Structure of Growth Hormone. 
Rat growth hormone is a polypeptide with a molecular weight of 
46,000 Daltons, an NH2 terminal phenylalanine, and a sedimentation co-
efficient, s20 of 3.21, as shown by Ellis et al (1968}. Complete 
sequencing of rat growth hormone has not been reported; however, it is 
known from the work of Li et al (1971) that all mammalian growth hormones 
contain 2 disulfide bridges, one spanning 110 residues and joining cys-
teine residues 53-164; the other spans only 6 residues and joins residues 
181 and 189. There is evidence that pituitary growth hormone contains 
50% of a helix, and all known species, such as human, porcine, and rodent, 
undergo similar structural transitions in acid or base. Of interest in 
this regard, two other peptide hormones, placental lactogen and prolactin, 
show remarkable structural similarities with growth. hormone. This is 
reflected in their similar placement of disulfide bridges and residue 
homology, and has led to the suggestion of a common evolutionary origin 
for the 3 hormones by Niall et al (1971), which may have arisen from 
repeated tandem duplication of a gene coding for a relatively small pep-
tide. These similarities in structure are not, however, reflected in the 
major biological activities of the 3 hormones. Growth hormone alone 
possesses the ability to increase the length of the skeleton, whereas 
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prolactin is found to be essential for such processes as mammary duct 
development, lactogenesis and, together with luteinizing hormone, for the 
maintenance of progesterone output of the corpus luteum. Metabolic 
actions resembling those of GH have been demonstrated for prolactin, but 
only after relatively large doses, and it is questionable whether pro-
lactin makes any significant contribution to somatotrophic activity under 
normal circumstances. Placental lactogen, produced by the placenta, is . 
highly lactogenic but cannot induce growth of the long bones. (Wallis 
et al, 1976- and Kelly et al, 1976) All three hormones have been found 
to exist in several forms with varying molecular weights in the serum. 
(Hambley et al, 1972, and Gordon et al, 1973) 
The suggestion has been made by Sigel and Lewis (1979) that the 
predominant form of growth hormone in pituitary extracts :ts itself a 
prohormone, and that after limited proteolysis by plasmin (Ellis et al 1 
1968), smaller molecular weight sequences still retain biological activ-
ity. (Li et al, 1974) This heterogenicity with respect to size of 
circulating human growth hormone (hGH) has been studied by Gordon et al 
(1973) and Bala et al (1970), these groups showing forms with molecular 
weights both larger and smaller than monomeric hGH. Some of the larger 
species dissociate when treated with urea, whereas others require dis-
ruption of the interchain disulfide bonds for conversion to a molecular 
weight comparable to monomer hGH. (Beneviste et al! 1978) Bioassay 
discloses hGH-like activity in blood which does not correspond to im-
munoreactivity, indicating the presence of circulating foUllS with. hetero-
genous immunogenicity. Enzymatic modification of the major polypeptide 
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chain b.y chymotrypsin, papain, or subtilisin results in proteolytic 
cleavage occurring in the large disulfide loop to produce two acidic 
isohormones. These exhibit a several-fold higher biological activity 
than other cleavage products, as shown by Singh et al (1974); however, 
the mechanism of this enhanced activity is unknown. Frigen and Lewis 
(1980) have shown that a 20,000 Dalton variant hGH lacks various insulin-
like and anti-insulin-like effects found with the principle form of hGH 
as reported by Goodman (1965); yet it is fully active in promoting growth 
by the GR bioassay measuring rat tibia. 
Human, and perhaps rat growth hormone as .. usually isolated, can 
therefore be considered as a complex of proteins, perhaps serving dif-
ferent functions. The diversity of effects exhibited by growth hormone 
on metabolism and growth may perhaps be accounted for by this heteroge-
neity. However, as shown from Sigel's (1980) latest work, the specific 
physiological activities required to make a protein a growth hormone are 
essentially unknown. 
Levels of circulating radioimmunoassayable growth hormone vary 
depending on such factors as age of the animal and the time of day the 
sample is taken. These factors are discussed in the next section on 
rat growth hormone. 
b. Growth Hormone Levels in Plasma and Pituitary. 
Birge et al (1967) found that GH was undetectable in the rat fetus 
in either plasma or pituitary before day 19 of gestation. Rieutort, in 
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1972, speculated that the origin of circulating GH after day 19 until 
birth at day 21-22 was the fetal pituitary, as growth hormone was absent 
in hypophysectomized animals, i.e., rats which had their pituitaries re-
moved. Jost (1959), working with encephalectomized fetuses with intact 
pituitaries, showed a lowering of plasma GH in the fetus, suggesting that 
the CNS, and in particular the hypothalamus, have an early role on soma-
totroph development and growth hormone secretion. Hypothalamic control, 
in terms of that fotmd in the adult, does not seem likely in the fetal 
rat, as somatostatin, the GH-inhibitory hypothalamic peptide, is tmde-
tectable in the CNS tmtil the fifth day after birth. There is evidence 
that fetal and not maternal levels of circulating GH control the release 
of pituitary hormone, as Grumback, in 1974, has shown little or no inter-
change of any pituitary hormone transplacentally. Gluckman et al (1979), 
Cornblath et al (1965), and Blasquez et al (1974) have also shown a rise 
in fetal plasma growth hormone in the last days of gestation of the sheep, 
rat, and human to levels exceeding maternal plasma hormone levels, indi-
cating that the two circulatory systems are independent in terms of growth 
hormone levels. Postpartum levels of plasma and pituitary hormone reach 
adult levels between 15 and 20 days as shown by Ojeda et al (1977). 
In the adult rat, a circadian variation in plasma hormone level is 
observed. Evidence indicates that all the pituitary hormones studied to 
date are secreted in such an episodic manner throughout the 24-hour day, 
with both plasma and urine concentrations manifesting a circadian rhythm 
(Satmders et al, 1976). It is now clear that, in the absence of stress, 
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whether physiological or psychological, endocrine activity, particularly 
the secretion of ACTH, GH, and prolactin, is extremely variable and under 
the control of some CNS mechanism other than a stimulus response and 
"feedback" system. Because of the absence of confirming evidence for a 
"steady state" system of neuroendocrine activity, a new hypothesis has 
developed that proposes that hormone secretion is temporally ordered and 
that the dominant determinant of this activity in man and other animals 
is the 24-hour sleep-wake rhythm (Weitzman, 1980). Studies by Weitz-
man' s group have shown that, in man, the release of growth hormone 
coincides with the onset of definitive sleep, characterized by slow, 
synchronous electrocortical activity, REM sleep, suggesting that the 
same mechanism precipitates both events. Saunders et al (1976) showed 
a more regular pattern of episodic release of GH with intervals 3 hours 
apart in the rat. Peak levels occurred in late morning, indicating that 
species-to-species differences to occur. 
In the female rat, the amplitude of pulses does not change during 
pregnancy (Willoughby et al, 1978) or with variation in temperature. 
This unresponsiveness to external stimuli is typical of circadian rhy-
thms in both man and animals (Zucker, 1980). The significance of cir-
cadian rhythms to endocrine systems lies in the need for the synergistic 
effects of hormones on the precise timing of secretory activity. 
Several. CNS areas have been implicated in such rhythms, especially 
the suprachiasmatic and preoptic nuclei and the pineal gland. Destruc-
tion of the suprachiasmatic nucleus appears to render animal behavior 
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aperiodic, and adrenal coricosterone rhythms are also eliminated. Pineal 
dysfunction has been implicated in cases of infertility where abnormal 
variations in the ovulatory cycle were the underlying cause (Wurtman, 1980). 
While these are certainly not the only mammalian circadian clocks, the 
suprachiasmatic nucleus in particular probably functions to integrate the 
activity of other oscillating systems that in turn regulate the periodic-
ity of numerous physiological and behavioral systems. 
c. Biological Effects of Growth Hormone. 
Initial recognition of the pituitary's relationship to growth came 
from the correlation of growth hormone producing pituitary tumors and 
gigantism with the pathology of the gland. Pituitary deficiency of growth 
hormone secretion was also found to be associated with dwarfism. The 
regulation of growth by growth hormone was first examined in the 1930ts 
when pituitary extracts containing growth hormone became available (Sil-
berberg, 1935). Growth of the mammalian skeleton was shown to occur at the 
epiphyseal plate where chondrocytes proliferate and synthesize a matrix 
composed of collagen and sulfated polysaccharides. Kibrick et al (1941} 
found that narrow epiphyseal plates in hypophysectomized rats became wider 
after growth hormone was given in vivo, a property which has since been 
used as a bioassay for GH. Other workers such as Murphy and Daughaday 
(1956) observed that cartilage metabolism could be measured by the 
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incorporation of radioactive sulfate into cartilage chondroitin sulfate. • 
Cartilage from hypophysectomized rats had low sulfate uptake, which was 
increased by growth hormone administration given in vivo. 
The classic experiments of Salmon and Daughaday in 1957 examined 
the mechanism by which growth hormone might stimulate growth. The in 
vitro addition of growth hormone to rodent excised rib cartilages in 
tissue culture did not accelerate radioactive sulfate incorporation; 
however, incorporation was stimulated by a component of normal serum. 
This sulf ation factor was absent in the serum from hypophysectomized 
animals and was restored to serum by the administration of growth hor-
mone to these hypophysectomized animals. From these observations, it 
was hypothesized that growth hormone stimulated skeletal growth indirect-
ly through generation of a circulatory "suJ.fation factor'' or somatomedin, 
as it was later termed, which acted directly to cause cartilage prolifera-
tion. 
Van Wyk.. et al (1972) found initially that thi:s active component in 
whole serum behaved as a large protein. After acid ethanol extraction, 
the active111aterial had a molecular weight between 4,000 and 12,000 D., 
suggesting that somatomedin was aggregated or bound to a larger carrier 
protein. Two such carrier proteins were isolated by Kauffman et al (1977), 
and "somatomedin1' was found to be not one but a family of small peptides. 
Three of these were named Somatomedins A -+ c, with molecular weights 
ranging from 5,000-7,000 Dalton by Van Wyk et al in 1974. Two other 
insulin-like growth factors have also been shown to stimulate cartilage 
proliferation by Ginsberg et al (1979). These growth factors resemble 
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proinsulin in amino acid sequence and tertiary structure but have limited 
cross-reactivity with insulin in binding to receptor sites on target 
tissues, as demonstrated by Blundell et al (1978). 
Structurally similar to proinsulin, the somatomedins have also been 
shown to have anabolic, insulin-like actions on fat and muscle by Clemmons 
et al (1974) and Uthne et al (1974), as well as their property to enhance 
cartilage proliferation. 
It is thought that growth hormone stimulates skeletal growth, in 
vivo, indirectly by regulating the level of the somatomedins. A contra-
diction to this idea is found in the observation that somatomedin levels 
are lower in the young animal than in the adult. This has led to specu-
lation that growth may be less dependent on somatomedins or that somato-
medins may be more available in the young due to reduced binding to a 
specific serum carrier protein or to an increase in somatomedin receptor 
sites as shown by Rosenfeld et al (1979). However, growth hormone excess 
in humans and rats is associated with an increase in somatomedins as shown 
by Firlanetto et al in 1977. Regulation of somatomedin production appears 
to occur mainly in the liver and reflects nutritional (Phillips et al, 
1978) and hormonal status, possibly insulin and GH levels (Hintz et al, 
1978), of the animal. Levels of somatomedins in perfusates of livers 
from hypophysectomized animals are below levels in normal animals and are 
restored to normal by treatment with growth hormone in vivo, as shown by 
Schalch et al (1977). Thus, the liver may respond to available hormone 
levels in altering the levels of circulating somatomedins. 
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In addition to somatomedin being a mediator of growth hormone's 
effects on collagen synthesis, it appears to mediate other actions of 
growth hormone, specifically, its anabolic effects on skeletal muscle. 
Salmon and DuVall (1970) have provided evidence that somatomedin is more 
potent than native growth hormone in increasing leucine incorporation 
into muscle protein. Earlier work by Kostyo et al (1966) had shown 
that leucine incorporation into protein, in excised diaphragm muscle 
from normal rats, to be twice that of tissue removed from hypophysectom-
ized rats. Treatment of these animals without pituitaries with growth 
hormone restored amino acid incorporation into new protein. Korner et al 
(1965) showed increases in the total number of ribosomes in rat liver 
cells, an increased capacity of ribosomes for incorporating amino acids 
into protein, and an elevation in messenger RNA in vivo after growth 
hormone administration. Wikland et al (1980) have studied the response 
to growth hormone on amino acid transport and protein synthesis in vivo 
in the rat diaphragm and find that stimulation is transient and followed 
after about 3h by a period of refractoriness. In contrast, they found a 
much longer lasting stimulatory effect of growth hormone on protein syn-
thesis in tissues of hypophysectomized rats. These "insulin-like" 
effects of growth hormone suggest that changes in responsiveness of 
tissues to growth hormone, or more likely to somatomedin, play a physio-
logical role in the regulation of protein metabolism in muscle tissue. 
As with effects on amino acid transportation, so also with respect 
to plasma free fatty acid levels, there is an early "insulin-like" action 
shortly after intravenous injection of growth hormone. Birnbaum and 
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Goodman (1979) showed that levels of free fatty acids fall within the 
first l/2h of injection before showing the secondary rise typical of the 
lipolytic action of the hormone. Somatomedins have been shown to stimu-
late incorporation of free fatty acids into lipids. (Clemmons et al, 
1974) This early antilipolytic effect of growth hormone could be 
mediated by somatomedin, or, Birnbaum and Goodman (1976) postulate, it 
may result from a decreased activity of protein kinase in the cytosol. 
The delayed rise in plasma free fatty acids after growth hormone 
administration can be blocked by administration of glucose. Also giving 
GH simultaneously with insulin, a potent inhibitor of free fatty acid 
release from adipose tissue, obliterates the lipolytic action. (Merimee, 
1979) It is possible that the inhibiting effect of glucose is mediated 
via stimulation of endogenous insulin release. Fain et al (1971), using 
isolated fat cells in the presence of dexamethasone, have demonstrated 
a requirement for RNA synthesis and for new protein synthesis in the li-
polytic action of the hormone. 
Growth hormone also has both an "insulin-like" and "anti-insulin" 
effect on the metabolism of glucose. An "insulin-like'' effect such as a 
fall in blood glucose levels has been seen within 10 minutes of an LV. 
injection of bovine growth hormone into a normal rat by Goodman (1967). 
An increase in glucose uptake and glucose oxidation due to an increase in 
cell permeability is postulated to account for this fall in serum glucose; 
however, Martin and Young (1965) have shown that very small concentrations 
of growth hormone depress glucose uptake when added to preparations of 
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excised rat diaphragm. The "insulin-like" effect of growth hormone on 
glucpse metabolism may therefore be merely a pharmacological effect. 
There is greater unanimity with regard to the less immediate effects 
of growth hormone administration on glucose metabolism, namely, its "con-
trainsulin" and its "insulinotropic" effect, i.e., enhancement of pan-
creatic release of insulin in response to a variety of stimuli as shown 
by Martin et al (1967). Daughaday and Kipnis (1966) compared the rate 
constant for glucose disappearance from human serum under control condi-
tions with that observed when an I.V. glucose load was administered 2h 
after the administration of growth hormone (5 mg. I.V.). The clearance 
rate of glucose from the serum fell from control values after GH admin-
istration, substantiating a "contra-insulin" effect for the hormone. 
Precisely in what manner this "contra-insulin" effect is mediated is not 
clear. 
A second aspect of the action of growth hormone on glucose meta-
bolism is the "insulinotrophic" action of the hormone. Pretreatment of 
normal subjects with human growth hormone results in an increase of in-
sulin release in response to a large number of secretogogues such as 
glucose and arginine, as shown by Rimoin et al (1968). In vitro data 
from Martin et al (1967) also supports a direct effect of growth hormone 
on the S cell of the pancreas. Isolated islets from hypophysectomized 
rats have a significantly reduced insulin content, output, and synthesis, 
which can be corrected by growth hormone treatment. 
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The biological effects of growth hormone can therefore be viewed 
as the result of a dual action: those of growth hormone per se, and 
those actions of growth hormone dependent on somatomedins. Factors con-
trolling the secretion of growth hormone by the pituitary are unusually 
complex; however, most stimuli appear to act via a neural mechanism 
through the hypothalamus to the pituitary. Such stimuli will be re-
viewed in the next section. 
d. Regulation of Growth Hormone Release. 
The direct release of growth hormone appears to be under the con-
trol of two substances: a growth-hormone-releasing factor, which has 
yet to be isolated, and an inhibitory agent, somatostatin. 
While searching for the releasing factor, Brazeau (1973) observed 
that the addition of crude hypothalamic extract to cultures of rat 
pituitary cells decreased the secretion of growth hormone. Further puri-
fication resulted in the isolation of the linear tetradecapeptide, soma-
tostatin. This peptide has been located by Setalo et al (1978) in the 
external layer of the median eminence around the capillary loops of the 
portal vessels which eventually lead to the pituitary. Somatostatin has 
also been located in substantial amounts by similar immunohistochemical 
methods in the ventromedial nuclear area of the hypothalamus by Hokf elt 
et al (1977a),as well as other areas of the CNS. 
Evidence for some form of "short-loop feedback" control mechanism 
for growth hormone involving somatostatin comes from experiments with 
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hypophysectomized rats performed by Baker et al (1976). A reduction in 
somatostatin levels in the median eminence was observed after pituitary 
removal, suggesting that this fall in inhibitory factor levels could be 
directly due to insufficient circulating growth hormone, and Hoffman et 
al (1977) claim to have been able to restore, partially to normal, levels 
of somatostatin by administration of exogenous growth hormone to hypo-
physectomized animals. Whether GH acts directly on somatostatinergic 
neurons in the hypothalamus to restore protein synthesis (Karatsuka et 
al, 1979), or indirectly through somatomedin has not been determined. 
Baker et al (1976) also caution that the partial recovery of somatostatin 
levels could be due to the regeneration of neurons destroyed during hypo-
physectomy. 
The mechanism by which somatostatin inhibits the release of growth 
hormone, induced by prostaglandins, dibutyril cyclic AMP, and theophylline, 
is possibly due to inactivation of adenyl cyclase. A rise in cyclic GMP 
due to somatostatin administration has also been observed in rat somato-
tropes. Takaha.ra et al (1980} have recently proposed that the release of 
growth hormone induced by y-a,minobutyric acid (GA,BA}, a neurot:ransmitter 1 
may also be partly due to the inhibition of hypothalamic somatostatin 
release. 
Evidence linking other neurotransmitters such as norepinephrine, 
dopamine, and serotonin with the release of GH has been reviewed by 
Martin (1973). These more indirect mechanisms of controlling growth 
hormone release are currently thought to be mediated via any of three 
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neural centers: the ventromedial nucleus (VMN) and arcuate :nucleus. (AC) 
of the hypothalamus, and the limbic system which includes the hippocampus 
and amygdaloid nuclei of the brain. 
Although somewhat of an oversimplification, norepinephrine can be 
thought of as the dominant neurotransmitter for stimuli reaching the VMN, 
dopamine for the AC, and serotonin for stimuli mediated via the limbic 
system. One can thus divide stimuli for growth hormone release on the 
basis of which of these three systems they may be activating. 
When lesions are placed in the VMN, suppression of growth hormone 
release has been observed to occur by Frohman et al (1968). If the neuro-
transmitter content in this area of the hypothalamus is norepinephrine, 
then excitation can be said to be via a adrenergic mechanisms. Vasa-
pressin (Heidingsfelder, 1968), exercise (Hansen, 1971), cholecystokinin, 
and renin (Vijayan, 1979) are thought to induce growth hormone 
release at the level of the VMN via such a adrenergic mechanisms. Black-
ard et al (1968) also showed that GH release, mediated by insulin-pro-
duced hypoglycemia, could be prevented by blockage of a-adrenergic 
receptors by phentolamine, an inhibitor of a adrenergic transmission. 
The exact method by which norepinephrine and adrenergic blocking agents 
act to regulate GH secretion is unknown but could be due to an effect on 
the production of releasing factors in the hypothalamus. Ascending nore-
pinephrine inputs to the hypothalamus have been shown by Jonsson and 
Hokfelt (1972) to terminate directly on the arcuate nucleus in the rat, 
and could therefore have some effect on somatostatinergic neurons. 
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This same group showed, by histochemical means, that dopaminergic 
nerve terminals surround the primary capillary plexus of the portal vas-
cular system, and that the arcuate nucleus is rich in dopamine. Con-
flicting results are found in the literature concerning the effect of 
dopamine on GH release. Administration of L-dopa by Kansal et al (1972) 
to rhesus monkeys led to the release of GH from the pituitary; however, 
no such release was observed if L-dopa was administered to rats (Kato et 
al, 1973). Muller et al (1967) and Boyd et al (1970) thought that L-dopa 
is taken up by the monkey dopaminergic terminals in the arcuate nucleus 
from the circulation and converted to dopamine by dopa decarboxylase. 
Increased storage of the neurotransmitter could then be postulated to 
lead to the release of some growth-hormone-releasing hypothalamic factor 
into the portal system. However, more recent work by Steiner et al (1978) 
argued against the view that GH release by L-dopa was mediated by a dopa-
mine receptor mechanism in the hypothalamus. Their work and the observa-
tion by Brown et al (1976) suggest that dopamine receptors are not found 
in the median eminence of the hypothalamus but only in the pituitary. 
This suggested to these authors and others such as Ben-Jonathan et al 
(1977) that dopamine in the median eminence may serve as a neurohormone 
carried by the portal vessels to the pituitary rather than as a neuro-
transmitter acting on the hypothalamic releasing and inhibitory factors. 
In sunnnary, the present data on the effects of the catecholamines, 
norepinephrine, and dopamine on GH release suggest that a-adrenergic re-
ceptors in the hypothalamus stimulate the release of GH, whereas dopamine 
receptors may inhibit GH, this area being somewhat controversial, and 
29 
wide species differences may also exist. 
. 
The third area of the brain associated with growth hormone release 
is the limbic system. Having a role involving the maintenance of wake 
emotional and behavior states, the limbic system also appears to play an im-
portant role in slow wave sleep. As previously noted in humans, this 
sleep state is associated with a rise in GH levels. Since nerve termin-
als of the limbic system terminate in the hypothalamus and are, in general, 
serotoninergic, the neurotransmitter serotonin may mediate the growth 
hormone release seen with slow wave sleep in man. 
There are a number of stimuli to GH release from the pituitary, 
whose locus of action is unclear. These include stress, protein deple-
tion, and the administration of morphine derivatives as shown by Greenwood 
et al (1966), Schalch (1969), and Pimstone et al (1966). As with stimu-
lation, there are other conditions that inhibit growth hormone release 
such as obesity, elevation of free fatty acid levels, glucocorticoids, 
and hypothyroidism, whose mechanism of action is likewise unknown. (Pim-
stone, 1966; Unger, 1965; and Frantz, 1964) Fragments of ACTH (4-10) and 
ACTH (18-39), a. MSH and S MSH also can be shown to inhibit growth hormone 
secretion in the rat. Here, the mechanism of action studied by Bruni et 
al (1977) appears to be mediated via the hypothalamus, not the pituitary, 
as they reported a failure to elicit hormones in vitro from pituitaries. 
E.vidence also exists for a "short loop feedback'' mechanism of growth 
hormone itself on both the hypothalamic and pituitary levels. For example, 
growth. hormone pellets implanted into the. hypothalamus can cause a 
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reduction in circulating pituitary GH levels (Voogt et al, 1970). Exo-
genous growth hormone can diminish the growth hormone response to insulin, 
exercise, or arginine in the rat (Muller et al, 1966). Similarly, Hagen 
et al (1972) observed a dampening of GH release to known stimuli such as 
arginine infusion in normal volunteers administered human growth hormone. 
In summary, factors that affect the release of growth hormone from 
the pituitary are complex, some being mediated via hypothalamic inhibi-
tory and possibly releasing factors, and others whose mechanisms of action 
remain unknown. 
The next section will review the relevant literature relating to 
thyroid stimulating hormone (TSH), another hormone which, like growth 
hormone, is derived from the pituitary gland. 
C. PITUITARY THYROID STIMULATING HORMONE (TSH) 
Thyroid stimulating hormone (TSH) is the principal hypophyseal 
hormonal regulator of thyroid growth and the biosynthesis and secretion 
of the thyroid hormones, thyroxine (T4) and triiodothyronine (T3). 
Using immunohistochemical methodology, Moriarty (1973) showed that 
thyrotrophs constitute 3%-5% of the pituitary cell population. Polygonal 
- cells, often appearing in clusters predominantly in the anteromedial 
portion of the gland, they contain small cytoplasmic granules. In the 
absence of the thyroid, these cells show a marked ballooning of the rough 
endoplasmic reticulum cisternae and a decrease in secretory granules, 
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implying a disruption of the transport processes of granules through the 
Golgi apparatus. (Farquhar et al, 1954) The concentration of TSR, which 
is synthesized on ribosomes and stored in the granules, may only be 5% 
of normal in a hypothyroid rat. The molecular structure of this pituitary 
hormone will be dealt with in the next section. 
a. Molecular Structure of Pituitary TSR. 
Thyroid stimulating hormone is a glycoprotein containing 15% carbo~ 
hydrate and having a molecular weight of 23,300 Daltons. Treatment of 
the molecule with dilute acid by Cornell et al (1973) resulted in its 
dissociation into two dissimilar subunits or peptide chains, designated 
alpha (a.) and beta UH. The a. subunit consists of 96 residues, which are 
almost identical to a. chorionic gonadotrophin (CG), a. luteinizing hormone 
(LR), and a follicle stimulating hormone (FSR) subunits. The S subunit 
is larger than the a., being composed of 110 amino acid residues, and is 
structurally dissimilar from the S units of CG, LR, and FSR. Both sub-
units contain many half cystine residues, assumed by Pierce (1974) to be 
in a covalent-disulfide bond form. 
Each TSH molecule contains three oligosaccharide moieties attached 
to the peptide via asparagine residues. The sugars and amino sugars 
include fructose, mannose, galactose, glucosamine, and galactosamine. 
Two of the three carbohydrate moieties are associated with_ the a. subunit? 
where sialic acid residues are similarly located. The significance of 
the carbohydrate constituents, in terms of biological expression on TSR 
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metabolism, has not been determined. The native structure of the molecule 
depends upon noncovalent interactions between the two subunits. A high 
glycine and proline content and the intrachain bonding preclude any long 
distances of a helix. An isolated a chain has no biological activity, 
and a separated S chain only a minimal ability to bind and activate TSH 
receptor sites. Recombination of a and S chains fully reactivates the 
hormone. Studies by Vaitukaitis et al (1973), generating antisera to 
both intact molecules and to both subunits, revealed that most immuno-
logical determinants reside on the hormone-specific B chain. Although 
TSHS, LHS, and CGB share extensive sequence homology, little immunologi-
cal cross reactivity has been encountered. A connnon ancestral molecule 
for the four different hormones has been proposed to account for the 
similarities between individual a and B subunits. 
Levels of TSH present in the circulation vary with age and are 
dependent in the young rat on the development of the hypothalamic pitui-
tary-thyroid axis. 
b. Thyroid Stimulating Hormone Levels in Plasma and Pituitary 
The development of the hypothalamic pituitary thyroid axis has been 
examined in the rat by several groups: Dussault et al (1973), Cons et al 
(1975), Kieffer et al (1976), and Friedman et al (1979). In all cases, 
pituitary TSH was found in low levels just before birth and postnatally 
reached a maximum at day 15 before falling slightly to adult levels. 
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At term, fetal rat serum TSH is found to be slightly higher than 
maternal serum levels. There is a falloff in hormonal levels of serum 
after birth followed by a surge to reach adult levels by day 12. A rise 
in human serum TSH is also observed at birth and is sustained for 2-3 
weeks postpartum (Conklin et al, 1973). In this study and those of the 
rat, maternal TSH was found not to traverse the placenta. 
Adult rats have been reported to show diurnal variation in their 
levels of serum TSH, a similar situation to that reviewed for GH except 
that Parket et al (1976) do not believe a link exists with sleep and TSH. 
Leppaluoto et al (1974) have reported diurnal variations in serum, peak 
levels being attained by late evening, the lowest levels in the afternoon, 
and a relatively high plateau between 8-10 a.m. The mechanisms respon-
sible for this rhythm are not completely understood, although Niles et al 
(1979) have suggested that melatonin or the precursor of melatonin, n-
acetyl serotonin, in the pineal, may have a role in the diurnal rhythm of 
TSH. Pinealectomy was found to increase circulating TSH in animals kept 
under one-hour-light/23-hour-dark lighting conditions, and a similar in-
crease in TSH levels was observed after active immunization against mela-
tonin and n-acetyl serotonin. 
The overall concentration of TSH in the periphery reflects a dynamic 
equilibrium between TSH secretion and TSH distribution, degradation, and 
excretion. This regulated level of circulating TSH is dependent on many 
factors; however, the condition of the thyroid gland, which requires TSH 
for the maintenance of euthyroidism, is one of the most important factors. 
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c. Biolagical Effects of TSH 
Effects of TSH on the thyroid gland include hyperplasia and hyper-
trophy, stimulation of I- transport into thyroid cells and its incorpora-
tion into the thyroid hormones T4 and T3, and the hormonogenesis and 
secretion of these two hormones. In order to comprehend the importance 
of pituitary TSH to the thyroid, a brief description of the thyroid and 
the production of T4 and T3 will be given. 
The thyroid gland consists of two lobes connected by a narrow 
isthmus crossing the rat trachea. These lobes are composed of follicles, 
which are spheroid structures consisting of a single layer of epitheleal 
cells enclosing a cavity or follicle lumen which is filled with a viscous, 
proteinaceous solution, the colloid. The shape of the follicle cells 
vary; however, in any one follicle, the cell height is almost uniform. In 
general, low cells are characteristic of hypoactive follicles, as seen 
in hypophysectomized animals, whereas high cells are hyperactive follicles. 
Administration of pituitary TSH to hypophysectomized animals can restore 
the height of thyroidal follicle cells to normal (Tice, 1974). 
The specific physiological processes of the thyroid include trapping 
of iodide required for the thyroid hormones, the synthesis by the follicle 
cell of a specific thyroid glycoprotein, thyroglobulin; storage of thyro-
globulin in the follicle lumen, reabsorption of thyroglobulin into the 
cell, degradation of this protein, and release of the thyroid hormones T3 
and T4 into the circulation. 
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The kinetics of TSH action appear to be biphasic on iodide trans-
p9~t. f>.n earl-y depressive phase lasts l-2h and is followed by overail 
enhancement, as shown by Williams et al (1975) using mouse thyroid tissue. 
The depressive phase is thought to be due to an acute increase in iodide 
efflux from the follicular cells, possibly reflecting a general increase 
in memh:i:-ane permeability~ and the enhancement phase by an increase 
in the unidirectional clearance of iodide by cells presumably reflecting 
the inducti.on of iodide carriers. 
The binding of iodide to protein and the formation of iodothyronine 
is a rapid process. Two enzymatic systems are involved in this step, the 
generation of H202 and the oxidation of r- by a i;eroxidase (Taurog, 1970). 
As no effect of TSH on peroxidase activity has been observed, it is prob-
able that the H2o2-generating system is the hormone's site of activation 
as proposed by Ahn et al (1970). 
Thyroglobulin is synthesized in the rough endoplasmic reticulum and 
passes via the Golgi apparatus to the cell surf ace in vesicles before 
reaching the follicular lumen by exocytosis. The influence of TSH in 
this process is observed in hypophysectomized animals where a decrease in 
the size and contents of the lumen is noted. Ekholm et al (1975) have 
demonstrated this phenomenon using radioautography to show that a rapid 
stimulation by TSH discharged radio-labeled thyroglobulin into the colloid 
space. 
The first step in the release and secretion of thyroid hormones is 
marked by pseudopod formation by the apical plasma membrane protruding 
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into the follicle lumen and by endocytosis followed by portions of colloid 
reappearing in follicular cells. Pseudopods are formed within two minutes 
of TSH addition to incubated thyroid slices, and 10 minutes later T4 can 
be measured in the external medium (Ekholm, 1979). 
Degradation of thyroglobulin in the follicle cell requires that 
hydrolytic enzymes gain access to the content of the colloid droplets; 
the source of these enzymes is the lysosomes, as shown by Wollman et al 
(1964). Lysosomes are found in all parts of the cell but accumulate 
towards the lumenal cell surface after TSH stimulation (Seljelid, 1967). 
The consensus, therefore, is that proteolytic enzymes reach the thyro-
globulin by colloid-droplet/lysosome fusion, whereby degradation of the 
protein and release of thyroid hormones are achieved. 
The precise way in which TSH achieves this regulation of thyroid 
protein synthesis is not clear. Adiga et al (1971) showed that certain 
effects of TSH on the thyroid such as the stimulation of RNA synthesis 
and RNA polymerase in porcine thyroid could be inhibited by protein or 
RNA synthesis inhibitors, indicating the possibility that TSH acts at 
the level of transcription. Although a direct effect on the synthesis 
of thyroglobulin messenger RNA has not been observed by Larry et al (1971) 
in rats, the continuous presence of TSH seems to be required to sustain 
the expression of the thyroglobulin gene, as postulated by Pavlovic-
Hournac et al (1971). 
The stimulation of incorporation of amino acids into thyroid pro-
teins in vivo (Pavlovic-Hournac et al, 1973), and in vitro (Lecocq et al, 
1972) is thought to be an effect at the translational level by such 
authors. However, a direct stimulatory effect of cyclic adenosine 
monophosphate (cAMP), the postulated intracellular mediator of TSH 
actions (Rapaport, 1976), on protein synthesis in an acellular system, 
devoid of nuclei, has only been observed at unphysiological concentra-
tions of the cyclic nucleotide by Wagar (1973). 
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With regard to thyroid metabolism, TSH enhances thyroid cell res-
piration, mainly mitochondrial, as shown by Dumond (1971), and enhances 
glucose uptake and its overall metabolism (Dumont et al, 1965). Dumont's 
group also showed an augmentation in the overall pentose phosphate cycle 
and the incorporation of glucose into protein after TSH administration. 
Glycogen and fatty acid levels in lipids decrease, reflecting an activated 
catabolism. TSH has been shown to enhance the incorporation of precursors 
into most phospholipids, as demonstrated by Scott et al (1970) using 32P 
incorporation into monophosphatidylinositol, phosphotidates, phosphatidyl-
ethanolamines, phosphatidylserine, and in some cases phosphatidylcholine. 
No effect of TSH was observed on 32P incorporation into sphingomyelin or 
phosphatidylglycerol in isolated cells or slices from pig thyroid. 
Extrathyroidal actions of TSH, the significance of which are not 
well understood, include the ability to stimulate lipolysis (Hartree ~ 
al, 1972) and intracellular levels of prostaglandins (Vale et al, 1972) 
in human adipose and rat pituitary tissue. 
The hormone can therefore be seen to have a wide range of effects 
both on the thyroid and other tissues. The secretion of TSH from the 
pituitary gland can be regulated by several factors which will be dis-
cussed in the next section. 
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d. Regulation of TSH Release from the Pituitary. 
The hypothalamic-pituitary-thyroid axis has been shown to be a 
dynamic "negatiye fee.dback" control loop, the actiyity of which is in-
fluenced by the peripheral consumption of thyroxine (T4) and modulated 
by hypothalamic control of pituitary responsiveness, by thyrotropin re-
leasing factor (TRH). 
Early experiments with pituitary stalk sectioning by Boler & Schally 
et al (1969) and Burgus & Guillemin et al (1969) led to the identification 
and synthesis of thyrotropin releasing hormone (TRH), a small peptide 
consisting of the 3 amino acids, Glu-His-Pro-NHz, which was inactivated 
within minutes by serum. Secreted into the portal blood vessels by hypo-
thalamic cells, TRH travels to the pituitary and binds to the thyrotroph 
membrane on specific receptor sites with high affinity, stereospecificity, 
and reversibility, as shown by Wilber et al (1973a). The magnitude of TSH 
release from the pituitary cells is dependent on the increase in membrane 
binding of TRH (Wilber, 1973b). TRH stimulation also causes augmented 
TSH synthesis, as judged by the incorporation of 14c alanine or 14c gluco-
samine into pituitary slices (Wilber, 1971). An interesting immunohisto-
chemical report of Moriarty et al (1978) suggests that TRH may also be 
located in the thyrotroph secretory granule within the pituitary gland. 
Whether this material is of hypothalamic origin is not known. 
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Control of TRH secretion is not well understood. Ablation of supra-
optic and paraventricular nuclei results in suppression of thyroid func-
tion, and destruction of the median eminence and arcuate nucleus results 
in a fall of TSH and T4 levels (Grear, 1951; and Hefco et al, 1955a). 
Attempts to correlate the hypothalamic content of TRH with metabolic 
status indicate minimal or no variation (Montoya et al, 1975), although 
possibly the augmented TSH secretion induced in rats by cold exposure is 
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via an elevation in TRH pro.duction (Hefko et.al, 1975 ). The synthesis 
of TRH is stimulated also by dopamine and norepinephrine and reduced by 
serotonin, as shown in vitro using mouse hypothalamic tissue by Grimm 
and Reichlin (1973). Further evidence of monoaminergic transmitter 
control of TRH comes from the work of Krulich et al (1977), who showed 
that systemic injection of a methyl-p-tyrosine and inhibitors of dopa-
mine S hydroxylase cause decreases in serum TSH, as does blockade of a 
adrenergic receptors. Stimulation of dopamine receptors with apomorphine 
and L-dopa will similarly cause decreased release of TSH, leading to the 
conclusion that central noradrenergic systems have a stimulatory effect 
on serum TSH via TRH. The opiate peptide, leu-enkephalin, also appears 
to inhibit TSH via TRH as shown by May et al (1979). 
Primary control of TSH secretion is, as described, from the posi-
tive input of TRH as well as the negative control exerted by the thyroid 
hormone (T4). The inability of pharmacological quantities of exogenous T4 
to prevent an increase in TRH in response to cold exposure suggests that 
T4 does not alter TRH secretion (Montoya et al, 1974), but rather has an 
effect on the pituitary thyrotroph. Reichlin et al (1973), however, 
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showed that intrahypothalamic implants of T4 do depress thyroid function; 
the controversy of where T4 exerts its negative feedback control over TSH 
release still exists. 
T4 stimulates in the pituitary thyrotroph the synthesis of nucleic 
acids and protein which, in turn, affects the secretion of TSH. Observa-
tion by Samuels et al (1973) has shown that the effects of T4 on the 
pituitary are mediated by effects on transcription of genetic material 
to increase protein synthesis. Thus, a metabolic effect of thyroid hor-
mone, rather than actual circulating level of hormone, modulates pituitary 
responsiveness. 
Other regulators of TSH secretion than TRH and T4 are also known. 
Knigge (1964) has shown that infusion of TSH itself into the cat 
hypothalamus will inhibit thyroid hormone release, and Motta et al (1969) 
have shown decreases in TRH after exogenous TSH was administered to thy-
roidectomized rats. Although TSH levels are not modified by activity, 
starvation, circulating free fatty acids, or amino acids, hypoxia can 
cause a lowering of TSH in rats, which is probably a stress phenomenon 
(Curbelo et al, 1979). This group also showed a decrease in circulating 
TSH after adrenalectomy. 
The last two main sections of this literature. review have dealt 
with the characterization of the two pituitary hormones, GH and TSH, 
whose presence in the brain is the subject of this dissertation. In 
order to introduce the next section, which reviews the present knowledge 
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on peptides present in the brain, it is necessary at this point to intro-
duce the "amine precursor uptake and decarboxylation theory" of A. Pearse. 
Thyroid releasing hormone has been located in a number of other locations 
besides the hypothalamus, in particular, the pancreatic islet D cells. 
Known to contain primarily the hormone somatostatin, they are also known 
to contain TRH-like immunoreactive material (Morley et al, 1978). The 
finding of this and other peptides in both brain and gut has led to the 
"APUD" theory of Pearse (1966), Pearse (19 77), and Pearse and Takor (1979). 
D. THE AMINE PRECURSOR UPTAKE AND DECARBOXYLATION THEORY (APUD) 
The idea that cells widely disp~rsed in the nervous and gastroin-
testinal system share the same ability to secrete similar peptides has 
been examined by Pearse. These cells, known as "APUD" cells, were pos-
tulated to be derived originally from the embryological neural crest. 
Such cells included thyroid C cells, ultimobranchial body C cells, supra-
renal medullary cells, melanocytes, mast cells, pituitary corticotrophs, 
melanotropes, somatotropes, pinealocytes, and a wide range of endocrine 
cells in the gastrointestinal tract and pancreas. These regulatory mole-
cules produced by such cells may enter the bloodstream to reach and alter 
the activity of distant target cells, an endocrine action; diffuse local-
ly through interstitial spaces to reach and influence groups of neighbor-
ing cells, a paracrine action; or cross a synaptic junction to activate or 
inhibit the postsynaptic cell, a neurocrine action (Zimmerman, 1979). 
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Although the APUD-neural crest theory suggested the existence of a 
widely dispersed neuroendocrine system, offering a unifying concept for 
understanding many tumor-associated endocrine syndromes and the phenomenon 
of ectopic hormone production by a wide range of tumors; it seems evident 
from more recent studies that the possession of APUD characteristics by 
cells does not imply necessarily a neural crest origin. Cheng et al (1974) 
conclude that APUD endocrine cells of the pancreas . and intestine arise 
from the endoderm of the developing gut wall, and that the development of 
"APUD" characteristics appears to be one of several pathways of differen-
tiation available to primitive and uncommitted epitheleal cells. 
However, APUD characteristics do seem to be associated with tissues 
producing small polypeptide hormones, and it was therefore not surprising 
to find such hormones in both brain and gut. The next section of this 
review of literature discusses in more detail such findings, and demon-
strates that many of the peptides found in brain and gut appear to have 
significant roles to play in the functioning of the brain. 
E. PEPTIDES FOUND IN THE CENTRAL NERVOUS SYSTEM 
The idea of chemicals being involved in neuronal communication is 
credited to Elliot (1904). His theories foresaw later results from micro-
electrode recordings of single cells and the microiontophoretic applica-
tion of peptides to neurons which showed that results could not be ex-
plained completely by the presence of purely electrical junctions. 
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The concept of the presence of chemical neurotransmitters, which 
convey information between adjacent nerve cells, and chemical neuromodu-
lators, which amplify or dampen neural activity but which are not respon-
sible for direct transfer of a nervous signal from the pre- to post-
synap tic element, has developed over the last 60 years. Monoaminergic 
catecholamines such as dopamine and serotonin are known to be among the 
class of substances known as neurotransmitters. Whether peptides recently 
found in the brain such as renin and the hypothalamic peptides act as 
neurotransmitters or neuromodulators is not as yet known. It is clear 
that many such peptides affect the ionic potential of a receptive mem-
brane as will be seen in the following review, and that these effects are 
not identical to those produced by conventional neurotransmitters. 
Hokf elt et al in 1979 proposed that the peptide receptor is re-
stricted to specialized areas of the post-synaptic membrane. Several 
theories have been discussed by this group, using the evidence available 
in 1979, for a neuromodulator role for neuropeptides. One such theory 
entertains that a peptidergic nerve terminal in the brain could release 
its product into the extracellular spaces adjacent to fenestrated capil-
laries. The peptide is then carried via the vascular system to a target, 
where it interacts with a receptor. Another possibility would be a syn-
aptic arrangement, where the peptide and possibly a neurotransmitter are 
released into the synaptic cleft where interaction occurs with receptors 
on the post-synaptic membrane. A third possibility would be a parasynap-
tic arrangement, whereby the peptide, on release from the nerve. terminal, 
would diffuse and interact with receptors at sites other than the post-
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synaptic membrane, possibly nearby neural membranes, or on the peptidergic 
terminal itself. These are some of the ideas at present being discussed 
to explain the presence of the large number of peptide hormones being 
discovered in the CNS. 
They could also be present in the brain due to incomplete suppres-
sion of the genome or as receptor-bound hormone originating from secretory 
tissue in areas other than the brain. In the following discussion of 
present-day knowledge of brain peptides, beginning with a review of the 
presence in extrahypothalamic areas of hypothalamic hormones, some of 
these points will be discussed. 
HYPOTHALAMIC HORMONES 
The localization of peptidergic neurons in the CNS had indicated an 
emerging pattern with respect to distribution. Thyroid-releasing hormone, 
somatostatin, and gonadotropin-releasing hormones have been found in cell 
bodies and nerve terminals, both intra- and extrahypothalamically. It 
appears that besides mediating anterior pituitary secretion, these peptides 
may also play a role in brain function by mediating extrapituitary events. 
They will be reviewed individually here. 
a. Gonadotropin-Releasing Hormone (GnRH). 
GnRH is a decapeptide with a blocked aminoterminal composed of 
pyroglutamic acid, which stimulates pituitary gonadotropins and was 
found in the hypothalamus by Matsuo and Sch ally (19 71), and Burgus and 
Guillemin (1971}. Kubek et al (1979) have identified immunoreactive 
GnRH in extrahypothalamic areas such as the mammillary body, thalamus, 
amygdaloid nucleus, and hippocampus. Very small amounts or no hormone 
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are found in the human cerebellum and cortex. Baker et al (1975) re-
ported the hormone to be present in fibers leading to extrahypothalamic 
areas of the rat brain. Extraction and analysis of this material showed 
molecular similarities to the original hypothalamic hormone. Studies uy 
Parker et al (1978) showed the presence of neurons, the terminals of which 
end in the median enimence, which contained GnRH-like material associated 
with dense cored granules. On fractionation, 52%-65% of the hormone was 
associated with the synaptosomes. In hypophysectomized, ovarectomized 
rats, the intraventricular application of synthetic GnRH produces a 
specific action on mating behavior in estrogen-primed animals (Foreman 
and Moss, 1977}. 
b. TRH (Thyroid-Releasing Hormone), 
TRH-like material has been found in varying concentrations in the 
rat brain extrahypothalamically by several groups including Oliver et al 
(1974) and Winokur et al (1974). Although the greatest concentration 
for any one brain part is found in the hypothalamus, over two-thirds of 
the total brain content of TRH is found outside of the hypothalamus. 
Areas rich in TRH include the cerebellum, thalamus, brain stem and cere-
bral cortex. Little or no hormone is found in the pineal, amygdala, 
hippocampus, or caudate, These two groups differ as to whether TRH is 
present or absent in the pituitary; however, Moriarty et al (1978), as 
previously reported, have shown histochemically, TRH associated with 
pituitary thyrotrophs. 
The TRH-like material found extrohypothalamically possesses the 
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same physiochemical and biological properties as the hypothalamic peptide 
(Nemeroff et al, 1979). The content of TRH in the CNS is not affected 
by hypophysectomy, thyroidectomy, or adrenalectomy (Nemeroff et al, 1979), 
whereas hypothalamic levels of TRH fall after such treatment. It was 
found by Nemeroff (1979) that hypothalamic TRH levels could be restored 
with a combination of T4 plus TSH treatments. In the rat brain, it 
appears that the synthesis of this tripeptide occurs in situ, independent 
of the possible transport of the hormone from the median basal hypothala-
mus (Jackson et al, 1977). Studies by Bennett et al (1975), Parker et al 
(1978), and Schaeffer et al (1977) indicate the presence of TRH in rat 
median eminence and hypothalamic synaptosomal fractions, and that depolar-
izing procedures can release the hormone from such preparations. Burt 
et al (1975) have shown the presence of binding receptors in rat brain 
membrane preparations. These receptors occur ubiquitously throughout 
the regions of the brain, except for their absence in the cerebellum, and 
give credence to a possible neurotransmitter, rather than neuromodulator, 
role for TRH. 
A study by Renaud et al (1975) on single neuronal activity in var-
ious brain sites showed that microiontophoretic application of TRH, soma-
tostatin, and GnRH reduced neuronal activity in the rat. Studies by 
Brown et al (1975) show that, although this effect may be similar for all 
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three hormones, the biological effects on the CNS suggest opposing mechan-
isms for the individual peptide. However, th~ independence of all these 
effects from those on the pituitary suggest a direct action on the CNS by 
the hypothalamic hormones. 
Pentobarbital toxicity is reversed by TRH but enhanced by somato-
statin (Prange et al, 1974), whereas a strychnine effect on convulsions 
is potentiated by TRH but antagonized by somatostatin (Moss, 1979). It 
has been shown that TRH not only increases norepinephrine turnover in the 
brain (Keller et al, 1974), but also potentiates the behavioral effect of 
L-dopa (Plotnikoff et al, 1972). Plotnikoff showed that this latter 
ability was reduced by castration or pinealectomy. It appears from the 
work of Metcalf (1974) that TRH markedly antagonizes the sedation and 
hypothermia induced by a wide variety of centrally acting depressants 
such as ethanol, and that adrenergic blocking agents such as propanolol 
do not alter this antagonistic effect. Cott et al (1976) have further 
shown that these effects of TRH are independent of TSH and T4 influences, 
since hypophysectomy and T4 administration failed to reverse these res-
ponses. Prompt emergence from ether anesthesia is also characteristic in 
rats following TRH treatment (Moss, 1979). Other behavioral effects seen 
after intraventricular injection of TRH by Schenkel~Hulliger et al (1974) 
include muscle tremor, excitation, tail lifting, and pilo erection. A 
noted resemblance of these effects to those induced by morphine with-
drawal has been noted, and it is of interest that brain areas where 
naloxone, a competitor for morphine binding sites, precipitates with-
drawal shaking, parallel the sites of TRH-induced shaking and endogenous 
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sites of TRH in the brain. Another behavioral effect by TRH administra-
tion was shown by Vijayan et al (1977) to be an apparent suppression of 
feeding and drinking behavior. Most catecholamine levels remain unchanged 
after TRH treatment; however, Nemeroff et al (1979) report an increase in 
norepinephrine release from presynaptic terminals. 
The range of CNS effects which TRH exhibits is therefore large. 
Apart from the CNS, thyroid releasing hormone has been identified in the 
spinal cord (HoKfelt et al, l975a), retina (Schaeffer et al, 1977), in the 
islet cells of the pancreas (Morley et al, 1978), and in the placenta 
(Shambaugh et al, 1978). Recent evidence from Engler et al (1980) has 
shown that circulating TRH in the neonatal rat is derived from the pan-
creas and GI tract. 
The third hypothalamic peptide to be isolated extrahypothalamically 
is the GR-inhibiting factor or somatostatin. 
c. Somatostatin. 
This linear tetradecapeptide has been found widespread throughout 
the CNS using histochemical and radioinnnunoassay techniques. Although 
the highest concentration is in the hypothalamus, other areas contain 
substantial amounts (Parsons et al, 1976). Subcellular studies by Epel-
baum et al (1977) indicate that 70% of the somatostatin is localized in 
the synaptosome fraction. This peptide has also been isolated in both 
cells and fibers of the hypothalamus as well as from cell bodies through-
out the rat brain, in particular the limbic system and cortical areas as 
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shown by the immunohistochemical studies of Hokfelt et al (1977a). 
Somatostatin's presence in synaptosomes and its ability to act on 
single neuron units to inhibit spontaneous electrical activity imply a 
role in neural function (Brown et al, 1975). Tan et al (1977) have 
suggested that somatostatin inhibits the release of a pool of ca++ taken 
up by synaptosomes. As ca++ influx is closely related to nerve depolari-
zation, neurosecretion in nerve cells, and secretory processes in endo-
crine cells, it is possible that somatostatin influences neuronal excita-
++ tion through modification of Ca transport at the synaptic membrane level. 
Injection of somatostatin into the amygdaloid nucleus has been studied by 
Rezek et al (1977). They revealed a dose-dependent dissociation of effects 
on behavior and motor control. Lower doses induced a behavioral excita-
tion accompanied by a variety of tremors, whereas higher doses prevented 
the expression of a normal behavioral pattern due to the severity of dis-
turbances in motor control and the sleep-waking cycle. The effect on 
behavior is almost opposite to that of TRH. This includes a reduction 
in locomotion (Segal et al, 1974), prolongation of pentobarbital sedation 
(Prange et al, 1974), a decrease in the duration of strychnine-induced 
seizures, and sedation and hypothermia induction (Brown et al, 1975). In 
general, therefore, somatostatin exhibits a CNS-depressant form of action 
as shown by Segal et al (1975) and Prange (1974). Somatostatin also 
potentiates the behavioral effects of L-dopa and can act as a partial 
antagonist-agonist on opiate receptors. 
From this review it is apparent that, as with the other hypothalamic 
peptides, a dual role exists for somatostatin. Extrahypothalamically, it 
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acts as a modulator of nervous function and hypothalamically as a peptide 
inhibiting the release of growth hormone, TSH, prolactin, glucagon, insu-
lin, gastrin, and cholecys&okinin. 
Somatostatin-like imm.unoreactivity has also been located in thyroid 
C-cells (O'Brian et al, 1979), and in the stomach (Arimura et al, 1975) 
and pancreas of the rat by Luft et al (19 74). In the pancreas, the ana-
tomical positioning of islet D-cells between a and S cells of the islets 
suggests that they may be involved in some form of control over insulin 
and glucagon secretion (Dubois, 1975) and (Goldsmith et al, 1975). Hok-
felt et al (197i1) have suggested the possibility that somatostatin is 
present in a population of peripheral sympathetic noradrenergic neurons, 
a fact which would violate Dale's principle of "one neuron, one trans-
mitter" to suggest concomitant storage of a small biologically active 
peptide and an amine in the same neuron. 
Another group of hormones f otmd in the CNS are those originally 
detected in the GI tract. 
d. Bomb es in. 
Originally detected in frog skin and mammalian gut by Wharton 
et al (1978) , bombesin has also been isolated from mannnalian hypothala-
mus by Villareal et al (1978). The "brain" hormone is able to stimulate 
the secretion of growth hormone, glucagon, and prolactin, and is chemi-
cally and immtmologically distinct from frog skin bombesin. If injected 
intraventricularly, a lowering of body temperature is noted and an 
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elevation in blood sugar levels also occurs (Brown et al, 1977). 
A second GI tract hormone to be found in the CNS is glucagon. 
e. Glucagon. 
This pancreatic islet hormone has recently been detected in several 
areas of canine brain by Conlon et al (1979). Found in concentrations 
lOOx the level in plasma, the glucagon-like peptide seems to be a variety 
of gut glucagon. 
A second pancreatic hormone recently found in the CNS is insulin. 
f. Insulin. 
Insulin has been demonstrated in the brain in concentrations higher 
than plasma by Havrankova et al (1979). This ''brain" insulin is indis-
tinguishable chemically and immunologically from pancreatic insulin and 
does not vary with extreme changes in plasma insulin, indicating that 
brain insulin and its receptors are probably regulated independently of 
their counterparts elsewhere. Whether this hormone is synthesized locally 
is not known. Specific binding sites for insulin are localized on axons 
and axon terminals in the external median eminence and hypothalamic arcuate 
nucleus, suggesting that a discrete population of nerve terminals exist 
as potential targets for the direct effects of insulin (Van Houten 
et al , 19 80) • This group suggests that, after the initial binding, in 
the median eminence, insulin may be internalized and transported by retro-
grade flow to the arcuate nucleus. 
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Highest concentrations of insulin receptors are found extrahypo-
thalamica1ly in the cerebral cortex and olfactory bulb. Other areas such 
as the hippocampus and amygdala have fairly high numbers of receptors, 
whereas the retina, spinal cord, and cerebellum have the least. Specu-
lation that insulin receptors are preferentially located within elements 
of the limbic system leads to an association between emotional behavior, 
feeding, and defense, characteristically limbic system functions, with 
insulin as a possible regulator of these actions. 
The hormone has been shown to promote, in cells of the hypothalamus, 
local glucose uptake (Smith et al, 19 72) and subsequent metabolism (Panks-
pepp, 1973), to be capable of altering the electrical activity of hypo-
thalamic neurons (Oomura, 1976), and to stimulate hypothalamic norepine-
phrine release (Mccaleb, 19 79) • 
A note of caution before assigning insulin as a peptide indigenous 
to the CNS is that apparently no close correlation between insulin levels 
and receptor content exists in the different regions so far studied. 
Two other GI tract peptides, gastrin and cholecystokinin, are also 
found in the CNS. 
g. Gastrin and Cholecystokinin (CCK). 
Vanderhaeglin et al (1975) first reported the finding of a peptide 
in hog, dog, and human CNS which reacted with antigastrin antibodies. 
From chromatographic elution patterns, they concluded that the molecular 
weight of this peptide was less than gastrin (2-17) and more like that of 
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cholecystokinin. Since then, it is apparent that both gastrin- and chole-
cystokinin-like activity are present, but that they exhibit distinct 
distribution patterns in the CNS. 
As reported· by Rehfeld et al (19 79), gastrin is found in the 
hypothalamus, pituitary, and peripheral nerves. Cholecystokinin distri-
bution has been studied histochemically by Innis et al (1979), Larsson 
et al (19798), and Strauss et al (1977). This peptide was found to be 
widely distributed in nerves throughout the body. In the CNS, neocorti-
cal as well as hippocampal, amygdaloid nucleus and hypothalamic regions 
are richly endowed with cholecystokinin-containing nerves and cell bodies. 
Rehfeld et al (19 79), using 35s methionine incorporation, have 
shown in vivo biosynthesis of cholecystokinin in human and hog cortical 
cells. Brain CCK has been shown by Dock.ray (1980) to be mainly the COOH-
terminal octapeptide (CCK 8) of the GI hormone. Cholecystokinin and CCK 8 
are present in amounts comparable to those found in the GI tract. Mal-
es ci et al (1980) have shown that the brain contains at least two enzymes 
involved in the conversion of CCK to CCK 12 and CCK 8; the twelve residue 
peptide appears to be more biologically active than CCK 8. 
In vivo and in vitro effects of CCK have been reported on gonado-
tropin, prolactin, growth hormone, and TSH release in the rat by Vijayan 
~ _(1979). Intraventricular injections, followed by assay of plasma 
hormone levels, showed an increase in growth hormone and a decrease in 
TSH levels. The mechanism of release of pituitary hormone appears to be 
mediated via a hypothalamic intermediary. Gastrin exhibits similar 
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properties in the release of growth hormone and TSH (Vijayan et al, 1978). 
A possible role for CCK in appetite regulation, as proposed by Gibbs et 
al (1973), is more controversial, as results may be due to the peripheral 
effects of the peptide. 
Evidence for serotoninergic and opiate modulation of brain chole-
cystokinin has been presented by Morley et al (1980). 
Vasoactive Intestinal Polypeptide (VIP), another GI tract peptide, 
has been isolated from CNS tissue. 
h. Vasoactive Intestinal Polypeptide (VIP). 
Vasoactive Intestinal Polypeptide (VIP) is a 28-amino-acid residue 
peptide originally found in porcine duodenum by Said et al (1972). It 
possesses similar amino acid sequences and pharmacology to secretin and 
glucagon. 
Its actions peripherally, as shown by Said and his co-workers, are 
systemic vasodilation, stimulation of myocardial contractility, glycogen-
olysis, lipolysis, stimulation of insulin secretion, and inhibition of 
gastric acid production. 
Said et al (1976) reported the presence of VIP in intra- and extra-
hypothalamic sites in the CNS, in neural tumor cell lines, as well as in 
the GI tract. A recent paper by Sims et al (1980) has demonstrated his-
tochemically the presence of four major VIP-containing systems in the 
brain. A major intracerebral cortical system, another innervating the 
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central amygdala and nucleus of the stria terminalis, a pathway originat-
ing in the suprachiasmatic nucleus of the hypothalamus, and another in 
the central gray of the midbrain. Specific cell body staining was seen 
in the limbic and neocortex, the suprachiasmatic nucleus of the hypo-
thalamus, and the central gray of the midbrain. Giachetti et al (1977) 
have shown VIP's localization in synaptosomes, and a K+-evoked, Ca++-
dependent release has been demonstrated by Emson et al (1978). Specific 
binding of VIP and stimulation of cAMP release has been demonstrated in 
brain synaptic membranes by Taylor et al (19 79) .• 
Intraventricular administration of VIP has been shown to stimulate 
the release of growth hormone, prolactin, and luteinizing hormone (Borghi 
et al, 1979) from the pituitary. Direct application of VIP to the pitui-
tary has no effect, but Samson and McCann et al (1980) have shown that 
VIP receptors are present in the hypothalamus and that VIP can act to 
stimulate LH release from hypothalamic synaptosomes obtained from ovar-
ectomized female rats. They propose a neuromodulator role on GnRH in the 
hypothalamus, as the mechanism for release of LH from the pituitary. 
The heavy VIP innervation of the central nucleus of the amygdala 
and central gray of the midbrain is similar to the reported distribution 
of the opiate, enkephalin, and for neurotensin (Basbaum et al, 1978). 
As hypothesized for these two peptides, VIP may also have a role in pain 
sensation. 
Evidence for synthesis within certain brain areas comes from the 
work of Besson et al (1979), who studied the effects of deafferentation 
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of the hypothalamus on levels of VIP. Two weeks after deafferentation, 
the VIP concentration of the caudal hypothalamus and stalk were lowered 
by 40%. In contrast, no change was shown in cortical VIP levels, sug-
gesting that the peptide is derived from neural cell bodies mainly out-
side the median basal hypothalamus. 
The next peptide to be discussed, Substance P, was known to be 
present for many years in other tissues before its recent isolation 
from the CNS. 
i. Substance P. 
Von Euler et al (1931) first isolated from equine tissues, other 
than brain, a factor which they designated Substance P and which caused 
intestinal contractions and lowered blood pressure by vasodilation. 
Substance P was not, however, more thoroughly characterized until 1971 
with the establishment of the amino acid sequence of a sialogogic peptide 
isolated from bovine hypothalamus (Chang et al, 1971). 
Using immunohistochemical techniques, Hokfelt et al (1977~ reported 
Substance P to be present in the central and peripheral nervous system, 
showing an uneven distribution in the CNS except in the cortex, cerebel-
lum, and in the sympathetic ganglia of the guinea pig, cat, and rat. 
Emson et al (1978) have reported the presence of Substance P in the medial 
and central nuclei of the amygdala and the bed nucleus of the stria ter-
minalis. Efferents lead from the amygdala to the hypothalamus via the 
stria terminalis. Highest concentrations are found in the substantia 
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nigra. The occurrence of Substance P in neurons of the medullary raphe 
nucleus projecting to the spinal cord is intriguing, since these same 
nuclei also have been shown to contain serotonin by Hokfelt's group, 
yet another possible violation of Dale's Law of "one neuron, one trans-
mitter." 
The levels of Substance P in the brain stem and spinal cord are 
higher in fetal than adult tissues, as shown by Gilbert et al (1979). 
Other areas of the brain such as the cortex, caudate, and hypothalamus 
show a rise in peptide level at 14-28 days postpartum and demonstrate a 
similar developmental pattern to that of VIP and noradrenaline. 
Substance P has been shown to have some neuroendocrine functions, 
particularly those mediated by dopamine. It has been shown by Fisher 
et al (1974) that Substance P can release LH and FSH but not GH, PRL, or 
TSH, in vitro, from pituitary slices, whereas Euler et al (1979) showed 
stimulation of prolactin, growth hormone release, and inhibition of the 
release of insulin, in vivo~ 
This peptide fulfills several criteria to support its postulated 
role as a transmitter of pain impulses (Otsuka et al, 1975); however, it 
has yet to be shown to be synthesized in sensory nerves mediating pain 
transmission. A close analogy exists between Substance P and the opiate 
metenkephalin. They both are present in the substantia gelatinosa of 
the spinal cord, and it may be that Substance P is a transmitter of brain 
signals carried by sensory nerves into the spinal cord and then relayed 
to the brain thalamus, where pain sensing terminals are located. Because 
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of their immediate proximity, it has been postulated that the endorphins 
may produce their analgesic effects by suppressing Substance P release 
in the spinal cord (Marx et al, 1979). 
Evidence that Substance P modulates synaptic transmission of cat 
motoneurons comes from the work of Krivay et al (1979). This effect ap-
pears biphasic: low doses inhibiting and high doses facilitating synap-
tic transmission, suggesting a neurotransmitter role. However, the slow 
time-course of some Substance P responses (neurotransmitters usually 
induce rapid responses), and the finding that the peptide depresses 
responses to other putative neurotransmitters, suggests that the peptide 
may not be a true neurotransmitter (Otsuka et al, 1975). Krnejevic et 
al (19 77) have proposed two operationally distinct actions of Substance 
P to explain these functional differences: a neurotransmitter-like 
action mediating excitatory synaptic events which are both rapid in on-
set and brief in duration, and actions of Substance P such as those in-
volving the depression of glutamate-activated events, more of a neuro-
modulator effect. The presence of Substance P, but not its exact role 
in the CNS, has clearly yet to be completely characterized. 
During the course of the purification of Substance P from bovine 
hypothalamic extracts, a new tridecapeptide was detected, sequenced, and 
synthesized by Carraway and Leeman (1973) and is reviewed below. 
j. Neurotensin. 
Neurotensin has been found by Kobayashi et al (1977) to be in the 
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highest concentrations in the median eminence, but also to be present in 
the amygdala, nucleus accumbens, and caudate. Low levels are found in 
the cortex, hippocampus, and pineal, and trace amounts are present in 
the cerebellum. Carraway et al (1976) showed that receptor binding con-
centrations differ from this hormonal distribution pattern in that highest 
concentrations are in the thalamus and cortex as well as the hypothalamus. 
Adrenalectomy or hypophysectomy does not seem to alter overall levels of 
the hormone in the brain, and the intestine, stomach, and pancreas have 
higher levels than those found in brain tissue (Leeman et al, 1977). 
Intraventricular doses of neurotensin were given by Carraway et al 
(1976) and found to lower body temperature, accentuate barbiturate seda-
tion, cause hypotension, increase vascular permeability, cyanosis, and a 
marked hypoglycemia. 
Disagreement exists as to its role in modulation of the secretion 
of the hormones of the pituitary. Rivier et al (19778)have shown that 
neurotensin is able to stimulate the pituitary secretion of growth hor-
mone, prolactin, luteinizing hormone, follicle stimulating hormone, and 
ACTH, postulating the effect is via a hypothalamic intermediate. However, 
in a recent abstract by Nemeroff et al (1980), intraventricular neuro-
tensin modulated neurotransmitter activity in the mesolimbic but not the 
nigroneostriatal dopamine system and reduced the secretion of TSH, GH, 
and prolactin. 
Neurotensin can therefore be summarized as being present in both 
the CNS and GI tract and appears to have some biological effects on brain 
tissue. 
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The next peptides to be reviewed are those originally associated 
with the renin-angiotensin system of the kidµey which have been isolated 
from CNS material over the last five years. 
k. Renin-Angiotensin. 
Angiotensin II is an octapeptide formed by the action of converting 
enzymes on the decapeptide Angiotensin I, which is normally the product 
of the enzymatic action of renin from the kidneys on angiotensinogen. 
Almost all parts of this renin-angiotensin system have now been isolated 
from brain homogenates. 
A renin-like activity was found in dog, human, and rat brain by 
Haulica et al (1975), exhibiting molecular and innnunological similarities 
to kidney renin. Renin levels were measured in hog brain by Hirose et al 
(1980), who showed that the pineal was the richest source of renin-like 
activity, followed by the hypothalamus, cerebellum, and amygdala. 
Reid et al (1977) reported that the pH optimum of brain renin dif-
fered from that of kidney renin and that the renin-like brain peptide 
behaved more liRe Cathepsin D, a nonspecific acid protease. However, 
more recent studies have shown that "brain renin" is indistinguishable 
from renal renin both biochemically and serologically (Slater et al, 1980, 
and Inagami, 1978). Studies also demonstrated that the distribution of 
renin and Cathepsin D were distinct and showed no overlap, as shown by 
Govindrajan et al (1974) and Daul et al (1975). Renin has been identi-
fied by Slater and Zimmerman (1980) in many neurons throughout the human 
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brain by inum.m.ohistochemical methods. 
Angiotensinogen, renin's natural substrate, was first located in 
brain tissue by Ganten et al (1976) and shown to have a molecular weight 
of 40,000-60,000 D, presumably too large to cross the blood brain barrier 
and, therefore, it was concluded by the authors to be endogenous to the 
brain. Wallis et al (1980) have shown a wide distribution for angioten-
sinogen in the rodent brain and that these levels can be modulated by 
glucocorticosteroids. The hypothalamus, preoptic area, and perlaqueductal 
gray regions showed the most consistent reduction in brain angiotensino-
gen after 14 days' adrenalectomy, other brain regions showing little or 
no effect. Treatment with corticosterone reversed the effect of adrenal-
ectomy in the four brain regions. 
The "converting enzyme" for Angiotensin I to Angiotensin II is 
present in rat and human brain in large amounts and is widely distributed 
(Yang et al, 1972, and Poth et al, 1975). 
Fuxe et al (1976) found positive fluorescence for angiotensin II-
like material in the median eminence and amygdaloid nucleus. The octa-
peptide is localized in neuronal cell bodies, fibers, and terminals in 
the paraventricular and perlfornical area of the hypothalamus, with 
highest concentrations in the terminals of the hypothalamic dorsomedial 
and basal nuclei. 
Bennet et al (1976) and Siret et al (1977) have identified high 
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affinity binding sites for I · angiotensin II on rat brain membranes 
which were saturable and reversible. Specific receptors exist only in 
the midbrain, thalamus, and hypothalamus. Baxter et al (1980) have 
shown that these binding sites reach maximum numbers, ten times those 
found in adult animals, in the first week of post-natal life. Levels 
of renin and angiotensin II are also higher at birth than those found 
in adult brains. 
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Nephrectomy does not change the levels of angiotensin II in the 
brain, indicating an independence from the renal system. This peptide 
has been shown to exert several actions on the CNS after intracerebral 
injections. These include stimulation of drinking, a rise in blood 
pressure, and vasopressin and adrenocorticotropin (ACTH) release after 
int;r:;ayentticula;r injection (Fitzsimon, 1972). The sites of action of 
intracerebral angiotensin II appear to be the same as for the circu-
lating peptide, that is, close to the ventricles in the septal region, 
anterior hypothalamus, and preoptic areas (Johnson and Epstein, 1975). 
Destruction of tissue at these sites abolishes the rise in blood pres-
sure and increase in water uptake, stimulated by angiotensin II (Anders-
son et al, 1975). Intracarotid injection of saralasin acetate, an 
inhi.bitor of angiotensin II activity, decreases blood pressure in gene-
tically hypertensive rats (Phillips et al, 1977). 
In this review, the site and mode of action of components of the 
brain iso-renin-angiotensin system have been discussed. Vasopressin, 
the posterior pituitary hormone, will now be reviewed. 
1. Vasopressin. 
Traditionally a posterior pituitary hormone, vasopressin is 
produced by neuronal cell bodies in the supraoptic and paraventricular 
nuclei of the hypothalamus and has recently been reported in extra-
hypothalamic areas of the brain. Kovacs et al (1979a) have studied the 
stimulatory effect of minute quantities of vasopressin injected into 
certain limbic-midbrain structures such as the hippocampus, and showed 
facilitation of memory consolidation processes. Oxytocin, another 
posterior pituitary hormone, was shown to attenuate passive avoidance 
behavior in a time-dependent manner, suggesting that memory consolida-
b 
tion is influenced by this peptide (Kovacs et al, 1979 ). 
Whether the presence of these peptide hormones extrahypothalami-
cally represents in-situ synthesis or axonal transport from the hypo-
thalamus is still unresolved, but results suggest that limbic-midbrain 
areas are involved in the mediation of action of both posterior pitui-
tary neuropeptides on memory consolidation. 
Not only posterior pituitary but anterior pituitary hormones are 
among those peptides being found localized in the CNS. The discovery 
of a family of related peptides in both brain and pituitary demands an 
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introduction to their relationships in terms of molecular characteristics. 
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m. A connnon precursor for some pituitary hormones. 
For many years it was known that the bioactive form of ACTH was 
only 39 amino acids long and yet antibodies to this peptide also reacted 
with a protein six times larger. The nature of this large precursor 
revealed new structural relationships among a group of peptide hormones. 
Eipper et al (1975) and Mains et al (1977) found by studying the 
synthesis of ACTH, using pulse chase experiments with pituitary tumor 
cells incubated in 3H tyrosine-containing media, that the biologically 
active ACTH 4.SK fragment was cieaved from the middle of a 31K.ACTH pre-
cursor molecule (Fig. 3). At the same time, a close relationship had 
been observed between ACTH and the 8 lipotropin (6 LPH) families of 
peptides. They had been shown to be released in roughly equivalent 
amounts by normal pituitary tissue, and also Moriarty (1973) and Pelle-
tier et al (1977) had shown that the two peptides were localized in the 
same secretory granules in pituitary cells. It had also been noted that 
the 31K precursor ACTH molecule contained peptide segments similar to 
both ACTH and the opiate 8 endorphin. Further work by Mains et al (1977) 
showed that the peptides of an ACTH biosynthetic intermediate, plus the 
peptides from 8 LPH, summed to equal the sequences from pro-ACTH/endor-
phin, thus establishing a connnon precursor relationship. 
The 8 LPH can further be broken down to yield 8 endorphin and also 
8 melanocyte-stimulating hormone (8 MSH). At the other end of the large 
precursor, a sequence of seven amino acids corresponded to the structure 
of a MSH, being the breakdown product of the ACTH part of the molecule, 
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together with a 21-amino-acid peptide known as "CLIP." In summary, ACTH, 
the lipotropins, and the endorphins all originate as controlled cleavage 
products from a common 31,000 D glycopeptide. 
The two lobes of the pituitary, anterior and intermediate, which 
contain the common precursor, exhibit differences in the levels of ACTH 
and 8-lipotropin-related peptides, apparently due to different cleavages 
and other post-translational processing steps (Eipper and Mains, 1980). 
These peptides are not only found in the pituitary, but the precursor 
protein and many of its breakdown products have been found in the hypo-
thalamus. 
Highest concentrations of ACTH, a MSH, S lipotropin, and the 
opiate peptide S endorphin have been found in the hypothalamus. However, 
significant amounts are also found in the limbic system and to a lesser 
extent in the midbrain, cortex, and cerebellum (Krieger et al, 1977b). 
Cell bodies containing these peptides have been isolated, histo-
chemically, lateral to the arcuate nucleus of the rat hypothalamus, and 
positively staining fibers have been shown projecting from this area to 
the amygdala, thalamus, and the stria terminalis by Zimmerman et al 
(1978) and Watson (1977 and 1978). Similar immunohistochemical studies 
on rat pituitaries, using antisera directed against S-lipotropin, S-lipo-
tropin/ S-endorphin, ACTH and a MSH showed innnunostaining of the same or 
similar cells in the anterior lobe of the gland (Jacobowitz et al, 1978, 
Martin et al, 1979~ 
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Parallel synthesis of ACTH, S lipotropin, and B endorphin has been 
reported by Krieger and Liotta (1980) in the pituitary, and Gramsch et al 
(1980) have shown parallel patterns of distribution of S lipotropin, S 
endorphin, ACTH, and a MSH in the pituitary and brain. Gramsch also 
showed that whereas B endorphin and a MSH are predominant in the brain, 
in contrast, their respective precursors, S LPH and ACTH, were predomi-
nant in the pituitary of both rat and man. Unlike the pituitary, no 
cells or fibers in the CNS appear to contain both ACTH and B lipotropin 
together (Krieger et al, 1977b). 
Local differences for concentrations of S LPH and ACTH have also 
been noted by Krieger et al (1979) in the regions of the CNS, such as 
lower S LPH than ACTH levels in hypothalamus, hippocampus, and amygdala, 
and higher S LPH than ACTH levels in the midbrain, pons, spinal cord,· 
and medulla. 
These data may be indicative of important differences in post-
translational processing of the common precursor molecule between hypo-
thalamus and pituitary tissues, and even between brain regions. Since 
the pituitary and hypothalamus are on opposite sides of the blood brain 
barrier, these two separate sources of peptides are therefore possibly 
regulated separately and exhibit differences in rates of synthesis, 
biological half-lives, and types of precursor present. Mains (1980) 
speculates that this compartmentalization may have evolved to allow the 
pituitary to stimulate glucocorticoid production by means of ACTH with-
out over-producing opiate activity, and to allow the hypothalamus to 
achieve the maximtllll brain effect of its common precursor, derived opiate 
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peptides, without causing cortisol release. 
Even though it seems from this discussion that the two pools of 
hormones are separate entities, the presence of pituitary-like hormones 
in the brain such as ACTH has been further investigated to prove this 
situation. 
n. Brain ACTH. 
The pattern of distribution of ACTH in the brain, as reported by 
Krieger (1977a), persists after hypophysectomy, adrenalectomy, and dexa-
methasone suppression. Immunohistochemical studies by Pelletier et al 
(1980) also confirm this observation. After long-term hypophysectomy, 
the level of hormone initially falls slightly in the median eminence but 
not in the median basal hypothalamus or other tissues (Liotta et al, 
1978}. An enhancement in ACTH concentration is, in fact, observed after 
removal of both pituitary and median eminence in the remaining hypo-
thalamic tissue. This data by Liotta tends to eliminate a pituitary 
source for brain ACTH, whether by contact with hypophyseal tissue or 
retrograde transport from the pituitary. Other lines of evidence to 
demonstrate that ACTH present in the brain does not have a pituitary 
source comes from the work of Allen (1974), who showed that the hormone 
is incapable of penetrating the blood brain barrier. Other evidence 
that indirect transport via the systemic system can be eliminated as a 
contaminating source of ACTH is that, in cases where a high level of 
ACTH is present in the circulation, such as following adrenalectomy~ no 
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corresponding rise in ''brain ACTH" has been observed (Krieger et al, 
19 79). 
There is a possibility, not proven, of retrograde transport of 
hormone up the portal vessels. Thus, brain ACTH could reflect both the 
contribution of a pituitary source, perhaps mediating a short-loop feed-
back suppression of pituitary ACTH and a brain source. Moldow et al 
(1978a) have suggested that all extrapituitary sites of ACTH are pitui-
tary-derived via such retrograde flow. Evidence for this comes from 
their observations that the distance from the pituitary at which ACTH 
is found and the concentration gradient in brain tissues are roughly 
comparable. However, this would seem to be invalidated by the biosyn-
thesis, in vitro, of an immunoreactive 3,000 D ACTH/endorphin-like material 
in bovine hypothalamic cells maintained in culture, which was measured by 
Liotta et al (1979a) by showing 3H-labeled amino acid incorporation into 
a high molecular weight material. The suggestion was made in this paper 
that cells within the hypothalamus, but not cortex, synthesize material 
with the immunological characteristics of the 31D ACTH precursor. Char-
acterization by Liotta et al (1979b) confirmed such similarities, which 
included apparent identical size, presence of oligosaccharide units, the 
basic nature of the protein, and the ability to be processed by trypsin-
like enzymes to smaller molecular weight products. The same group has 
shown that rat arcuate nucleus cells, maintained in culture for 17 days, 
release twice the amount of ACTH and ~ endorphin than is present in the 
tissue on day one. 
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Other lines of evidence for a brain origin include studies by 
Krieger's group where destruction of the arcuate nucleus in newborn rats 
by monosodium glutamate was associated with a decrease in brain ACTH but 
no change in pituitary ACTH levels. Immunohistochemical studies by Wat-
son et al (1978), using colchicine to block axonal transport along nerve 
fibers, have shown an increased density of staining of arcuate nucleus 
cell bodies after such treatment, indicating accumulation of the hormone 
in the cells and therefore probable in-situ synthesis. Ether stress and 
chronic immobilization, which normally are associated with changes in 
ACTH pituitary levels, appears to have no effect on the levels of the 
brain hormone (Krieger, 1979). 
These studies tend to weaken the hypothesis that the presence of 
ACTH extrapituitarily is due to diffusion from the pituitary alone, and 
strengthens the idea that the hormone may have specific functions on 
nervous tissue. 
ACTH and ACTH fragments are reported to play a role in motivation, 
learning, and memory (Gispen and de Wied, 1977). Other fragments are 
reported to induce excessive grooming, stretching, and yawning when ad-
ministered intraventricularly (Gispen et al, (1976~. These activities 
are not mediated by adrenal steroids. Sufficient evidence is available 
from Dunn et al (1977} to indicate that ACTH affects cerebral protein 
synthesis, RNA synthesis~ protein phosphorylation, and cyclic nucleotide 
metabolism. It has been reported by Terenius et al (1975) that ACTH 
interacts with opiate receptors. This could possibly interfere with the 
analgesic action of morphine on the CNS. Naloxone can suppress the 
excessive grooming seen after intraventricular administration of ACTH 
(Gispen et al, 1976b). 
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ACTH also affects the acetylcholine, norepinephrine, and serotonin 
content or turnover of various brain regions, selectively modifies unit 
activity in midbrain limbic structures, and enhances the dephosphoryla-
tion of membrane proteins leading to membrane permeability changes, pro-
perties reviewed by Gispen et al (1977). 
These changes in behavior and the general metabolism of nervous 
tissue brought about by ACTH in the brain indicates its probable impor-
tance as a neuromodulator. 
Another important product of the large precursor protein associated 
with ACTH synthesis is a melanocyte-stimulating hormone or a MSH. The 
primary function of pituitary a MSH is known -to be the regulation of 
pigmentation changes in many vertebrates. 
o. a Melanocyte-Stimulating Hormone (a MSH). 
Before the work concerning the existence of a large precursor 
protein for a MSH in both brain and pituitary; the sole source of a MSH, 
a basic tridecapeptide amide, was thought to be the pituitary gland. 
Dube et al (1978) reported finding a MSH-containing nerves in both 
rat and man. The source of a MSH fibers appeared to be the a MSH-con-
taining perikarya of the arcuate nucleus in the hypothalamus (Vaudry et 
al, 1978), and the peptide has been localized within vesicles of nerve 
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endings by Barnea et al (1977). Warburg et al (1977) demonstrated the 
release of a MSH from a synaptosome-enriched fraction prepared from 
hypothalamic tissue. 
Over 40% of the immuno-assayable total brain content has been 
found in the hypothalamus, the limbic system containing substantial 
amounts also (Eskay et al, 1979a). Surgical isolation of the arcuate 
nucleus of the hypothalamus resulted in a significant fall in extrahypo-
thalamic a MSH levels, whereas no reduction in hypothalamic peptide con-
tent was noted. This data gives further evidence that a MSH-containing 
cells in the arcuate region send projections to extrahypothalamic areas 
and are the source of a MSH in the CNS. Treatment of rats with mono-
soditnn glutamate (MSG) results in destruction of tne neurons in the 
b 
arcuate nucleus (Eskay et al, 1979 ). This study measured the levels 
of a MSH in the hypothalamus and the pituitary after treatment with MSG 
and showed, again, that levels of peptide fell in brain tissue, whereas 
pituitary a MSH levels remained constant. This same treatment by Hughes 
et al (1979) also resulted in a reduction of ACTH-like and endorphin-
like concentrations in the hypothalamus, substantiating the theory of a 
common precursor origin of a MSH, ACTH, and S endorphin. 
Bap:tea et al (1977) examined the cosequestration of ACTH and a 
MSH in both hypothalamic and hypophysial neuronal granules. The ratio 
of one peptide to the other found in the granules was dependent on loca-
tion. In the hypothalamus, 5 times more a MSH than ACTH was found, 
whereas 20 times more ACTH than a MSH was seen in the pituitary. The 
peptide granules for each peptide were distinguishable, and the peptides 
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are likely to be released simultaneously. There must be differences in 
the intragranular conversion of AC!H and a MSH, as has been alluded to 
previously, to account for the differences in hormone levels in pituitary 
and hypothalamic neurons. Similar data has recently been reported for 
human brain tissue (Kleber et al, 1980). 
On the basis of chromatographic, electrophoretic, and biological 
characteristics, a MSH present in the rodent brain has been shown by 
Oliver et al (1978) to be identical to synthetic a MSH. 
In support of the hypothesis that a MSH is a neurotropic substance, 
its effect in vitro on neural tissue has been shown to alter electrical 
activity (Krivoy and Guillemin, 1961, and Denman et al, 1972); to alter 
biochemical events such as the metabolism of biogenic amines (Leonard 
et al, 1976); and to increase the levels of c-AMP in the occipital cortex 
(Christensen et al, 1976). Administration of a MSH has also been shown 
to have an effect on various behavioral tasks such as avoidance behavior 
(Wimersma, 1977, and Greven et al, 1977). 
Significant diurnal variation in a MSH has been observed by O'Dono-
hue et al (1979), and the hypothesis that the hormone may participate in 
the manifestation of the diurnal rhythms of such behavioral effects as 
arousal, attention, and vigilance has been proposed. Panksepp et al 
(1976) have also reported an a-MSH effect on other obvious circadian 
rhythm patterns such as sleep-waking activity. 
a MSH, therefore, appears to be a peptide found both in brain and 
pituitary, similar in structure, but each pool of hormone being indepen-
dently regulated. Its importance as a neuromodulator has been discussed. 
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The next section deals with a group of endogenous substances which 
bind to opiate receptors and mimic the biological effects of morphine, 
the endorphins, which include a and i3 endorphins, and the enkephalins. 
p. The endorphins . 
Endorphins have been isolated from various tissues including the 
brain by Hughes et al (1975), the pituitary by Teschenmacher and Goldstein 
(1975), and the GI tract (Elde et al, 1976). 
Historically, opiate receptors were found using immunohistochemical 
techniques by Kuhar et al (19 73) to be concentrated in the mesolimbic 
system of the brain. It seemed unlikely that such highly stereospecific 
receptors should be developed merely to interact with alkaloids from the 
opium poppy. Early experiments by Akil et al (1972) showed that analgesia 
produced by electrical stimulation of the periaqueductal gray region of 
the brain stem of rats could be reversed by the administration of nalox-
one, a pure opiate agonist. Jacob et al (19 74) found that mice could be 
made more sensitive to pain by injection of small amounts of naloxone. 
These observations indicated that there existed an endogenous analgesic 
opiate;· the action of which could be blocked by naloxone. 
By 1975, Hughes et al (197511 isolated from pig brain a peptide with 
a molecular weight of 1000 D, which could combine as an agonist at opiate 
receptor sites and whose actions could be blocked by naloxone. Cox et al 
(1975) isolated a similar opiate peptide from human cerebral spinal fluid 
and pituitary extracts. Furthermore, in the brain, these opioid peptides 
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were localized in the same areas anatomically as Kuhar's opiate receptors, 
as shown by Pert and Sneider (1976). 
Two related pentapeptides with opiate activity were isolated by 
Hughes (1975a). The most abundant, in pig brain, was named methionine-
enkephalin and the other, leucine-enkephalin. .As previously noted (Fig. 
3), their sequences were contained within the structure of S lipotropin 
(Fig. 4). Low levels were also found in the pituitary. Evidence for 
separate populations in the brain of the met- and leu-enkephalin have 
been reported by Larsson et al (19 79b) using histochemical techniques. 
The enkephalin-containing nerves also showed a distribution distinct 
from nerves containing S endorphin, a larger opiate peptide (Guillemin 
et al, 1976), ACTH, and S lipotropin (Bloom et al, 1978). 
At the present time, there is no definitive evidence that the en-
kephalins in the brain are derived from S lipotropin (Guillemin, 1980). 
The perinatal development of the endorphin- and enkephalin-contain-
ing systems has been studied in the rat brain by Bayon et al (1979). 
Endorphin levels were much higher than enkephalins in the 16-day fetus, 
dropping to lower levels by the 20th day of gestation. The enkephalin 
content rose at day 20 and continued to increase at a faster rate than 
the endorphins from the 6th to the 25th day postnatally to achieve adult 
levels. This would suggest an independent development of the endorphin 
and enkephalin systems due to the lack of correlation between rates of 
increase; however, the authors suggest that certain endorphin-like systems 
could develop differentially into enkephalin systems during gestation. 
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This concept is in agreement with observations that small local inter-
neurons, like the enkephalin-containing cells, frequently migrate and 
differentiate more than larger neuron-forming pathways. 
Evidence for distinct pools of brain endorphins and pituitary endor-
phins comes also from the work of Kobayashi et al (1978) and Cheung et al 
(1976). These groups showed that hypophysectomy failed to alter the brain 
content of opioid peptides after as long as 34 days without a pituitary. 
Guillemin et al (1977) also demonstrated that S endorphin levels in the 
brain did not change in experiments causing marked variations in pitui-
tary S endorphin levels. 
Two functions have been suggested for opiate peptides in brain. 
They may act as hormones or neuromodulators transported to their target 
organs by CSF or the vascular system; or, they may act as neurotransmitters, 
liberated from nerve terminals and binding to postsynaptic membranes. 
Several studies suggest a role as neurotransmitters. In support of 
this role, they have been found concentrated in the synaptosomal fraction 
of brain homogenates and are localized in nerve endings (Simantov et al, 
1976b). They appear to be able to inhibit neurotransmitter release, a 
response apparently related to changes in the Ca+t flux. It has been 
shown that morphine can decrease acetylcholine (Yaksh et al, 1975), and 
norepinephrine release (Arbilla and Langer, 1978), an effect antagonized 
++ by Ca • Evidence by Guerrero-Munoz et al (1979) indicates that a single 
++ dose of S endorphin causes a decrease in Ca concentration in synapto-
somal fractions, attributable to reduced Ca++ binding and uptake. 
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Sustained administration of S endorphin showed a reversal of this effect 
and the development of tolerance and physical dependence or addition, 
supporting the concept that S endorphin may inhibit the release of trans-
++-
mitters by inhibition of Ca influx in a mode similar to that of mar-
phine. 
The rapid degradation of the pentapeptide endorphin in serum seems 
to exclude a hormonal function (Simantov and Snyder, 1976a), although 
Sarne et al (1978) have postulated that a larger enkephalin-like substance 
found in sera was resistant to degradation and could act as a neuropeptide 
stimulating pituitary GH and prolactin release, as shown by Rivier et al 
(1977b). Drouva et al (1980) have shown that this may be mediated by the 
inhibition of release of somatostatin in the hypothalamus by opiate pep-
tides such as met-enkephalin. This inhibition of release of hypothalamic · 
hormone was naloxone reversable and was consistent with the hypothesis 
that opiates interfere with Ca++- influx. Met-enkephalin and morphine 
were also shown to inhibit GnRH, and therefore LH release, from the pi-
tuitary, and opiate receptors were isolated on GnRH as well as somatosta-
tin nerve endings in the hypothalamus. S endorphin has been reported to 
promote the secretion of prolactin, the exact mechanism of this being 
unclear (Rossier et al, 1980, and Spies et al, 1980). 
Dawson et al (1979) have studied another aspect of the effect opiate 
peptides may have on nervous tissue. The presence of opiates in cultured 
mouse neuroblastoma cells modified the biosynthesis of both membrane gly-
cosphingolipid and glycoprotein. These effects seem to be mediated by 
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opiate receptors, of which this cell line has a prolific quantity, as 
they were stereospecific and naloxone reversible. Neuroblastoma cells 
treated with a-AMP- are known to undergo morphological differentiation and 
show enhanced glycosylation of a ntllllber of secretory proteins (Truding 
et al, 1975). As other studies have demonstrated that opiates and enke-
phalins inhibit PGE1-stimulated adenylate cyclase activity (Klee et al, 
1976), it appears that the modifications of membrane glycosphingolipid 
and glycoprotein seen by Dawson et al (1979) may represent a c-AMP 
mediated event. 
Interest in the endorphins stems from the possibility that they or 
their analogues may be non-addictive pain killers to replace opiates such 
as morphine. It has been demonstrated that they are distributed in the 
pain-mediated pathways of the CNS. However, a lack of effect in produc-
ing analgesia has been observed when enkephalin is injected intraventri-
cularly into rat brain. In vitro, indications are that enkephalins have 
a more profound opiate ef feet and bind to receptors about half as avidly 
as morphine. All these effects and those such as the induction of a state 
resembling catatonic schizophrenia by S endorphin (Bloom et al, 1976) 
can be blocked by the specific antagonist of opiat~ action, naloxone. 
Evidence is opposed to the fact that the opiates are non-addictive, 
as both enkephalins and S endorphins are found to produce tolerance and 
dependence effects (Pert et al, 1976, and Blasig et al, 1976). S endor-
phin appears to resemble morphine pharmacologically. As an analgesic, it 
is 20-30 times more potent when given intraventricularly (Li et al, 1977). 
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Recent work by Pasternak. et al (1980) supports the concept of multiple 
opiate receptors and gives evidence for mediation of opiate analgesia by 
a subpopulation of high affinity opiate receptors. 
A role for enkephalins in the mediation of behavioral reinforcement 
is supported by several lines of evidence. Central injection of enkepha-
lin serves to reinforce self-administered behavior, and electrical stimu-
lation of enkephalin-rich regions of the brain also serves to reinforce 
self-stimulated behavior. Both effects are blocked by naloxone. Gunne 
et al (1977) reported that chronic schizophrenics exhibit elevated levels 
of endorphins in their CSF during symptom-rich phases of their disease. 
When their condition improved, a return to low endorphin levels was ob-
served, implying that some psychological symptoms might be due to exces-
sive endorphin activity. 
The endogenous opioids clearly have powerful effects, are involved 
in behavior, and interact with other neuronal systems. While enkepha-
lins potentially appear to conform to definitions of a neurotransmitter, 
S endorphin may be a neuromodulator. The enkephalins seem to be situated 
in such a way to influence basic processes such as pain transmission, res-
piration, motor integration, endocrine responses, and limbic functions 
involved in the elaboration of emotions. S endorphin seems more likely 
to affect various structures by interacting with other local neuroregula-
tors. 
Apart from ACTH and S LPH, there have also been recent reports of 
other pituitary hormones, such as prolactin, in extrapituitary locations. 
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q. Prolactin. 
Evidence from Fiixe et al (1977) showed innnunohistochemically that 
prolactin appears to be present in the nerve terminals of several hypo-
thalamic nuclei such as the arcuate and ventromedial areas. Furthermore, 
Toubeau et al (1979) have recently noted the similarity in distribution 
of prolactin and ACIH immunoreactivity throughout the rat brain. Adren-
alectomy and hypophysectomy have been reported to produce no effect on 
levels of prolactin in the hypothalamus. 
A direct effect of prolactin on the CNS is suggested by reports 
that impotence present in males with hyperprolactinemia and normal tes-
tosterone concentrations may be corrected by lowering the prolactin con-
centrations by bromocryptene administration (Carter et al, 1977). Little 
else is known of the effect of prolactin on the CNS, as there is of the 
finding of TSH in extrapituitary tissues. 
r. Thyroid stimulating hormone (TSH). 
As long ago as 1967, using a bioassay, Bakke et al reported the 
presence of TSH in the rat median eminence, which was apparently inde-
pendent of circulating TSH levels. In more recent findings, Moldow et al 
(1978b) attributed the presence of TSH outside the pituitary to retrograde 
flow from the pituitary. Further investigation into these observations 
will be particularly considered in this dissertation as will the locating 
and biochemical characterization of radioinnnunoassayable growth hormone-
like material in the CNS. 
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s. Growth Hormone (GH) 
Pacold et al (1976) were the first to report the finding that dis-
persed rat brain cells grown under standard tissue culture conditions 
produced an immunoassayable growth-hormone-like material, indicating the 
possibility that GH could be added to the growing list of brain peptides. 
The continuance of these observations, together with the finding 
of an innnunoassayable TSH-like peptide in the rat brain, represents the 
thrust of the independent investigations that form the basis of this 
thesis. 
To reiterate, my research has been oriented to the further con-
firmation of the presence of pituitary-like GH and TSH within discrete 
areas of the rat brain. Having developed a substantial background li.ter-
ature review of recent developments dealing with the unusual, if not un-
expected, finding of diverse peptides in the brain, subsequent consider-
ation will deal with my independent investigations dealing with the dis-
tribution of GH- and TSH-like peptides in the rat brain, and with studies 
designed to ascertain the physiological meaning of these novel observa-
tions. 
3. PROPOSED INVESTIGATION 
Specific Objectives 
The distribution in the rat and primate brain of the anterior 
pituitary hormones, growth hormone, and thyroid-stimulating hormone will 
be studied. Experimental work will involve the development of working, 
sensitive, and specific radioimnumoassays for two rat hormones, TSH and 
GH. Another line of approach will be the development of primary cell 
cultures of neuronal tissue from various brain regions and the use of 
imnnmohistochemical staining techniques to further characterize the dis-
tribution of pituitary-hormone-like material in the adult rat brain. 
Ultracentrifugation of brain homogenates will determine the association 
or lack of association of the hormones with a particular brain fraction, 
either nuclear, mitochondrial .. synaptosomal, or microsomal. Also to be 
examined will be the ontogenetic developmental pattern of these hormones 
in fetal, neonatal, and adult brain regions. 
In an effort to determine the similarities or dissimilarities be-
tween pituitary and brain hormones, a part of this study will attempt to 
characterize biochemically and biologically the brain hormones. Using 
gel chromatography, the molecular weights will be determined, parallelism 
studies with the radioimml.llloassy will examine imml.lllological similarities, 
and bioassays will show the extent of biological activity of brain hor-
mones as compared to hormones of pituitary origin. 
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Although it appears unlikely that these brain-based hormones could 
be of pituitary origin, one aspect of this investigation will be to test 
that concern. This will be accomplished by examining the intactness of 
the blood-brain barrier to circulating radiolabelled pituitary hormones. 
Furthermore, the use of hypophysectomized animals will provide the 
opportunity to compare levels of brain hormones in animals with and 
without an intact pituitary gland. In other studies, neural cells from· 
hypophysectomized rats will be cultured in monolayers to test their 
ability to release GH and TSH hormone in vivo. 
If two distinct pools of hormone, brain and pituitary, exist, 
these may turn out to be regulated in different ways. In an attempt to 
discern these interrelationships, experiments such as endocrine target 
organ ablation studies will be undertaken in order to understand this 
problem and its ramification. 
From these different study areas it is hoped that the objective of 
this work will gain some insight into the physiological implications in-
volved in the finding of pituitary-like hormones in discrete areas of 
the rat brain. 
4. MATERIALS AND METHODS 
A. THE DEVELOPMENT OF RADIOIMMUNOASSAYS (RIA) FOR RAT GROWTH HORMONE 
AND THYROID STIMULATING HORMONE 
The radioimmunoassay, as introduced by Yalow and Berson (1959) for 
the measurement of serum insulin concentrations, is a method of detect-
ing trace concentrations of any substance that can serve as an antigen. 
Based on competition for antibody; directed against the antigen; 
between a standard amount of radioactive antigen, C*, and its unlabeled 
counterpart C, at unknown concentration in the test sample (Fig. 5). The 
higher the concentration of unlabeled competitor, the lower the ratio of 
bound C* to unbound C* which can be measured. Separation of bound from 
unbound C* can be achieved by the precipitation of bound labeled and 
unlabeled antigen by a second antibody directed against the antibody 
moiety of the immune complex, and measurement of the radioactivity rep-
resenting bound C* in this precipitate. The higher the concentration of 
unlabeled competition, the lower the ratio of bound C*, (B) to unbound C* 
(Bo). 
In order to determine the concentration of unknown C in a sample 
of blood, urine, or tissue extract, the amount of competitive inhibition 
observed in the unknown is compared with that obtained in separate solu-
tions to which known amounts of purified C is added. A standard curve 
plotting the known concentrations of C against the ratio of bound to 
unbound C* can thus be obtained (Fig. 6), and the level of unknown C in 
a sample determined by its ratio of bound C* to unbound C*. 
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Fi~ure 5. Schematic diagram illustrating the principle 
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Basic requirements for a radioimmunoassay therefore include a spe-
cific antigen-directed antiserum; a radioactive-labeled, purified antigen; 
appropriate standard reference preparations of the antigen, and a method 
for the clear, clean and consistent separation of antigen-antibody com-
plexes from the unbound fraction. 
In the double antibody method of separation, which was selected for 
the RIA's for rat GR and TSH in this study, the first antibody, which is 
specific to the antigen to be determined, is added at a level that en-
hances competition between labeled and unlabeled antigens or ligands. 
That is, the antibody/antigen ratio corresponds to the antigen-excess side 
of the equivalence zone in a liquid precipitin reaction (Fig. 7). The 
second antibody (anti-antibody) is introduced in excess to ensure complete 
precipitation of the first antibody and its complexes with antigen, that 
is, the antibody-excess side of the equivalence zone of the curve. The 
method of RIA is exceedingly discriminating because of the possibility to 
choose antisera with great specificity and sensitivity for the test activ-
ity. 
I. THE RAT GROWTH HORMONE RAD IO IMMUNOASSAY 
a. Production of specific antiserum to rat growth hormone. 
The larger molecular weight protein hormones, such as growth hormone 
(GH) and thyroid-stimulating hormone (TSH), generally elicit a good anti-
genic response, and it was therefore decided to produce our own rat growth 
hormone antibody from guinea pigs. Since a very pure antigen is 
ANTIBODY EXCESS EQUIVALENCE 
ANTIBODY 
PRECIPITATED 
ZONE _. ~ZONE,.. 
ANTIGEN ADDED 
ANTIGEN EXCESS 
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Figure 7. Precipitin curve for a monospecific system: 
one antigen and the corresponding antibody. 
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radioactively labeled and used as the radioactive tracer in the RIA, the 
presence in the antibody preparation of other antibodies does not inter-
fere with the reaction between labeled antigen and its antibody (Straus 
et al, 1977). It is therefore possible to use a relatively impure anti-
gen, in this case growth hormone, for immunization. Extraction and iso-
lation of crude rat pituitary GH was accomplished using a modification of 
the method of Stroud et al (1973). Approximately 50 rat pituitaries were 
removed from decapitated animals, weighed, and homogenized in a 3:2 mix-
ture of 10% annnonium acetate and 96% ethanol. The mixture was stirred 
for two hours at 4° C, centrifuged for 20 minutes at 2000 rpm at 4° C , 
and the supernatant decanted off. The residue was stirred overnight in 
30 mls of O.lN NaOH, pH 10.0. After adjustment to pH 8.4 with 4N HCl, 
the slurry was stirred for 30 minutes and then centrifuged for 15 minutes 
at 3000 rpm at 4° C. The supernatant was reserved, and the residue re-
extracted overnight with O.lN 0 NaOH, pH 10.0 and centrifuged at 4 C , 
after which the supernatants were pooled. 
Using 4N HCl, the pH of the pooled supernatants was adjusted to 4.8 
and stirred for 30 minutes. The heavy precipitate that formed was removed 
by centrifugation for 15 minutes at 3000 rpm at 4° C and the supernatant 
reserved. The precipitate was then dissolved in O.lN NaOH and the solu-
tion adjusted to pH 4.8 by addition of 4N HCl and stirred for 30 minutes. 
After centrifugation, the precipitate was discarded and the supernatant 
combined with the previous pooled supernatant. The volume of the resul-
tant solution was measured and 96% v/v alcohol, cooled to -30° C, was 
added slowly to give a final alcohol concentration of 25% v/v. After 
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stirring for a further 30 minutes, the precipitated crude growth hormone 
. 0 
was collected by centrifugation for 15 minutes at 3000 rpm at 4 C. A 
total of twelve guinea pigs each received 0.5 ccs of crude Bordatella 
pertussis vaccine (E. Lilly Corp., Indianapolis, Indiana) intradermally 
into 30-50 sites over a small area of their backs. 
Twenty-four hours later, each received, subcutaneously, approxi-
mately 1 mg of the crude rat growth hormone, prepared as described 
above, dissolved in 0.5 ccs of saline together with an equal volume of 
complete Freunds adjuvant (Difeo). Five subsequent similar booster im-
munizations were given with this crude extract over a five-month period, 
Within 10 days of each injection, the guinea pigs were bled from 
a leg vein and serum collected for evaluation of antibody "titre", which 
reflects the binding affinity of the antibody to labeled antigen. The 
"sensitivity" of the antiserum was judged as the ability of small amounts 
of unlabeled hormone to displace the radioactive labeled hormone, and the 
"specificity" or degree of cross-reactivity of an antiserum to one hor-
mane with other closely related hormones was examined. 
Effective competition upon addition of unlabeled hormone occurs 
only under conditions of limited antibody, and in the RIA, that amount 
of antibody which shows a binding of 35%-50% of labeled hormone is usually 
chosen, depending on the levels of unknown hormone to be measured. Where 
levels of unknown hormone to be measured are expected in the lower range, 
35% binding conditions are used, as they are known to give a more sensi-
tive standard curve for the lower concentrations of standard hormone. 
In order to determine the best titre of antibody for a sensitive assay, 
a level of 35% binding of labeled hormone was therefore set for testing 
the individual test bleedings for antibody titre. 
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Dilutions of antiserum were prepared from 1:1000 to l;l,000,000, 
and the binding and dissociation characteristics of radiolabeled purified 
growth hormone were examined, as shown for 5 different animals at one 
test bleeding (Fig. 8}. Antibody binding characteristics not only varied 
between animals but between bleedings from the same animal. Serum from 
guinea pig 11, at a dilution of 1:65,000, was eventually selected for the 
growth hormone RIA on the basis also of the "sensitivity" of this parti-
cular antiserum. 
The "sensitivity" of a particular antiserum was assessed by adding 
graded amounts of purified standard GH and testing their ability to dis-
place the radiolabeled hormone under the conditions of our radioimmuno-
assay. If a standard curve was too flat, the antiserum was rejected as 
being "non-sensitive". A "sensitive" curve was one with a steep fall in 
the range of hormone concentration expected from our samples. 
The "specificity" of the antibody from guinea pig 11 was evaluated 
by examining the degree of cross-reactivity with other molecules similar 
in their primary structure to GH, such as rat prolactin. A standard curve 
using growth hormone antiserum #11, radiolabeled GH, and known quantities 
of purified prolactin showed that less than 1% of the purified prolactin 
was being measured. The antiserum to GH from #11 guinea pig was there-
fore sensitive and specific and could be used in a radioimmunoassay. The 
second essential ingredient of an RIA is the radiolabeled hormone. 
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Figure 8. Determination of titer of G.H. antibody binding 
35% of the total radiolabelled G.H. antigen from 
one test bleeding of five guinea pigs (12/18/78). 
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b. Radioiodine labeling procedure for rat growth hormone. 
125r has proved to be the radioisotope most suitable for labeling 
peptides. The labeling reaction consists of substitution of radioactive 
iodine, produced by iodide oxidation in the presence of protein, for the 
tyrosine in peptide linkages. 
The chloramine-T technique of isotope labeling deve.loped by Hunter 
et al (1962) was used. This method produces radiolabeled GH with a high 
specific activity, that is, with a high amount of radioactivity per amount 
of hormone, while using smaller amounts of isotope than other techniques. 
This is important, as to achieve maximum sensitivity the concentration of 
labeled antigen 1IlUSt be kept below the minimum concentration of antigen 
to be measured. Rat GH was obtained from the NIA.MDD Pituitary Hormone 
Distribution program through Dr. A. F. Parlow. 
In this method, radioiodide is oxidized at pH 7.6, with chloramine-
T to iodine, which in turn iodinates 
residues, specifically. 
the protein's tyrosyl and histidine 
The unreacted radioiodine is reduced to iodide by the addition of 
sodium metabisulfite to the reaction mixture, and albumin is added to 
protect the hormone from further radiation damage by a mechanism not 
entirely clear. The labeled protein is innnediately separated from un-
labeled iodide and damaged protein fractions to protect the labeled hor-
mone from further radiation damage. This separation is achieved using 
gel filtration on coarse Sephadex G-50. 
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(i) Labeling Procedure. 
Lyophilized, purified growth hormone was obtained from the NIAMDD, 
Bethesda, and 100 µg was weighed out and dissolved in 10 µl O.OlN NaOH 
and 90 µl distilled water. This was aliquoted in 20 µl amounts and stored 
0 
at -70 C. 
At all times, adequate radiation safety procedures were ob-
served and the iodination procedure carried out under a hood to avoid 
contamination of the surrounding area by volatilized material. Iodina-
tion was perforoed in a glass vial 5 cm x 0.5 cm by addition of reagents 
in the following order: 
1. 20 µl GH (purified from NIAMDD), 
2. 50 µl Phosphate· buffer. 0.5 M pR 7~6. 
3. 125 10 µl I, approximately 1 m curie (New England Nuclear, 
Boston, Mass.). 
4. Mixed well. 
5. 10 µl Chloramine-T solution (35 mg Chloramine-T, Eastman 
Kodak, Rochester, N. Y.) in 10 ml freshly prepared 0.05 M 
P04 buffer, pH 7.6). 
6. 45 seconds contact by swirling. 
7. 15 µl Sodium metabisulfite solution (75 mg sodium meta-
bisulfite, Fisher Scientific, New Jersey) in 10 ml freshly 
prepared 0.05M P04 buffer, pH 7.6. 
8. 100 µl 2"'."'5% bovine serum albumin (Miles Laboratories, Inc., 
Elkhart, Ind.) in 0.05 M P04 buffer~ pff 7.6 .. 
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This mixture was then transferred to a freshly prepared Sephadex G-50 
coarse 0.9 x 20 cm plastic column (Pharmacia Fine Chemicals, Uppsala, 
Sweden) , which had previously been coated with a few drops of 22% bovine 
serum albumin (BSA). The column was eluted with 0.075 M veronal buffer, 
pH 8.6, and 15 drop fractions were collected in albumin-coated glass 
tubes. The two tubes showing the highest radioactivity in the first peak 
were saved, diluted with 10 ml 1% BSA, 0.01 M phosphosaline buffer, pH 7.4, 
and stored in 1 ml amounts at -20° C. The stability of this iodinated 
growth hormone could be maintained for approximately 4 weeks. After this, 
there was an increase in free radioactive iodide indicating a breakdown 
of the labeled hormone, perhaps due to radiation damage. An approximate 
specific activity between 90-110 mC/mg was obtained by this procedure. 
Prior to setting up each radioimmunoassay, the labeled rat growth 
hormone was repurified using a Sephadex G-100 column 0.9 x 50 cm. The 
Sephadex was first equilibrated with 0.075 M veronal buffer and approx-
6 imately 1 ml containing 1 x 10 cpm labeled hormone applied. One ml 
fractions were collected and the top two tubes of the second peak used 
for the assay. The labeled hormone was immediately diluted in 0.01 M 
"working" phosphosaline buffer, pH 7.4, to approximately U,000 cpm/ 
100 µl. 
Solutions Used in Labeling Procedure for Rat GH 
Phosphate Buffer 
Stock solution, 0.1 M 
24.2 g Na2HPo4 7H20 
2.62 g NaH2Po4 H2o 
Distilled H2o to 1 litre, pH 7.6 
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Working solution: 1% BSA, phosphosaline buffer 
(0.15 M NaCl, 0.01 M P04), pH 7.6 
5.14 gm NaH2Po4H2o 
26.6 gm NaCl 
22.7 mls of 22% BSA/litre 
0,1% Thimerosol (Sigma) 
Final volume, 3.0 litres, pH 7.6. 
Veronal Buffer 0.075 M , pH 8.6 
292 g Sodium diethyl barbiturate (Fisher). 
52.44 g Barbituric acid (Fisher) 
4 liters distilled Rio 
Heat to dissolve 
Make up to 19 ·litres 
Stored at 4° C 
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c. Preparation of GH standards. 
For validation of the RIA procedure, the unknown GH substance to be 
assayed must be immunochemically identical with the substance used as an 
antigen standard. For this purpose, lyophilized reference preparations 
of rat growth hormone were obtained from the NIAMDD, the stock standard 
solutions were prepared as follows: 
100 µg was weighed using a Mettler balance, dissolved in 
100 pl 0.01 N NaOH, and made up to 1 ml with 0.01 M phos-
phate buffer, pH 7. 6. 
Aliquots of 50 µl containing 5 µg were then stored at -20° 
C for up to 6 months without loss of activity. 
The standard curve for a RIA was made up using the following dilutions of 
stock hormone as growth hormone standards in working phosphosaline buffer, 
pH 7. 6: 
50 µl stock + 2.5 cc buffer = 2000 ng/ml 
Standard 9 == 100 ng/ml 
Standard 8 = 50 ng/ml 
Standard 7 == 40 ng/ml 
Standard 6 == 20 ng/ri:il 
Standard 5 = 10 ng/ml 
Standard 4 = 8 ng/ml 
Standard 3 = 5 ng/ml 
Standard 2 = 4 ng/ml 
Standard 1 .. 2 ng/ml 
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d. Separation of bound and free antigen in the GH RIA. 
In a radioimmunoassay, the labeled peptide-antibody complexes are 
generally soluble, and some technique must be employed to distinguish 
between the bound and the unbound labeled peptide. One of the most 
accepted and least troublesome methods is that depending on precipita-
tion of the complex with an antibody directed against the r globulin of 
the first antibody in the complex, the "double antibody" method. The 
precipitate formed is isolated by centrifugation. After several trial 
runs, a 1:10 dilution of goat anti-guinea pig IgG (Pel-Freeze) was found 
to give the optimum degree of precipitation in the RIA for GH. 
e. Assay protocol. 
The final protocol for the rat growth hormone double antibody RIA 
was as follows, and the assay was incubated throughout at 4° C in 12 x 75 
mm glass tubes. All samples were run in triplicate with individual non-
specific binding controls (NSB). 
DAY 1 100 pl GH antibody 1:65,000, produced in guinea pig, made as 
follows: 
(1) 10 µl stock GH antibody in 6.5 ml working P04 buffer + 
5 µ1/ml normal guinea pig serum (Miles Laboratories, 
Elkhart, Indiana) 
or 
100 µl non-specific binding buffer, made as fallows: 
5 µl normal guinea pig serum/! ml working P04 buffer. 
DAY 5 
DAY 7 
(2) 100 µl standard or unknown. 
(3) 125 100 µl I GH, 12,000 cpm. 
(4) 100 µl goat anti-guinea pig serum, 1:10. 
(5) 200 µl working P04 buffer. 
Incubation for ~ hours at 4° C. 
(6) 1 ml ice cold saline. 
Centrifugation for 30 minutes at 2,200 rpm using an 
IEC 418 head in a refrigerated IEC Model PR-6000 
centrifuge. 
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The supernatant was decanted and the precipitate counted in a Micromedic 
System 2/200 automatic gamma counter. 
f. Treatment of data obtained from the GH RIA. 
Calculation of data was handled using a Hewlett-Packard Clinical 
Laboratory Radioimmunoassay computerized program cassette with a Hewlett-
Packard Model 7830A calculator and printout. This program performed a 
weighted and unweighted least squares regression analysis using the log 
of dose vs. % bound, legit of % bound, probit of % bound, and arcsin of 
% bound. The "best fit" of these linearizing transforms was automatically 
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selected and all useful standard curve statistics and plots were outputted 
to verify acceptability of each dose response variable. 
Typical data processing of standards and unknowns are seen in 
Figs. 9 - 13. In Fig. 9, the standard curve data is shown as the total 
amount of cpm of tracer present per tube, and nonspecific binding (NSB) 
as cpm/tube, representing the bound antigen. The concentration in GH 
ng/ml of each set of three tubes per standard is given plus the cpm in 
the bound fraction for each standard assayed. Fig. lOa illustrates the 
computer's assessment of the correlation, or how this data best fits a 
straight line, using different ways of handling the data such as "Logit," 
"Probit," and "Arcsin." In this case, Logit was chosen as the best fit, 
and a weighted regression was performed on the data of the standard curve 
as shown in Fi~. lOb. The coefficient of variation for each point in this 
assay was acceptable, i.e. under 10%, and Logit transformation was used to 
plot the curve, shown in Fig. 12, from which the unknown samples were 
calculated, as in Fig. 12. Fig. 13 shows the standard curve plotted 
using the data B/B0 vs. ng GH/ml. The "sensitivity" of this assay ap-
peared good over the range of 2-100 ng of growth hormone. 
g. Validation of the GH radioimmunoassay. 
After the reagents were obtained and the method established, it was 
necessary to validate the RIA of GH in brain extracts. Primarily, assay 
validation consists of a demonstration that the assay is measuring what 
it is designed to be measuring, in this case, rat growth hormone. Mul-
tiple dilutions of brain extract and pituitary extract should give lines 
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RGH 6SD 
3/6/79 TECHHOLOGIST s. 1-0JIIAT 
TOTALS (CPI1) 
11586 
11599 
11725 
TUBE NO. CONCENTRATION CPM 
IH HG/ML 
1 HSB 410 
2 HSB 333 
3 NSB 309 
4 0 4034 
5 0 4116 Bo 
6 0 4194 
7 2 3987 B s 2 3951 
9 2 3790 
10 4 3522 
11 4 3574 
12 4 3730 
13 5 3542 
14 5 3589 
15 5 3612 
16 8 3203 
17 8 3326 
18 8 3351 
19 10 3263 
20 10 3167 
21 10 3141 
22 20 2273 
23 20 2416 
24 20 2408 
25 40 1398 
26 40 1403 
27 40 1425 
2C 50 1174 
29 50 1•)73 
30 50 1080 
31 100 764 
32 1(19 743 
:::~: 100 70::) 
Figure 9. Computerized output of G.H. standard curve. 
ASSAY: RGH 68D 
3/6/79 TECHNOLOGIST S. ~OJVAT 
~IODEL rNTERCEPT SLOPE CORRELATION 
========================================================= 
F:ftH DATA 
LOG IT 
PRO BIT 
APSS!t·! 
1.257956973 
4.034257617 
7.430118155 
1.431518075 
-0.599259583 
-3. 134433938 
-1.876054213 
-0.699741408 
BEST FIT FOR RGH 68D IS LOGIT 
~IE I GHTED REGRESS I ON. 
Figure lOb. 
ASSAY RGH 68D 
3/6/79 TECHNOLOGIST S. ~OJVAT 
DOSE 8/BO STD. DEIJ. 
0.00 1.0000003 0.0213562 
2.00 0.';1454481 0.0279642 
4.00 0.8655685 0.0288450 
5.oa 0.8582182 0.0095649 
8.00 0,?817924 0.0211258 
10.20 0.7544279 0.0171477 
20.00 0.5353348 0.0214009 
40.00 0.2810840 0.0038443 
50.00 0.2014701 0.0150043 
100.00 13.1028162 0.0078120 
v LOG IT TRANSFOI'M 
" 
2 2.933497406 
4 1 • 8785615729 
5 1.80200039 
8 1 • 278911 035 
10 1.123850082 
20 0.141728422 
~-0 
-0.939142958 
5(i 
-1. 378:?.1 0207 
lOll 
-2.168243684 
0. 989075873 . 
0.997675286 
0.996794585 
0.972278768 
VARIANCE STD ERROR 
0.0004561 0.0123300 
0.0007820 0.0161452 
a.oea832a 0.0166536 
0.0000915 0.0055223 
0.0004463. 0.0121970 
0.13002940 0.01399002 
0.0004580 0.0123558 
0.0003148 0.0022195 
0.0002251 0.0086627 
0. 000061 ~J 0.0045102 
10'3 
C. JEFF OF YAR 
2.1356199 
2.9577765 
3.3324872 
1.1145030 
2.7022286 
2.2729378 
3.9976582 
1.36768513 
7.4474094 
7.5979873 
Figure lOa. Best fit analysis for growth hormone standard 
curve data. 
Figure lOb. Weighted regression analysis of G.H. standard 
curve. 
ASSAY RGH 681> 
3/6179 TECHNDLDGIST 5. HDa.JVAT 
~ 1.11 :r 
X LDBIT Y • '1 .... • ( :J, Ul'l) 
II • I .18711'1E2118 Ull ••• 
~ 
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~ ~ X X 15:1 
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-2 
X 
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Figure 11, Growth hormone standard curve plotted as B/Bo vs (ng/ml), 
Figure 12, Gro\vth hormone standard curve p 1·o t te.d as logi t vs ( ng /ml) , 
Figure 13. Calculation of growth hormone content of 
unknown samples. 
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parallel to the standard curve line of purified pituitary rat growth 
hormone, which would indicate immunological similarities between the 
brain and pituitary hormones. Physiological changes in the rat's cir-
culating GH levels are brought about by hypophysectomy. These changes 
should be reflected in pre- and post-surgical serum samples, and were 
found to be distinguishable by this rat GH RIA. Another method of con-
trolling and detecting interassay variation is the use of internal 
standards of pooled brain extract in each assay performed. A possible 
error source frequently encountered in RIA's are "false positive" 
measurements due to damage of the labeled antigen during the iodination 
process, or by enzymatic breakdown by tissue homogenates, which leads to 
a reduction in bound labeled hormone and a misinterpretation of these 
low counts,so obtained,as indicative of large amounts of growth hormone 
in the sample. 
Recovery studies were therefore performed in order to test the 
assay for this type of error. Purified rat growth hormone was added in 
graded, known amounts to brain extracts in triplicate, each sample with 
its own nonspecific binding control (NSB). These NSB tubes, generally 
run in duplicate, contained no first antibody in order to detect the 
binding of labeled antigen nonspecifically to the walls of the assay 
test tube or to some protein, for which it has a nonimmunological affinity, 
and which is present in the sample. 
As shown in Table 1, the detection of added known amounts of puri-
fied GH was approximately 100% from this growth hormone RIA, indicating 
no change in the hormone molecule or to the destruction of the labeled 
107 
TABLE 1 
RECOVERY OF ADDED AMOUNTS OF REFERENCE PREPARATION GH 
IN NORMAL BRAIN HOMOGENATE 
Recovery 
- ng added. GH obtained (0) expected (E) 0/E x 100 
0 8.0 = amount of hormone indigenous to 
brain homogenate 
2 11.9 10.0 119.0% 
4 16.6 12.0 138.3% 
5 11.9 13.0 91.5% 
8 16.2 16.0 101.3% 
10 13.9 18.0 77.2% 
20 24.3 28.0 86.8% 
40 60.7 48.0 126.5% 
50 63.2 58.0 109.0% 
100 127.5 108.0 118.1% 
Average 107.5% 
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growth hormone by brain homogenate. From previous "specificity" studies 
and the "recovery" studies of purified GH, it seemed that this RIA, as 
developed for rat GH, was a valid assay and the results were not sub-
jected to any artifactual problems. 
The radioimmunoassay to detect thyroid-stimulating hormone in brain 
homogenates was developed in a similar way to that of GH and will be 
described in detail in the section to follow. 
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II. THE RAT THYROID STIMULATING HORMONE RADIOIMMUNOASSAY 
a. Antibody to TSH. 
For this assay, antiserum to rat TSH, prepared in rabbits, was 
obtained from Dr. Parlow, NIAMDD. This was stored as a 1:10 dilution 
at -70° C in a phosphosaline EDTA buffer (0.01 M P04 , 0.15 M NaCl) with 
0.05 M EDTA and 3% normal rabbit serum, pH 7.6. For the TSH RIA, a 
dilution of antibody 1:15,000 in the same buffer was found to give the 
most sensitive assay. 
b. Radioisotope Labeling Procedure for Rat TSH. 
A purified rat TSH was obtained from NIAMDD and stored in 20 pl 
aliquots containing approximately 5.0 pg of hormone in 0.01 M phospho-
saline buffer, pH 7.6 at -70°C. The Chloramine-T oxidation method was 
again successfully employed for labeling of TSH with radioactive iodine 
(Hunter et al, 1962). The procedure was carried out using similar radia-
tion safety measures as that of GH and was as follows: 
1. 20 ~1 stock rat TSH (5.0 pg, NIAMDD). 
2 10 1 125 I · 1 1 . (N E 1 d N ) • p - approx~mate y m cur~e ew ng an uc. 
3. 25 ~1 P04 buffer, 0.05 M, pH 7.6. 
4. 10 pl Chloramine-T (25 mg Chloramine-T in 10 ml freshly 
prepared 0.05 M P0 4 buffer, pH 7.6). 
Mixed for 40 seconds. 
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5. 25 ~1 Sodium metabisulfite (25 mg sodium metabisulfite 
in 10 ml freshly prepared 0.05 M P04 buffer, pH 7.6). 
6. 50 ~1 0.4% KI (Fisher). 
This mixture was then transferred to a Sephadex G-50 coarse, 0.9 x 20 em 
plastic column, coated with bovine serum albumin, and eluted with 0.01 M 
phosphosaline buffer, pH 7.6. Fifteen-drop fractions were collected 
in 16 x 100 em glass tubes, and those tubes showing the highest radio-
activity in the first peak were diluted in 0.01 M phosphosaline, 1% albu-
min buffer, pH 7.6, pooled and stored in lml aliquots at -20° C. The 
stability of this iodinated TSH was for approximately two weeks at this 
temperature. 
Repurification of labeled hormone was performed the day of an assay 
using a Concanavalin-A, Sepharose column (Pharmaci~ Fine Chem.). The 
principles behind this method of purification of TSH are described brief-
ly here. 
"Affinity chromatography" using Con-A Sepharose is a well established 
preparative technique which can be used for isolating glycoproteins which 
contain aD-glucose or aD-mannose residues. In such a procedure, glyco-
proteins in a sample are washed into the column and are retained due to 
their affinity for the lectin, Concanavalin-A, which has been previously 
immobilized on the Sepharose beads. These glycoproteins can now be sep-
arated from other proteins in the sample which are not retained on the 
beads. After a thorough washing of the column with a phosphosaline buf-
fer to remove any traces of non-glycoprotein, the bound glycoprotein may 
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be eluted off the column by 1-0 methyl-=<D-glucopyranoside, pH 9.0 (Shore 
et al, 1973). The glucopyranoside competes with bound glycoprotein for 
Con-A binding sites and at sufficient concentration can remove all glyco-
protein from the ligand. 
The following procedure, adapted from the method of Patritti-Laborde 
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et al (1979), was employed to recover repurified I TSH using a small 
Con-A Sepharose column, 0.9 x 19 em. Glass wool was placed on the scin-
tered glass disc at the base of the column and the gel poured to a height 
of 9 em. The column was then washed continuously with 20 mls of 0.5 M 
phosphosaline, 1% BSA buffer, pH 7.6, and then approximately 1 ml of 
freshly 125 I labeled purified TSH applied. The column was then washed 
with 60 ml of 0.5 M phosphate buffer and the radiolabeled bound glyco-
protein TSH, subsequently eluted with 0.2 M 1-0-methyl~-glvcopyrano-
side (Sigma Chemical Company, St. Louis, Missouri) in 0.5 M phosphosaline 
buffer, pH 7.6. 
Three ml aliquots were then collected in 16 x 100 em glass tubes 
and the two peak radioactive tubes pooled and diluted to yield approxi-
mately 9,000 cpm/100 pl in "TSH buffer." The specific activity of the 
125 I l.;ilieled TSH ranged from 80-95 mC/mg. 
Solutions: 
Phosphate buffer - 0.5 M 
6.9 gm NaH2P04 H20 in 100 ml 
7.1 gm NaHP04 in 100 ml 
1:9 monobasic to dibasic, pH adjusted to 7.6. 
0.05 M P0 4 = 0.5 M diluted 1:10 with distilled H2o. 
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"TSH buffer" = 1% BSA, 0.01 M phosphate, 0.15 M saline. 
2 mls 0.5 M phosphate buffer 
100 mls 0.155 M saline (9g NaCl/litre) 
4.5 mls 22% BSA 
pH 7.6 
c. Preparation of TSH Standards. 
Rat TSH reference preparations from NIAMDD were stored as 10 ~g 
0 TSH/100 Jll of "TSH" buffer in aliquots at -20 C. Standards were pre-
pared by double dilution of this stock solution in the same buffer, and 
ranged from Standard 1 = 39 ng/ml to Standard 8 = 5000 ng/ml. 
d. Assay Protocol. 
The rat TSH double antibody assay was run at room temperature and 
required 3 days of incubation in 12 x 75 mm glass tubes. 
DAY 1 
or 
1. 200 Jll TSH antibody, 1:15,000 rabbit anti-rat TSH 
(NIAMDD), made in 3% normal rabbit serum phosphosaline 
EDTA buffer; 
200 ~1 non-specific binding buffer (3% normal rabbit 
serum in phosphosaline EDTA buffer). 
2. 100 Jll standard or unknown. 
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3. 100 ~1 I TSH, 9,000 cpm. 
4. 200 ~1 "TSH" buffer. 
Mixed well. 
113 
DAY 2 5. 100 pl anti-rabbit IgG produced in goat (PelFreeze, 
Roger, Arkansas) 1:10 dilution in "TSH" buffer. 
DAY 3 6 • 1 ml saline • 
The samples were spun for 30 minutes at 2,200 rpm, decanted, and 
the antigen-antibody precipitate counted. 
e. Treatment of Data Obtained from the TSH Radioimmunoassay. 
Data was treated in a similar way to that described previously 
for GH. Typical standard, and logit vs. cone. curves, for the TSH 
radioimmunoassay are given in Figs. 14 and 15. The sensitivity of this 
assay was in the range of 39-5,000 ng/ml. 
f. Validation of the TSH Radioimmunoassay. 
Attempts to validate the TSH assay were similar to those described 
for GH. Cross-reactivity to FSH and LH was less than 0.14%, and recov-
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ery studies using I TSH added in varying amounts to brain homogenates 
showed an average 97.3% recovery (Table 2). 
ASSAY TSH 12E 
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Figure 14,TSll standard curve Ilbtted as B/B ( 1 1) 
_ 0 vs ng rn . • 
Figure 15,TSH standard curve plotted as logit vs (ng/rnl}. 
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TABLE 2 
RECOVERY OF ADDED AMOUNTS OF REFERENCE PREPARATION TSH 
IN NORMAL BRAIN HOMOGENATE 
Recovery 
ng added TSH obtained(O) expected(E) 0/E x 100 
0 266.8 = amount of hormone indigenous to 
brain homogenate. 
39 265.0 305.8 86.7% 
78 348.2 344.8 101.0 
156 389.4 422.8 92.1 
312 548.1 578.8 94. 7 
625 850.6 891.8 95.4 
1250 15 77.3 1516.8 104.0 
2500 2902.7 2 766.8 104.9 
5000 5248.4 5266.8 99.7 
Average 9 7. 3% 
III. RADIOIMMUNOASSAYS FOR GROWTH HORMONE AND TSH IN PRIMATE BRAIN 
HOMOGENATES 
a. Growth Hormone 
A solid phase radioimmunoassay in antibody-coated tubes was set up 
after the method of Catt et al (1967). The principle of this solid phase 
radioimmunoassay is based on the ability of antibody-coated polymers, such 
as plastic test tubes, to bind radioactive tracer antigen. The use of 
antibody in this form is a technique, other than the "double antibody" 
method .• ' for the rapid removal of unbound from bound radioactive tracer 
antigen by washing of the solid phase material with water on completion 
of the immune reaction. The solid phase consists at this point of bound 
radioactive tracer antigen-antibody complexes and competing bound unlabeled 
sample antigen-antibody complexes. This solid phase is then counted, after 
removal of unbound antigen by water, for the quantitation of bound tracer 
which varies inversely with the total quantity of antigen present in the 
original mixture. 
In our assay, one ml of first antibody, anti-human growth hormone 
produced in rabbits and obtained from L. Kirstei~I1S, was used at a 1:1500 
dilution in 0.05 M bicarbonate buffer, pH 9.6, to coat the sides of 12 x 
75 mm plastic tubes overnight at 37° c. An irreversible antibody-polymer 
complex was thus formed. After washing, to remove non-complexed antibody, 
radioiodinated growth hormone (Abbot) was added at a concentration of 
10,000 cpm to each coated tube containing either standard growth hormone, 
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internal controls, or unknown tissue homogenate, plus bovine serum. This 
0 
mixture was incubated at 37 C for 36 hours and, after rinsing, the tubes 
were counted for bound radioactivity. Levels of primate growth hormone 
were calculated for each tissue homogenate as pg/mg wet weight of monkey 
brain and pituitary tissue. The range of this assay was 1 to 100 ng of 
growth hormone. 
b. Thyroid Stimulating Hormone 
Samples of monkey brain were homogenized,and a double antibody 
radioimmunoassay for human TSH was carried out by the late Dr. A. Guan-
sing, Wood Veterans Administration Center, Milwaukee, Wisconsin. The 
data obtained were calculated as pg/mg wet weight of tissue. 
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B. DESCRIPTION AND CARE OF ANIMALS USED THROUGHOUT THIS STUDY. 
Sprague Dawley male and female rats were used for these 
studies. All animals were kept at day/night ambient light and temper-
ature regimes and were fed Purina rat chow with water ad libitum. Preg-
nant female Sprague Dawley rats were housed in separate cages throughout 
pregnancy, and no more than three animals per cage were allowed for other 
studies. 
Hypophysectomized and thyroidectomized rats were purchased from 
Hormone Assay Laboratories, Chicago, Illinois, and were fed a liquified 
rat chow and orange slice diet for the first week post-operatively. 
Animal sacrifice was routinely performed between 8 a.m.-10 a.m. 
using a guillotine. 
C. BRAIN DISSECTION PROCEDURES. 
After allowing at least a one-hour period of acclimatization to a 
new locale, animals were killed by instantaneous decapitation using a 
guillotine, and trunk blood was collected by gravity flow from the 
severed neck. Handling prior to decapitation was kept to a minimum to 
prevent possible anomalous, stress-mediated rises in pituitary hormones. 
To minimize the possibility of retrograde portal blood flow after death, 
the occipital-parietal calvarium was cut away within two seconds of de-
capitation and the frontal lobes of the brain gently lifted in order to 
separate the brain from the pituitary stalk without disruption of the 
diaphragm sellae (Figs. 16 and 17). 
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CORTEX 
.HYPOTHALAMUS 
CEREBELLUM 
Figure 16. Isolated rat brain. 
CORTEX 
\ 
.------.------ \ 
HYPOTHALAMUS 
HIPPOCAMPUS 
Figure 17. Coronal section of rat brain, 
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For tissue extraction studies, the brain was placed rapidly onto 
ice and, using separate instruments, individual brain parts were dis-
sected free and immediately frozen on dry ice to minimize proteolytic 
enzyme activity. Brain parts intended for tissue culture experiments 
were placed directly from the animal into Basal Media Eagles (Gibco, 
Grand Island, New York) at room temperature before further processing. 
Brains from the primate, Macaca mullata, were obtained from the 
Department of Dentistry, Loyola University of Chicago, after a lethal 
pentobarbital dose, dissected, and placed in acetone before extraction 
and hormone analysis. 
For the harvesting of pituitary glands from intact rats and pri-
mates, the diaphragm sella was gently excised and the anterior hypo-
physis lifted from the sella turcica and placed on dry ice. 
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All separately dissected specimens of rat brain and pituitary were 
stored in aluminum foil at -70° C and serum samples at -20° C until ra-
dioinnnunoassayed or bioassayed for the detection of hormone content. The 
method of extracting hormones from brain and pituitary tissues is outlined 
in the next section. 
D. TISSUE EXTRACTION METHODS. 
Individual rat brain parts and pituitaries were thawed at room tem-
perature. The anterior pituitary, hypothalamus, and serum samples were 
assayed individually. However, GH and TSH concentrations in other brain 
regions required pooling tissue from at least five animals in order 
to extract sufficient material to be measured within the sensitivity 
limits of the radioimmunoassay. 
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Fetal animals of appropriate gestational ages were obtained by 
maternal decapitation and hysterectomy. The brains of younger fetuses 
were frozen within six seconds of maternal death. The older fetuses 
were carefully removed from the uterine horns and kept warm and under as 
little stress as possible before decapitation. 
Individual brain parts and pooled material were weighed and homo-
genized in 1 ml of ice cold buffer (PBS O.OlM, pH 7.6) for twenty seconds 
using a Tekmar homogenizer. The samples were spun at 3,000 rpm in a 
refrigerated centrifuge for 30 minutes, supernatants removed, and the 
pellets resuspended in 1.0 ml of cold buffer and stored overnight at 
4° C. Tubes were recentrifuged in the cold and the two supernatants 
pooled. These were either assayed immediately or stored at -70° C until 
the time of assay. 
In addition to being radioimmunoassayed for hormone content, 
materials for assay were thawed and a determination of protein content 
of tissue made on each sample using the method of Wadell (1956). Hormone 
levels for each brain area were determined using the radioimmunoassays 
of rat GH and TSH, and the results were expressed as either ng of hormone/ 
mg wet weight tissue, or ng of hormone/mg protein or ng hormone/total 
brain part. In this manner, the distribution of pituitary-like hormones 
was mapped for the rat brain. A rough mapping of the primate Macaca mu-
lata brain was also determined. 
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E. TISSUE CULTURING OF BRAIN CELLS 
Culture of tissue falls into two broad areas: the use of explant 
cultures of small fragment~ or single cell preparations from tissue dis-
sociated by mechanical or enzymatic procedures. The preparation and 
culture of single cell suspensions was the method of choice for this study 
in which distinct brain areas and pituitary tissue were further tested 
for their ability to release hormone into the growth media. The principle 
behind single cell suspensions, that of removing tissue from the influence 
of the whole organism and placing it in a more defined environment, has 
been validated by the demonstration that neurons in culture can develop 
physiological properties similar to those seen in comparable cells in situ, 
including the formation of new synaptic connections with one another and 
small aggregates (Fischbach, 1972, and Dichter et al, 1975). Some latent 
difficulties are, however, involved in the tissue culturing of nervous 
tissue. Cell division is a limited phenomenon resulting in the inability 
of primary cell cultures to remain viable indefinitely. Furthermore, long 
term subculturing of nervous tissue generally yields a nonfunctioning 
population of cells, as shown by Yasamura (1968). One alternative to 
these problems has been to culture functioning differentiated neoplasms 
which can be serially propagated in tissue culture indefinitely without 
losing functionality, for reasons not fully understood. 
To obtain successful cell separation from primary tissue for tissue 
culture, it is necessary to begin with a suspension of single viable cells, 
relatively free of damaged cells, cellular debris, and red and white blood 
cells. Brain parts and pituitaries are dissected , using sterile instruments, 
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from 30-day-old male rats or 30-60-day-old males who have been hypophy-
sectomized for various ttme periods beforehand. Tissue from approximate-
ly 10 animals is placed in a petri dish containing sterile Basal Medium 
Eagle plus 10% fetal calf serum (Gibco), and cleaned of any adhering 
meninges or connective tissue. To remove debris and red blood cells, 
the tissue is washed four times in sterile media before being cut into 
small 1 mm cubed pieces using two sharp scalpels to avoid tearing. Dis-
sociation is carried out using 10 mls of 0.25% Pronase (Calbiochem-Behring 
Corp., San Diego, California) in an Erlenmeyer flask shaken gently in a 
37° C water bath. Freshly released cells ara harvested at 10-minute in-
tervals and stored at 4° C with an equal volume of growth medium. The 
separated cells are triturated with a Pasteur pipette approximately five 
times and clumps of cells removed by passing the suspension through a 
sterile nylon sieve of 35 micron pore size (Tetko, Inc., Elmsford, N.Y.). 
The cells are spun gently for 10 minutes at 1,000 rpm in a Sorvall GLC-2 
centrifuge at room temperature. After four washes with growth medium to 
remove Pronase, the cells are counted in a Petroff Hauser counting chamb-
er. Viability is simultaneously checked by the trypan blue exclusion 
method, where only dead cells take up the blue due and ther~fore can 
be distinguished from live cells. From 90%-95% viability is generally 
recorded with this methodology. After gentle mixing, the cells are 
diluted up to 10~)~ {iiid 1 ml aliquots plated with 2 mls of growth medium 
2 in plastic tissue culture flasks, 25 em (Falco~ Oxnard, California). 
These flasks and controls containing no cells are then placed in a hori-
0 
zontal position and incubated at 95% humidity, 37 C, and 94% air/6% co2 • 
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The medium is changed every 3-5 days· and the spent medium removed and 
frozen to await radioimmunoassay for both GH and TSH. Cell viability is 
checked at th~s time in each culture. It was determined that results 
obtained from such cultures were markedly altered and variable with 
cultures over 30 days old, and therefore only media harvested by 30 days 
is generally used. Cellular morphology is examined throughout the entire 
30 days. Initially, the nervous tissue is plated as a population of 5-10 
llm spherical cells and after 3-4 days the cells are observed to adhere to 
the walls of the flask. By 8 days, a differentiated population of neurons 
and glia are present which resemble cells from the original tissue (see 
Fig. 18 ) . 
Pituitary cells remained as spherical cells throughout culture and 
became attached to the culture flask after 3-4 days. 
A mouse neuroblastoma cell line, N4TGI, was obtained from Dr. R. 
Miller, University of Chicago, and cultured in a similar fashion to that 
described for primary tissue. The medium from such cultures was tested 
for immunoassayable GH and TSH. Cells from these cultures were also 
homogenized and extracted, as previously described for other tissues, and 
the supernatants analyzed for their hormone content by RIA. 
Pooled samples of media from actively growing cultures of this cell 
line were lyophilized and reconstituted in 1 cc of 0.01 M phosphate buf-
fer, pH 7.6, before elution on a Sephadex G-100 column to test the mole-
cular identity of the immunoassayable TSH-like material. 
--------
Figure 18, Representative samples of 10 day old nervous 
tissue culture obtained from the amygdala of 
adult rats. 
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Somatostatin, 1 ~g/ml (Bachem Inc., Marina del Ray, California, 
90201), and 1-thyroxine, 1 ~g/ml (Sigma) can be added to selected pri-
mary, neural, and pituitary cultures to observe any possible regulatory 
mechanisms governing GH and TSH release from monolayered cells in tissue 
culture. 
Data from all tissue culture experiments are expressed as the aver-
age amount of hormone present/ml of medium taken from five individual Fal-
con flasks. The amount of hormone found intrinsically in the medium, due 
to the serum content, can be determined from the controls containing no 
cells and subtracted from all results obtained from flasks containing cells. 
Solutions used for tissue culture experiments involving brain and pitui-
tary tissue: 
Phosphosaline buffer 7.4 (PBS) 
8.0 g NaCl 
0.2 g KCL 
2.0 g Na
2
HP04 
0.4 g K H2Po4 
pH adjusted with 7.5% sodium bicarbonate (Gibco) 
Pronase solution 
1.25 g Pronase (Calbiochem) 
500 m1 PBS 
0 Mix and allow to stand 30' RT • 
Centrifuged for 10 minutes and sterilized by filtration 
(Millipore, Filter Corp., Bedford, Mass., 0.22 pore size). 
0 Store at -20 C in aliquots. 
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Trypan Blue 
1 ml Trypan Blue (Gibco) 
3 ml Growth Medium 
Filter before use. 
Growth Medium 
100 ml Basal Medium Eagle + 10% Fetal Calf Serum (Gibco) 
1 ml L-glutamine, 200 mM (Gibco) 
1 ml MEM non-essential amino acids, 10 mM (Gipco) 
0.1 ml Gentamicin Sulfate, 5 mg/ml (Sigma) 
pH adjusted with 7.5% sodium bicarbonate to 7.4. 
F. SUBCELLULAR FRACTIONATION OF BRAIN HOMOGENATE TO DETECT THE LOCALIZA-
TION OF PITUITARY-LIKE HORMONES IN THE BRAIN 
Subcellular fractions of brain homogenates were prepared by dif-
ferential centrifugation, as outlined in Fig. 19 . 
In a typical preparation, 10 adult male rats are sacrificed by 
decapitation, their brains rapidly removed and the hypothalamus, amyg-
daloid nucleus, and thalamus immediately dissected and separated out at 
4 ° C. Homogenization is accomplished for each pooled brain part in 1 ml 
ice-cold 0.32 M sucrose, 10 ]..lM Cac12 , pH 7.4, by 12-15 up and down strokes 
using a glass teflon homogenizer, 0.22 ]..lm clearance, driven at 800 rpm. 
The homogenates are sedimented at 1,000 g for 15 minutes in a Sorvall 
RC SB refrigerated centrifuge. Supernatant, s1 , is removed and the 
pellets, P1 , resuspended in 0.01 M phosphosaline buffer, pH 7.6, for 
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Brain Homogenate 
0.32 M sucrose, 10 ~M CaC12 
1000 x g (10 minutes) 4° C 
Precipitate 
I 
washed 
I washings added to supernatant 
p tl---~-_____.._~ 
1 sl 
Nuclear 20,000 x g (20 min.) 4° C 
Precipitate 
I 
washed 
p2 
Synaptosomal 
Precipitate 
I 
washed 
washings added to supernatant 
s2 
150,000 x g (60 min.) 4° C 
I washings added to supernatant ! 
p3 J~--__.;;;__ _ _...;;__---t 
Microsomal 
Fig. 19 
s3 
Soluble 
Fractionation Scheme utilized to determine the growth hormone content 
of subcellular fractions of rat brain. 
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radioimmunoassay. Pellet, P1 , contains cellular debris, nuclei, and some 
myelin. Supernatants, s1 , are sedimented at 20,000 g for 20 minutes in a 
FA 65 rotor using a Beckman LS-65 preparative ultracentrifuge. The second 
pellet, P2 , primarily contains synaptosomes, mitochondria, and myelin and 
is resuspended for further analysis. Supernatant, s2 , is sedimented at 
150,000 g for 60 minutes. The resulting pellet, P3 , consists of micro-
somal and other membrane fragments. 
Due to the possibility of contamination of low-speed pellets with 
high speed components, the pellets are washed 3-4 times before each step 
of the centrifugation scheme. Samples of all three pellets and superna-
tants are then analyzed for both protei~ TSH,and growth hormone content. 
125 125 Furthermore, addition of I GH and I TSH during one subcellular 
fractionation can be used to check the possibility of hormone binding 
preferentially to a particular fraction and to determine whether pepti-
dase activity is present in any fraction. No enhanced degradation of 
125I hormones and no selective binding to any particular fraction was 
observed using this fractionation scheme in this study, thus validating 
the data obtained. 
The detection of antigenic material in cells of various tissues has 
been aided by the development of various immunohistochemical techniques. 
131 
G. IMMUNOHISTOCHEMISTRY OF PITUITARY AND BRAIN TISSUES 
Microscopic sections of tissues whose cells contain various anti-
genic substances, such as hormone can, in the simplest case, be incubated 
with specific antibodies to such antigen~ and antigen-antibody complexes 
will form within the sectioned tissue's cells. If this second antibody 
is conjugated to a fluorescent or colored probe, these antigen-antibody 
complexes will be easily detectable in antigen or hormone-containing cells 
when examined under the microscope. 
In order to study the tissues of various rat brain and pituitary 
parts for the localization of the peptide hormones GH and TSH, such im-
munohistochemical techniques were employed. One of these, the unlabeled 
antibody-enzyme-peroxidase method of Srernberger et al (1970), has pro-
vided a highly sensitive histochemical technique for the localization of 
antibody-antigen complexes. Its permanent reaction products provide an 
advantage over immunofluorescent histochemical techniques, in terms of 
long-term study of preparations, as no rapid fading of the labeled complex 
occurs with immunoperoxidase techniques as it does in immunofluorescence-
treated material. 
The antibody-enzyme peroxidase method of Sternberger allows the 
possibility of attaching an enzyme such as horseradish peroxidase to 
tissue antigens via a specific antibody without the use of a covalent 
labeling reaction. In this method, an antibody bridge system involving a 
soluble peroxidase-antiperoxidase complex (PAP) is bound to the primary, 
specific, tissue-bound antibody through a second antibody bridge. Cells 
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containing the specific bound-antibody are stained dark brown by the 
precipitated peroxidase. Schematically, the components of the peroxidase-
antiperoxidase complex, unlabeled antibody stain for microscopic sections 
of tissue are given in Fig. 20 . 
As a guide to the concentrations of antibody and times of incubation 
to be used in such a technique to detect TSH in tissue sections, the op-
timum conditions for the TSH radioimmunoassay were used. Sprague Dawley 
male rats, weighing approximately 200 g, were used for this study of the 
immunohistochemical localization of TSH in the CNS and pituitary. These 
animals were anesthetized using 0.1 ml/100 gm body weight, sodium pento-
barbital (Holmes Serum Co., Springfield, IL). The thorax was quickly 
opened and the left ventricle of the exposed heart cannulated. The right 
atrium was cut and, using a large glass syringe, 50-75 ml of ice-cold 
calcium-free Tyrodes solution was very slowly perfused through the aorta. 
This was followed by a 30-minute perfusion of 300-500 ml ice-cold para-
formaldehyde in Sorenson's buffer into the rat. The animal was kept on 
ice throughout this procedure. Following perfusion, the entire brain and 
pituitary were removed and immersed in the same fixative for 90 minutes, 
after which they were transferred to 5% sucrose in 0.1 M Sorenson's phos-
0 phate buffer and stored at 4 C. Before sectioning, the tissue was 
routinely dehydrated through a series of graded alcohols and xylene before 
embedding in paraffin. 
Sections 6 microns in thickness were cut through the whole brain and 
pituitary and placed on gelatin-coated glass slides. After drying, these 
sections were gently heated to 40-45° C to melt the paraffin and the slide-
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(\ (\ TISSUE ANTIGEN- TSH.IN RAT BRAIN 
~---:-----......_.._______ OR PITUITARY 
STEP I ~-------¥ 
STEP2 r------¥ 
STEP 3 
-RABBIT ANTI-RAT TSH 
-ANTI-RABBIT lgG 
PRODUCED IN GOAT 
RABBIT 
- PEROXJDASE-
ANTIPEROXI OASE 
COMPLEX 
Figure 20. Components of the peroxidase-antiperoxidase 
complex unlabeled antibody stain used for 
the detection of rat TSH in brain and 
pituitary tissue. 
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bound tissue rehydrated through a series of xylene, alcohols (absolute -
0 70AP, and finally in distilled water before commencing immunohistochemi-
cal staining. Staining procedures for TSH were modifications of histo-
chemical protocols given by Moriarty (1973) and Moi Yoi et al (1979). 
Deparaffinized sections were incubated in methanolic peroxide (1 
vol. 3% H202/5 vol. methanol) for 30 minutes at room temperature to elim-
inate endogenous peroxidase activity. After washing in phosphate buffer 
(0.1 M), these sections were incubated for a further 30 minutes at room 
temperature with 5% aqueous egg albumin (Schwarz-Mann, Orangeburg, N.Y.) 
to minimize background nonspecific binding of antibody. Without washing, 
the sections were treated as in step 1 of the immunocytochemical staining 
procedure, by covering the tissue mount with the first antibody, rabbit 
anti-rat TSH antibody at a 1:15,000 dilution. Incubation of the slides 
was then carried out at room temperature for 48 hours in a moist chamber 
consisting of a sealed box containing dampened foam rubber so that the 
sections were never allowed to dry out throughout the entire procedure. 
After this two-day incubation, slides were thoroughly washed with 0.05 M 
phosphate buffer and then overlaid with the second antibody, a 1:10 dilu-
tion of goat anti-rabbit IgG. Incubation with this antibody was for 18 
hours at room temperature, and after a wash step, sections were incubate.d 
for a further 30 minutes with a 1:50 dilution of rabbit peroxidase anti-
peroxidase (PAP) complex in phosphate-albumin buffer. After rinsing in 
phosphate buffer (0.05 M), the peroxidase was localized by incubating the 
tissue in a solution containing hydrogen peroxide and 3.3' diaminobenzidene 
tetrahydrochloride for 30 minutes. Oxidation of the reagent formed a brown 
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precipitate at the site of the peroxidase - anti-peroxidase complexes, 
which was intensified by incubation in 1% Os04 for 30 seconds. The slides 
were then washed in phosphate buffer and mounted in Permount (Fisher) be-
fore examination microscopically using a Leitz Diavert inverted micro-
scope. Sections were photographed using Kodak Ektachrome fast color 
400 daylight film with a 35 mm microscope-mounted Leitz camera. Valida-
tion of the specificity of the reaction was tested via the following 
controls, which were stained for the same length of time for each tissue 
examined. 
Negative controls were those in which the first antibody was replaced 
by buffer or by normal rabbit serum, diluted to 1:15,000. In some sections, 
the second antibody step was also replaced by addition of buffer. Immun-
absorption of the anti-rat TSH serum before use in the procedure with 
purified TSH, overnight at room temperature at a concentration of 100 ~g/ 
TSH/ml of diluted primary antisera, was also used to test the specificity 
of the reaction. 
The methodology described so far has applied to the histochemical 
detection of TSH in slices of brain and pituitary. Histochemical detection 
o~ GH in brain slices was also attempted with less success, using a less 
sensitive method of immunoperoxidase staining than the method of Stern-
berger, the "indirect method of staining." 
Although the method of section preparation was similar for GH as 
that for TSH detection? no PAP-complex was used in the immunohistochemical 
staining procedure. Instead, the immune reaction was terminated at the 
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point of formation of an antigen-antibody complex between the second anti-
body, labeled with peroxidase, and the initial complex formed between 
first antibody and tissue-bound GH. Although cells containing a dark-
colored complex could be observed, this work will have to be repeated 
using Sternberger's technique in an effort to obtain better histochemical 
resolution. 
Solutions used for the histochemistry study to detect TSH and GH in brain 
tissue. 
Sorenson's phosphate buffer 0.2 M 
8.06 g KH2Po4 
37.75 g Na2HPo4 7 H20 
Made up to 1 litre with distilled water, pH= 7.2. 
Paraformaldehyde in Sorenson's buffer 
Dissolve 40 g paraformaldehyde in 450 ml distilled water. 
Heat to 55-60° C. 
Add 2 N NaOH dropwise until solution clears. 
To the above paraformaldehyde, add 500 ml 0.2 M Sorenson's 
. phosphate buffer, pH 7.2. 
Bring final volume to 1 litre. 
Yields 1 litre of 4% paraformaldehyde in 0.1 M buffer. 
0 
Filter and store at 4 C. 
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Calcium (Ca++) free Tyrodes 
Add 800 mls distilled water to a 1-litre flask. 
NaCl 6.80 g Glucose 1.00 g 
K Cl 0.40 g NaHC03 2.20 g 
MgC12 0.15 g Swirl after each component. 
MgS04 7 H2o 0.10 g 
Na~SP04 2 H2o 0.19 g 
Slide gelatinization technique 
For 100 ml: 
Dilute to 
95% 02/5% 
0.5 g swine skin gelatin (Sigma) 
1 litre. Gas with 
co2 on ice. 
0.05 g chromium potassium sulphate 12 H2o (Fisher) 
Heat 100 ml water, dissolve gelatin and chromium potassium 
sulphate. 
Dip slides quickly, dry in open air. 
Store at 4° C wrapped in Parafilm. 
Phosphate buffer O.lM 
Used for wash after fixation. 
Solution A: 
27.80 g NaHzP04,. H2o 
1000 mls distilled H2o 
Solution B: 
53.65 Na2HPo4 7 HzO 
1000 mls distilled H2o 
(Solution B, continued) 
19 mls of A+ 81 mls B diluted to 200 mls, pH 7.4. 
For wash between stains, diluted with water to 0.05 M. 
For dilution of antisera and PAP: 0.05 M. phosphate buffer + 
2.5 mg/ml bovine serum albumin. 
The "PAP" complex 
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Made in rabbit from the method of Sternberger by Miles Laboratories, 
Elkhart, Indiana. 
An antigen-antibody complex dissociated and solubilized in excess 
peroxidase antigen forming a stable soluble complex. 
Maintained at -70° C in 0.1 ml aliquots. 
Tris buffer 0.5 M 
30.285 g THAM (Tris lHydroxy-methyl/ amino methane) 
250 ml H2o 
pH with LN HCl to 7,.6 
Add 250 m1 H2o 
Diaminobenzidine - H2o2 solution 
Always freshly made; good for 60-90 minutes. 
6 mg 3 · - 3' diaminobenzidine hydrochloride (Sigma) 
10 ml Tris buffer 
11":':2 drops 3% ~02 (not more than 2 months old) 
Filtered and kept stirred throughout staining reaction. 
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Dehydration protocol for all tissues 
2 X 80% alcohol 30 minutes 
2 X 95% alcohol 30 minutes 
2 X absolute alcohol 30 minutes 
2 X chloroform 30 minutes 
Paraffin 
Hydration protocol for all tissues 
2 X xylene 3 minutes 
2 X absolute alcohol 3 minutes 
2 X 95% alcohol 3 minutes 
2 X 80% alcohol 3 minutes 
2 X distilled HzO 3 minutes 
The next studies to be described were designed to determine the 
approximate molecular weight of the brain hormone in compay;ison to that 
of the hoi;mone of pituitary origin. 
H. COLUMN CHRQHATOGRAPHY OF BRAIN EXTRACTS 
A calibrated column of Sephadex gel provides a simple way of deter-
mining the molecular weights of proteins such as GH and TSH. Sephadex is 
a bead-formed gel prepared by cross linking dextran with epichlorohydrin. 
As a solute passes· down a vertical column packed with such chromatographic 
beads, its movement depends on the bulk flow of the mobile phase and upon 
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the Brownian movement of the solute molecules. These movements cause the 
diffusion of molecules in the solute both in and out of the stationary 
phase of the beads. The separation of solutes in gel filtration depends 
on the different abilities of the various sample molecules to enter pores 
which contain the stationary phase. Very large molecules which never 
enter the stationary phase therefore move through the chromatographic gel 
bed faster than smaller molecules which can enter the gel pores, and 
thereby move more slowly through the column since they spend a part of 
their time in the stationary phase. Molecules are therefore eluted in 
order of decreasing molecular size. Results are ~sually expressed in the 
form of an elution diagram showing the variation of solute concentration 
in the eluent with the volume of eluent passed through the column. Sepha-
dex G-100 was the gel of choice for these experiments, being able to 
separate clearly molecules with a molecular weight range between 4,000 -
150,000 Daltons. This range was chosen in order to detect the possibility 
of any larger prohormone-like molecules that may have been present in 
brain homogenates. 
From a total of 40 male, 200 gm rats, brains were dissected into 
the amygdaloid nucleus, hypothalamus, and thalamus. Each brain region 
was pooled and kept on dry ice before processing. Extraction was as des-
cribed in section D, except that the final supernatant was spun at 3,000 g 
for 10 minutes in a FA-65 rotor of a Beckman ultracentrifuge to remove 
nuclei and other debris. This supernatant was then lyophilized and re-
constituted either in 1 ml veronal buffer, pH 8.6, for GH studies, or in 
1 ml 0.01 M phosphosaline buffer, pH 7.6, for TSH column work. 
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Sephadex G-100, 0.9 x 50 em columns were prepared, coated with al-
bumin, and calibrated using blue dextran 2000 (Pharmacia) bovine serum 
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albumin, mol. wt. 68,000 D, and I insulin, mol. wt. 5,700 D, to give 
reliable calibration points. 
A trace amount, approximately 7,000 cpm in 100 ~1 buffer of either 
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I rat pituitary GH or TSH, was applied to the column together with 1 ml 
of reconstituted brain homogenate. One-ml fractions were collected in a 
Gilford automatic fraction collector. These were analyzed for both 
radioactivity, using a Micromedic gamma counter, or for hormone content, 
using the radioimmunoassays for TSH or GH. In this way the elution 
pattern of the radioactive-labeled pituitary growth hormone could be 
compared to that of the radioimmunoassayable brain hormone. Similar 
studies were performed using material from fetal brain and pituitaries. 
Another parameter of the brain "pituitary-like" hormones examined 
was thei,r immunological similarity to their respective pituitary counter-
parts .• 
I. STUDIES TO DETERMINE THE IMMUNOLOGICAL IDENTITY OF "BRAIN" HORMONES 
Immunological similarities between brain and pituitary hormones 
were determined by preparing serial dilutions of both tissue extracts and 
subjecting them to radioimmunoassay. Parallelism, or lack of parallelism, 
between logit log transformed displacement curves produced for each tissue 
was used as an indicator of probable similar or different interaction with 
antibody sites to a particular hormone. 
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The biological activity of brain hormones was also compared with 
that of pituitary GH and TSH. 
J. BIOLOGICAL ACTIVITY STUDIES 
a. Growth Hormone Bioactivity in Brain Extracts. 
The traditional bioassay for the measurement of pituitary growth 
hormone has been that perfected by Greenspan et al in 1949. It had been 
shown earlier by Li et al (1945) that pituitary growth hormone extract 
stimulated growth of the bony epiphyseal plate of hypophysectomized rats. 
This observation formed the basis for the Greenspan assay which is based 
on the ability of growth-hormone-like material in tissue extracts to 
increase the width of the epiphyseal cartilage in hypophysectomized 
animals, a parameter measured quantitatively with a microscope micrometer.· 
Li et al (1945) showed that a total dose of 100 ~grns of pure growth hor-
mone administered to 30-day post-hypophysectomized adult rats was neces-
sary to produce a significant response in an increase in body weight bio-
assay for GH, whereas in the tibia epiphyseal cartilage test, as noted 
by Greenspan, a total dose of only 5 ~grns would produce a significant 
response. Therefore without necessarily obtaining a growth hormone res-
ponse in terms of weight gain, the use of the tibia bioassay provides a 
characteristic of growth hormone action which is able to be measured. 
This experiment was repeated four times in hypophysectomized rats, 
twice using female and twice using male recipients. For each experiment, 
250 donor rats were sacrificed by decapitation and the amygdaloid nuclei 
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and pituitaries harvested individually and placed immediately on dry ice. 
Each tissue was then weighed, pooled, and homogenized separately, taking 
care to avoid any possible contamination of brain homogenate with pitui-
tary tissue. The supernatants obtained from extraction of the tissues 
with 0.01 phosphate buffer, pH 7.6, were spun at 5000 g to eliminate any 
debris and nuclear material, dialyzed against 0.15 M saline, lyophilized, 
and reconstituted in 20 m1 of physiological saline (0.15 M, pH 7.4). The 
final concentration of GH in both pituitary and brain extracts was measured 
by the RIA described earlier and appropriate dilutions to give approxi-
mately 20-30 ~g of immunoreactive GH/ml obtained. A more concentrated 
pituitary extract was found to give no advantage over the lower pituitary 
dosage. 
For the actual bioassay, forty-two-day-old male and female rats, 
which had been hypophysectomized at age 28 days, were kept in groups of 
five in separate cages and fed a diet of oranges and rat chow mash. 
Groups of five animals received twice a day for four days either: 0.5 ml 
saline, 0.5 ml rat pituitary extract, or 0.5 ml of amygdaloid nucleus 
extract intraperitoneally. Animals were weighed daily at the time of 
injection to measure any weight gain. Twenty-four hours after the last 
injection, all animals were weighed and sacrificed using sodium pento-
barbital injection. One or both tibias were dissected free of soft tis-
sue and split with a sharp razor in the mid-sagittal plane. The two-bone 
halves were either stained immediately or fixed in 10% neutral formalin. 
Thyroids, ovaries, and testes were similarly dissected from all control 
and assay animals and fixed in 10% neutral formalin. 
The staining procedure for the tibia epiphyseal cartilage halves 
is as described by Evans et al (1943) and is as follows: 
1. Bone washed in H20 - 30 minutes 
2. Acetone - 60 minutes 
3. Wash in H2o - 30 minutes 
4. Freshly prepared 2% silver nitrate - 1-3 minutes 
5. Wash in H2o and while under water, expose to a strong light 
until calcified portions appear dark brown. 
144 
6. 10% sodium thiosulfate - 25-30 seconds 
7. Wash in running H2o - 30 minutes 
8. Store in 80% alcohol in dark at room temperature. 
The width of the uncalcified epiphyseal cartilage, which remained un-
stained and easily observable, is measured under the low po'tver of an 
American Optical microscope using a micrometer eye piece calibrated with 
a stage micrometer so that results can be expressed as micra units. A 
minimum of 10 measurements should be made along each epiphyseal cartilage 
in areas selected at random. This study was carried out ''blind", and 
two independent observers used. The data between saline-; pituitary-; and 
amygdaloid-injected groups was statistically analyzed using the Student 
T test. The cartilage plate increases in width slightly from anterior 
to posterior, and there is therefore an inherent error in the measure-
ment of mean width. For this reason, all readings should always be from 
narrow to wider areas and the variation accounted for by the multiple 
readings. There was usually no significant difference between left and 
right tibias, but only one tibia, usually the left, was used for the 
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measurements. A comparison in the total body weights and wet weights of 
testes and ovaries from both control and hypophysectomized rats was also 
statistically analyzed. 
b. Thyroid stimulating hormone bioactivity in brain extracts. 
The effects of TSH on the histology of the thyroid follicle cell 
were previously discussed in the Review of Literature section of this 
dissertation. Briefly, the presence of TSH influences the size and shape 
of the follicle epithelial cells and the distribution of colloid in the 
follicle lumen. Follicles from hypophysectomized rat thyroids contain 
cells which are flattened, and little colloid is found in the central 
lumen of the follicle, as compared to normal, euthyroid animal thyroid 
follicles. 
A minimum dose of 20 ng immunoreactive pituitary TSH/hypophysec-
tomized animal, given over a four-day period, is necessary to restore the 
histology of the thyroid to that of an intact rat. To demonstrate another 
biological effect of pituitary TSH on the thyroid, that of an increase in 
thyroidal radioiodide uptake, at least 10 ~gm of TSH/rat are required. 
For our experiments, aimed at assaying TSH-like activity of CNS 
extracts, thyroids from the three groups of animals used in the GH bio-
activity experiments were used, i.e., hypophysectomized animals receiving 
saline, or CNS extract, or pituitary extract. A fourth group of hypophy-
sectomized animals were also used in this TSH bioassay which received a 
higher dose of pituitary extract than the animals used in the GH bioassay. 
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In terms of levels of radioimmunoassayable TSH, these four groups of rats 
received 0 ~g of TSH in the saline-injected group; 4.5 ~g TS~from amyg-
daloid tissue, in the CNS-injected group; 5 ~g TSH, obtained from pitui-
tary extracts, in the third group; and 100 ~g TSH, from pituitary extracts, 
in the fourth group of rats. 
Twenty-four hours after the last injection, the thyroids were re-
moved, en Bloc, with the trachea, fixed in neutral formalin, and subse-
quently paraffin-sectioned at a width of 6 microns and stained with hema-
toxylin eosin. Sections were photographed in order to examine the follicle 
cells for any histological changes which could be related to the type of 
material injected. This method of bioassaying TSH represents a modifica-
tion of the work of Tice (1974). 
Another test of TSH's biological effectiveness was to examine this 
hormone's property to facilitate the uptake of circulating radioiodine 
by the thyroid. Hypophysectomized animals' ability to take up radio-
labeled iodine into the thyroid with, and without, injections of immuno-
assayable TSH in extracts from brain and pituitary were compared. Simi-
larly, the effectiveness of brain and pituitary extracts to increase the 
circulating levels of T4 in hypophysectomized animals was examined as a 
measure of the bioactivity of brain TSH-like material. 
In these two groups of experiments, i.e., measurement of iodine 
uptake and measurement of circulating T4 levels, four groups of 5 adult, 
14-day, post-hypophysectomized animals received one of the following 
treatments over a 4-day period: either an IP injection of 0.5 ml of 
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saline daily, or a total dose of 100 ~g immunoassayable TSH from pituitary 
extracts in 0.5 ml saline, or a total dose of 2 1-1g TSH from pituitar;r ex-
tracts, diluted saline, or 4.3 ~g TSH obtained from amygdaloid tissue 
homogenates diluted in saline. Eighteen hours before sacrifice, approxi-
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mately 1.5 ~ curies I was injected intraperitoneally into all groups, 
and after sacrifice, thyroid and muscle levels of radioactivity were 
measured. Thyroxine (T4} levels of samples of blood, taken ;t;rom the 
trunk by gravity after decapitation, were measured by means of a commer-
cial RIA kit (Tetra-Tab}, which is described in detail in section K of 
this Materials and Methods chapter. 
Although the blood-brain barrier prevents the passage of a majority 
of blood-borne materials into the brain, its effectiveness in preventing 
the contamination of CNS tissue by pituitary-derived GH and TSH was tested 
by methods described in the following section. 
K. EXMtiNATION OF RAT BLOOD-BRAIN BARRIER INTACTNESS TO PITUITARY GROWTH 
HORMONE AND THYROID STIMULATING HORMONE 
Numerous chemical substances do pass from the bloodstream into the 
brain at rates which are slower than for entry into all other organs in 
the body. There are similarly slow rates of transport between the CSF 
and the brain. The permeability barrier appears to be the end result of 
numerous contributing factors that present diffusional obstacles to chem-
icals on the basis of molecular size, charg~, solubility, and specific 
carrier systems.. The difficulty has not been in establishing the exis-
tence of these barriers, but rather in determining their mechanisms. When 
the relatively small protein, 43,000 D, horseradish peroxidase is injected 
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intravenously into rats, its intracellular location within most tissues, 
such. ~s ~uscl~ can be demonstrated histochemically with the electron 
microscope. As opposed to the easy transv~scular movement of horseradish 
peroxidase across muscle capillaries into muscle tis·sue, in brain the 
peroxidase molecule is unable to penetrate through the continuous layer 
of vascular endqthelial cells constituting the blood brain barxier. This 
single layer of brain capillary endothelium differs from those of other 
tissue capillaries such as muscle and heart, in that the intercellular 
zones of cell membrane apposition are much more highly developed in the 
brain and are virtually continuous along the entire surface of these 
cells. They also show a lack of pinocytic vesicles. These vesicles, 
characteristic of capillaries found elsewhere throughout the body, have 
been related to transvascular carrier systems of both large and small 
molecules. Since the horseradish peroxidase enzyme marker can neither go 
through nor between the endothelial cells comprising the vascular system 
of the CNS, an operationally defined barrier is said to exist, i.e., the 
blood-brain barrier. 
For a solute to enter the brain easily, it appears to have to be 
either highly lipid-soluble and be able to diffuse through cell membranes 
or have an affinity for certain specific and selective carrier-mediated 
transport systems present in the endothelial cell plasma membrane, as 
shown by Oldendorf (1977}. 
In orde.r to test the possibility that circulating GH or TSH of 
pituitary origin could be reaching the CNS tissue via possible weak areas 
in the blood-brain barrier, systemically administered radiolabeled 
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hormones were used as markers of distribution, as described by Stern et al 
(1975). Using freshly iodinated GH or TSH, five adult animals per hormone 
were injected intravenously via the tail vein with approximately 1 x 106 
cpm hormone in 200 '].11 phosphosaline buffer, ph 7.6. Thirty minutes later 
the animals were decapitated and the brain areas and various peripheral 
tissues dissected out. All tissue samples were weighed and counted in a 
gann:na counte.r to detect the presence of radioactivity arising from the 
labeled hormone injection. Results were expressed as cpm/mg wet weight 
of tissue. Control rats injected with 200 ]..ll of buffer alone were simi-
larly killed and the tissues dissected out for detection of iirununoassay-
able hormone, expressed as ng/mg wet weight of tissue. 
For the studies involving fetuses, to test the possibility that 
the blood-brain barrier develops with age, the following protocol was 
used. 
Pregnant females in the 20-2lst day of pregnancy were decapitated 
and the fetuses in the uterine horns gently lifted out of the body cavity 
and kept warm. Once released from the uterus, these full-term fetuses, 
released from their attached placentas, were able to survive for several 
hours. To test the intactness of the blood brain barrier at this early 
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age, 1 x 10 cpm of either labeled GH or TSH were injected intraperiton-
eally in 10 1-11 PBS into the fetuses. Thirty minutes later, the fetuses 
were sacrificed by decapitation with scissors and various brain parts and 
organs dissected out to determine the location of the radiolabeled tag. 
If there was the possibility of some breakdown in the blood brain barrier, 
and if the blood content of the brain is approximately 50 1-1 litres/gm of 
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brain tissue, by assaying the hormonal content of sera, it was possible 
to calculate the possible level of contamination from circulating hormone 
of brain tissue. 
L. THE EFFECTS OF HYPOPHYSECTOMY ON BRAIN-BASED PITUITARY-LIKE GH AND TSH. 
In this series of three experiments, the effect of removing the pi-
tuitary on levels of immunoreactive hormone in various areas of the brain 
and in serum were compared to levels obtained from intact, sham-operated 
controls of equivalent age. For each experiment, approximately 80 hypo-
physectomized animals and 80 controls were obtained from Hormone Assay 
Lab., Inc., Chicago. The hypophysectomized animals were operated on at 
28 days of age,and batches of 20 animals were kept for 7, 14, 28, and 48 
days post-surgery on a diet of oranges and mashed moist rat chow before 
sacrifice. Salinated water was found to be unnecessary for these animals. 
Equivalent groups of intact controls, in terms of age, were sacri-
ficed within one hour of the sacrifice of the hypophysectomized rats. 
Trunk blood was collected for hormone analysis and the brain parts dis-
sected out on dry ice as previously described in section C. Extraction 
and homogenization were also performed as previously noted in section D 
of this dissertation, and levels of hormone were calculated, after radio-
immunoassay, as ng hormone/mg protein or ng hormone/mg wet weight of tissue. 
The effectiveness of hypophysectomy was determined by gross examina-
tion of the sella turcica with a dissecting microscope and also by measur-
ing the levels of circulating hormones GH, TSH, and the thyroid hormone T4 , 
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as well as the "T3 resin uptake," another indicator of thyroid and indir-
ectly pituitary function,which will be described in the next section. 
M. THYROXINE (T4) AND T3 RESIN UPTAKE ASSAYS 
The levels of circulating total thyroxine or T4 were obtained using 
a commercial T4 diagnostic kit, "Tetra-Tab RIA" (Nuclear Medical Lab., 
Inc., Dallas, Texas), and the "T3 uptake" estimation of unsaturated thy-
roid binding globulin capacity was also run using a kit, "Tri-Tab," from 
the same company. 
a. Measurement of T 4 
Thyroxine circulates in the bloodstream as free (1%) and thyrobind-
ing globulin-bound hormone. In the T 4 radioimmunoassay, total thyroxine, 
T4 , is released from endogenous thyroxine-binding proteins present in the 
serum by the chemical inactivation of the binding protein by 0.025 N HCl. 
The T4 so released is then available for assay of total T4. The principle 
of the RIA is as described for GH and TSH. Specifically for T4 detection 
in the assay, a serum sample is mixed with 200 ].ll of 0.025 N HCl and a 
constant amount of iodinated T4 is added and the mixture incubated at 
room temperature for 30 minutes with a highly specific antibody to T4 
prepared in rabbits. Free and antibody-bound fractions are then separ-
ated by ammonium sulfate precipitation and centrifugation of the antibody-
bound fraction. Following centrifugation, the supernatant was discarded 
and the radioactivity in the precipitate measured directly in a gamma 
counter. A standard curve was prepared calculating the percent of the 
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total radioactivity remaining in the bound fraction for the five serum 
standards ranging from 1 - 2§ ~g T4/dl and plotted against T4 concentra-
tion. Unknown T4 values were calculated for the experimental serum samples 
directly from the standard curve as ~gm/dl. 
(i) Assay procedure for the detection of Tq in serum 
Assay carried out in triplicate in 12 x 75 mm plastic tubes, and 
reagents added in the following order: 
1. 200 ).11 
2. 10 ).11 
0. 025 N HCl. 
standard or serum sample. 
Standards = 1 - 28 ).lg T4/dl. 
All tubes shaken 10-15 seconds and incubated at RT for 60 minutes. 
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3. 400 ~1 I T4• 
All tubes shaken and incubated for 60 minutes. 
4. 2.0 ml - 35.5% ammonium sulfate containing 0.4% calf serum. 
All tubes mixed gently and incubated 20 minutes before centrifugation 
for 10 minutes at 1000 g. 
The supernatant was decanted and the precipitate counted, accumulat-
ing a minimum of 20,000 counts/tube. Reproducibility was assessed using 
frozen serum pools as internal standards for each assay. 
b ·~ Measurement of the radio labeled T 3 resin uptake in serum 
samples. 
The radiolabeled T resin uptake test which. is not a measurement of 
3 
circulating t 3 or T4 hormones is designed to assess the unsaturated 
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binding capacity of certain serum proteins, primarily thyroxine-binding 
globulin (TBC}. This assessment is accomplished in the assay by the 
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addition of an excess of I-labeled L-tr;i.iodothyronine (T3) to serum in 
order to saturate all available TBG binding sites in the serum sample. 
I.f the endogenous T4 level is increased, as in hyperthyroidism, the TBG 
will be relatively saturated. 125 More I-labeled T3 remains in a free 
state to be adsorbed by a secondary silicate binder. Conversely, when T4 
output is low, as in hypothyroidism, more of the added labeled T3 will 
bind to the serum TBG, yielding a comparatively low percentage of the 
remaining radioactivity to be adsorbed secondarily. For a secondary 
binding agent, the commercial kit uses an inorganic adsorbent, silicate, 
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as binding of I-labeled T3 reaches over 99% of the maximum uptake 
within five minutes and remains constant for up to three hours. Basically, 
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this test involves mixing a serum sample with excess I-labeled T3 which 
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occupies all unsaturated binding sites on the TBG in the serum. I T3 
not bound to TBG was removed by addition of the secondary silicate binder. 
Following centrifugation, the supernatant was discarded, and the radio-
activity in the sample compared to the amount of radioactivity in a normal 
control serum, with an established percent uptake. Interassay reproduci-
bility was assessed using a pooled, frozen internal serum standard. 
(i) Assay procedure for the measurement of the T3 resin uptake in 
Assay carried out in triplicate in 12 x 75 mm plastic tubes at room 
temperature. 
1. 100 ~1 standards or serum sample. 
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2. 2 1111 - I T3 in 0.07 M barbi.tal buffer containing 0.125% BSA. 
Mixed thoroughly. 
3. T adsorbent tablet containing 10%-40% silicate by weight added. 
3 
Mixed for 5 seconds and incubated 10 minutes. 
Centrifuged 5 minutes at 1000 g, supernatant discarded and the pellet 
counted, in a gamma counter, each tube accumulating at least 20,000 counts. 
The percent T uptake is determined by dividing the test counts/the total 
3 
counts x 100. An accurate and practical assessment of thyroid status,and 
therefore indirectly of pituitary TSH status, can be made by calculating 
the product of the radiolabeled T3 resin uptake and the total T4 value, 
the "Free Thyroxine Index." 
N. ALTERATION OF FEEDBACK CONTROL MECHANISMS 
.I. TARGET ORGAN REMOVAL 
The effect on pituitary hormones of removing a target organ has 
previously been alluded to in the discussion on feedback control mechan-
isms.. For example, removal of the thyroid gland serves to remove the 
"negative feedback'' control which thyroxine, T4 ? the major product of the 
thyroid gland, has upon TSH production from the pituitary. Adrenalectomy 
and gonadal removal also affect the levels of GH and TSH in the pituitary, 
indicating that circulating steroid hormones have a certain amount of 
influence in the release of hormones from the pituitary. The question 
posed by this series of experiments was whether target gland removal would 
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affect the levels of pituitary-like peptide hormone found in the central 
nervous system in a similar way to effects of target gland ~emoval on 
pituitary hormone content and release. If the answer was "no", it would 
be another indication supporting a separate and distinct pool of pitui-
tary-like peptides in the brain. 
a. Oophorectomy. 
Groups of 20, sixty-day-old female rats were oophorectomized under 
light sodium pentobarbital anesthesia through bilateral paraspinal 1-cm 
incisions. A single ligature was made behind the ovary around the fallo-
pian tube and the ovary with its surrounding capsule and fat cut away. 
Sham-operated animals were similarly handled without the tying of the 
fallopian tubes or removal of the ovaries. Both sham and operated ani-
mals were sacrificed either one or four weeks post-operatively. 
b. Orchidectomy. 
Groups of 20, 60-day-old male rats were lightly anesthetized and a 
longitudinal incision made in each scrotal sac. The testicle, along with 
the epididymus, were exposed and vascular structures were ligatured. The 
testicle was removed and the scrotal sac reanastomosed with 2 0 silk. 
Sham operated animals were similarly handled without ligaturing. As in 
the oophorectomized animals, both sham and castrated rats were sacrificed 
either one or four weeks post-operatively. 
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c. Adrenalectomy. 
Under light anesthesia, groups of 20, sixty-day-old male rats were 
adrenalectomized or sham adrenalectomized. Bilateral paraspinal 1-cm 
incisions were made to expose the kidney and adjacent adrenal gland em-
bedded in perirenal fat. Care was taken to remove the adrenal gland as 
gently as possible with curved forceps, in order to avoid disruption and 
dispersal of adrenal cells. Adrenalectomized animals were kept on 0.9% 
saline and normal rat chow. Both sham and adrenalectomized rats were 
sacrificed after one or four weeks post-operatively. 
d. Thyroidectomy. 
Thyroidectomized animals were obtained from Hormone Assay Labs, Inc. 1 
and kept for one or four weeks before sacrifice. Sixty-day-old male rats,· 
equivalent to the thyroidectomized animals,were sham operated by making an 
incision over the trachea and gently parting the muscles overlaying the 
trachea to reveal the thyroid gland. Sacrifice was as for the thyroid-
ectomized animals. Efficiency of thyroidectomy was confirmed by analysis 
of the levels of TSH, T4, and T3 
uptake obtained from serum samples. 
In all target organ experiments, the animals were sacrificed by 
decapitation, trunk blood collected, and brain parts and pituitary re-
moved for tissue homogenization and radioimmunoassay. The levels of 
pituitary hormone and similar CNS peptides in intact and operated animals 
were compared after one week and four weeks of target organ absence. 
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II. THYROXINE 
The effect of injecting intramuscularly 0.4 ~g T4/gm body weight 
daily for seven days into groups of 20 hypophysectomized or intact ani-
mals on levels of brain and pituitary hormones was also examined using 
saline-injected animals as controls. 
Trunk blood was collected at sacrifice and TSH, T3 uptake, and T4 
levels analyzed for all groups. 
Brain parts were homogenized and treated as before with levels of 
immunoassayable hormone being detected by radioimmunoassay. 
Preparation of thyroxine: 
9 mg L-thyroxine/sodium salt-pentahydrate (Sigma) 
90 mls phospho-buffered saline 0.01 M, pH 7.6 
The thyroxine required dissolving in a few drops of 1 N NaOH before addi-
tion of phosphosaline buffer to make a 0.1 mg in 1 m1 solution. Appro-
priate dilutions with buffer were made to give the correct dosage for 
individual rats according to weight. Control rats were injected with 
buffer only. 
0. ONTOGENEY STUDIES 
Accumulating knowledge of the importance of the fetal endocrine 
system on morphogenesis, differentiation, and parturition in both man and 
other mammals prompted this study of the ontogenesis of brain pituitary-
like hormones. It was also hoped that the presence of CNS peptides could 
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be detected earlier than pituitary peptides which would give further ere-
dence for thei.r separate identities. 
Eight pregnant rats were housed in separate cages from the day of 
insemination, which was taken as day one of gestation. Staging of estrous 
cycle periods and confirmation of fertilization was determined from daily 
microscopic examination of vaginal scrapings suspended in saline and 
viewed with a 10 x ocular. Fetal and neonate animals were decapitated at 
various stages of development, pre- and post-partum. Trunk blood, amniotic 
fluid, and samples of brain and pituitary tissue were frozen prior to 
determination of GH and TSH levels by radioimmunoassay. Levels of hormone 
in maternal blood and brain were also determined. Levels of hormone were 
expressed as ng/mg protein. Immunologic and physiochemical characteristics 
of the two fetal brain hormones, GH and TSH, were compared with those of 
pituitary origin in a similar manner to adult hormones, i.e., by column 
chromatography and radioimmunoassay parallelism studies. Attempts to 
trace the origin of fetal brain hormones centered on the measurement of 
placental, amniotic, fetal, and maternal sera levels of hormon~and the 
intactness of the fetal blood brain barrier was examined as described in 
section I. In order to confirm the presence of a placental barrier to 
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material pituitary hormones, 1 x 10 cpm of I GH and TSH were injected 
into the pregnant mothers at 21 days of gestation in 200-~1 amounts via 
the tail vein. Thirty minutes later, fetuses were removed and the kidney, 
pituitary, and brain checked for radioactivity. The presence of radioac-
tivity would indicate the possibility of pituitary hormones crossing the 
placental barrier; its absence would indicate barrier intactness. 
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P. STATISTICAL ANALYSIS OF DATA 
Except for the target organ experiments, all data was analyzed by 
the two-tailed Students T Test which compared the mean and standard 
error of the mean to give the probability or "p" values of any differ-
ence between two groups being significant. This "p" value can be ex-
pressed, as for example p = <. 0.05, which would indicate that the two 
sets of data compared have less than a 5% chance of being the same, or 
if p =~0.01, in which case the two sets of data-would have a less than 
1% chance of being the same (Steel and Torrie, 1960). 
As there was unexplainably wide variation in the data from the 
target organ experiments, it was decided to handle the data from these 
experiments using the Mann-Whitney ~-Two-Tailed Statistical Test in 
which the non-parametric confidence interval is based on the rank sum 
test (Mann and Whitney, 1947). 
5. RESULTS 
A. PITUITARY GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE 
IMMUNOREACTIVE PEPTIDE DISTRIBUTION IN RAT BRAIN 
Brain extracts from specific parts of the CNS of adult rats were 
examined for their hormonal content using the radioimmunoassays for rat 
growth hormone (GH) and rat thyroid stimulating hormone (TSH). There-
sults are depicted in Tables 3 - 8 and Figures 21 and 22. 
a. Growth Hormone-Like Immunoreactivity in the Rat Brain 
The data in Tables 3 and 4 demonstrate the levels of immunoreactive 
growth hormone present in various brain regions and in the pituitary of 
the adult male rat expressed in terms of ng/mg protein or pg/mg wet weight 
of tissue, respectively. The amygdaloid nucleus was found to contain the 
largest amounts of this particular immunoreactive material per mg of pro-
tein, 5.28 ± 0.21 ng, and 284 ± 10 pg/mg wet weight of tissue. The hypo-
thalamus, 3.16 ± 0.33 ng/mg protein, 119 ± 6 pg/mg wet tissue, and the 
caudate, 2.09 ng/mg protein, 117 + 5 pg/mg wet tissue, had lower levels. 
Even smaller quantities were detected in the hippocampus: 1.35 ± 0.04 
ng/mg protein, 95 ~ 3 pg/mg wet tissue; cortex, 1.23 ± 0.13 ng/mg protein, 
48 ± 7 pg/mg wet tissue; and thalamus, 1.59 ± 0.15 ng/mg protein, 99 ± 8 
pg/mg wet tissue, with barely detectable amounts being found in the cere-
bellum--0.03 ± 0.01 ng/mg protein, and 5 + 2 pg/mg wet tissue. These 
values are to be contrasted to the amount of GH found in the anterior 
pituitary gland, i.e., 1.3 x 106 + 0.45 ng/mg protein and 2.8 x 105 + 0.26 
pg/mg wet tissue. 
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TABLE 3 
DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN 
(ng/mg protein)** 
n GH (ng/mg protein)** 
Amygdaloid nucleus 13* 5.28 ± 0.21 
Hypothalamus 50* 3.16 ± 0.33 
Caudate 10* 2.09 ± 0.24 
Thalamus 13* 1.59 ± 0.15 
Hippocampus 11* 1.35 ± 0.04 
Cortex 12* 1.23 ± 0.13 
Cerebellum 13* 0.03 ± 0.01 
Anterior 
106 6 pituitary 30 1.3 X ± 0.45 X 10 
n = number of experiments. 
* represents a pool of 10 animals. 
** Mean ± S. E. M. 
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TABLE 4 
DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN 
(pg/mg wet weight tissue)** 
n GH (pg/mg wet wt.)** 
Amygdaloid nucleus 13* 284 ± 10 
Hypothalamus 50* 119 -± 6 
Caudate 10* 117 ± 5 
Thalamus 13* 99 ± 8 
Hippocampus 11* 95 ± 3 
Cortex 12* 48 ± 7 
Cerebellum 13* 5 ± 2 
Anterior 
105 ± 0.26 X 105 pituitary 30 2.8 X 
n = number of experiments. 
* represents a pool of 10 animals. 
** Mean ± S. E. M. 
TABLE 5 
DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN REGIONS 
(ng/ total brain region)** 
n = 12 ng GH/brain region 
*Cortex 38.40 ± 0.74 
*Amygdala 14.20 ± 1.20 
* Hippocampus 6.11 ± 0.56 
*Caudate 5. 40 ± 0.11 
Hypothalamus 4. 76 ± 0.27 
*Thalamus 3.96 ± 0.63 
* Cerebellum 1.00 ± 0.05 
Anterior pituitary 3 • 6 X 10 6 ± 0 • 39 X 106 
n =number of experiments. 
* represents a pool of 10 animals. 
** Mean ± S. E. M. 
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Figure 21. Distribution of immunoreactive growth hormone 
in the adult rodent brain. 
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When expressed as the total amount of hormone present in an entire 
brain region, as shown in Table 5, the cortex was shown to contain the 
largest overall amount of immunoreactive growth hormone-like immunoreac-
tive material in the brain. Nevertheless, the total amount of growth 
4 hormone-like material present in an adult rat brain is still 1.5 x 10 
less than that found in the adult rat pituitary. 
The amount of immunoreactive growth hormone found in the systemic 
circulation was shown to be approximately 249.80 ± 35.32 ng/ml, a value 
similar to what has been previously reported (Ojeda et al, 1977). The 
amount of hormone per mg of brain tissue which could be attributed to 
circulating hormon·e contamination was determined to be approximately 
5-12 pgs/mg wet weight of tissue, assuming the blood content of brain 
tissue to be 50 pl/gm. Taking into account this level of possible con-
tamination and ignoring the blood-brain barrier effectiveness factor, 
the amount of hormone detected in cerebellar tissue could therefore be 
considered artifactual or merely the amount of immunoreactive GH present 
in the vasculature of the cerebellum. However, all other brain areas 
have immunoreactive material in amounts considerably greater than that 
possibly due to contamination of the tissue by blood-borne products. 
b. Thyroid Stimulating Hormone-Like Immunoreactivity in the Rat Brain. 
When the levels of immunoreactive TSH were similarly mapped for the 
brain areas of the adult rat, the results obtained are shown in Tables 7 
and 6 for ng/mg protein or ng/mg wet weight of tissue, respectively. The 
distribution of TSH-like material/brain region was calculated as shown in 
TABLE 6 
DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN 
(ng/mg wet wt. tissue)** 
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n TSH (ng/mg wet wt. tissue)** 
Hypothalamus 50 
Amygdala 17* 
Thalamus 10* 
Caudate 11* 
Cerebellum 12* 
Hippocampus 9* 
Cortex 13* 
Anterior pituitary 50 
n =number of experiments. 
*Represents a pool of 10 animals. 
** Mean :!: S. E. M. 
5.443 :!: 0.56 
1.100 :!: 0.42 
0.967 :!: 0.10 
0. 810 :!: 0.12 
0. 799 :!: 0.05 
0. 798 :!: 0.04 
0. 726 :!: 0.09 
1.9 X 105 :!: 0.50 X 105 
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TABLE 7 
DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN 
(ng/mg protein)** 
n TSH (ng/mg protein)** 
Hypothalamus 50 204.20 ± 3.6 
Amygdala 17* 29.42 ± 6.3 
Cerebellum 12* 16.98 ± 2.5 
Thalamus 10* 16.50 ± 1.4 
Caudate 11* 15.21 ± 2.6 
Cortex 13* 13.89 ± 0.5 
Hippocampus 9* 11.88 ± 2.4 
Anterior pituitary 50 6 1. 2 X 10 ± 0. 75 X 106 
n =number of experiments. 
* Represents a pool of 10 animals. 
** Mean ± S. E. M. 
TABLE 8 
DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN REGIONS 
(ng/total brain region)** 
n = 15 ng TSH/brain region** 
*Cortex 580.21 ± 5.6 
Hypothalamus 217. 72 ± 7.3 
* Cerebellum 158.03 ± 2.5 
* Hippocampus 49.47 ± 3.0 
*Amygdala 44.88 ± 3.6 
* Thalamus 39.06 ± 4.1 
* Caudate 37.42 ± 3.9 
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Anterior pituitary 2. 7 X 10 6 ± 0.65 X 106 
n = number of experiments. 
* represents a pool of 10 animals. 
** Mean ± S. E. M. 
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Figure 22. Distribution of immunoreactive TSH in the 
adult rodent brain. 
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Table 8. If measured in terms of total amotmt of hormone/brain region, 
the cortex contains the highest level of any other brain region, 580.21 
± 5.6 ng/cortex, although the total amount of brain TSH :j.s; 103 times less 
than TSH fotmd in the anterior pituitary, 2. 7 x 106 ± 0.65 ng/pituitary. 
When calculated as per mg of protein or as wet weight of tissue, the 
hypothalamus shows by far the highest concentration of immunoreactive TSH, 
204.20 ± 3.6 ng/mg protein and 5.443 ± 0.56 ng/mg tissue, followed by the 
amygdaloid nucleus, 29.42 ± 6.3 ng/mg protein and 1.10 ± 0.42 ng/mg wet 
tissue. Lesser amounts were detected in other regions of the brain and 
varied from the cerebellum, 16.50 ± 1.4 ng/mg protein, 0.799 ng/mg wet 
tissue, to the hippocampus, 11.88 ± 2.4 ng/mg protein and 0.798 ± 0.04 
ng/mg wet tissue. 
Assuming the level of TSH in serum to be approximately 489.67 ± 52.59 
ng/ml, as measured by the RIA, and using the same factor as for growth 
hormone, the amotm t of hormone which could be contributed by possible 
blood borne contamination of brain tissue would be 24.5 pg/mg wet weight 
of tissue. Thus, significant amotmts of a TSH-like material were fotmd 
to be present in all brain regions examined. 
B. GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE IMMUNOREACTIVE 
PEPTIDE DISTRIBUTION IN PRIMATE BRAIN 
These data are considered preliminary as only 3-8 brains were ex-
amined; however, because they show findings comparable to those observed 
in the rodent brain and extend relevancy to these observations, they will 
be reported here. Variables beyond the control of the experimenter such 
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as prior treatment of the animals and the use of fixed material may have 
been present to alter these results. 
a. Growth Hormone-Like Immunoreactivity in the Primate Brain 
From a total of 8 adult monkeys, the amount of immunoreactive growth 
hormone in various brain regions was calculated and expressed in Table 9 
as pg/mg wet tissue. In the primate, the hypothalamus appeared to con- · 
tain the largest concentration of growth hormone-like material, 164.01 ± 
9.5 pg/mg tissue, although fairly substantial amounts were also shown to 
be present in the amygdala, 56.20 ± 7.6 pg/mg tissue and many other brain 
regions. As with the rat, GH-like material in the monkey cerebellum 
showed the lowest amounts of GH/mg of tissue, only 19.66 pg/mg of brain 
tissue. 
b. Thyroid Stimulating Hormone-Like Immunoreactivity in the Primate 
Brain 
Measured as pg/mg wet tissue in Table 10, the hypothalamus and 
cortex were shown to contain the highest amounts of thyroid stimulating 
hormone-like activity, 133.92 ± 9.20, and 54.10 ± 2.36 pg/mg wet weight 
tissue, respectively. Several other areas of the primate brain showed 
little or no immunoreactive TSH activity such as the amygdala, cerebellum, 
thalamus, and putamen. 
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TABLE 9 
DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT MONKEY BRAIN 
(pg/mg wet wt. tissue)** 
GH 
n = 8 (pg/mg wet wt. tissu~* 
Hypothalamus 164.01 ± 9.5 
Amygdala 56.20 ± 7.6 ·:ft' 
Pallidus 39.20 ± 2.5 
Thalamus 36.80 ± 2.1 
Cortex 35.50 ± 1.8 
Hippocampus 30.88 ± 3.3 
Caudate 25.80 ± 1.2 
Putamen 23.80 ± 3.6 
Cerebellum 19.66 ± 2.4 
Pituitary 1. 78 X 10
4 ± 0.51 }C 104 
n =number of experiments. 
** Mean ± S. E. M. 
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TABLE 10 
DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT MONKEY BRAIN 
(pg/mg wet weight of tissue)** 
TSH 
n = 3 (pg/mg wet w,t. tissue)** 
Hypothalamus 133.92 ± 9.20 
Cortex 54.10 ± 2.36 
Mid Brain 13.28 ± 4.63' 
Hippocampus 5.92 ± 2. 79 
Amygdala NM 
Caudate NM 
Cerebellum NM 
Pallid us NM 
Putamen NM 
Thalamus NM 
Pituitary s talk. 1. 5 X 10 4 ± 0 • 2 3 x I 0 4 
n =number of experiments. 
NM = not measurable. 
** Mean ± S. E. M. 
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C. GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE IMMUNOREACTIVITY 
IN EXTRAPITU!TARY REGIONS OTHER THAN THE RAT CNS 
a. Growth Hormone-Like Immunoreactivity in the Pineal Gland and GI 
Tract 
In Tables 11 and 12, the levels of immunoreactive GH, expressed as 
ng/mg protein and as pg/mg wet weight tissue, respectively, for extra-
pituitary regions other than the CNS, show that substantial amounts of 
material exist in such areas. Certain areas of the gastrointestinal 
tract (GI) such as the small intestine, 1.23 ± 0.3 ng/mg protein, 42.6 
pg/mg tissue, and the pancreas, 1.12 ± 0.05 ng/mg protein, 30.2 ± 7.6 
pg/mg tissue, contain fairly high levels of a growth hormone-like material. 
In an effort to determine whether these results were artifactual, 
due to enzymatic destruction of the labeled growth hormone in the RIA, 
a study of the recovery of added amounts of purified pituitary growth 
hormone to tissue extracts was carried out. Near to 100 % recovery of 
added hormone revealed no breakdown of the radioactive tracer, strongly 
indicating that these levels of immunoreactive growth hormone in the GI 
tract are probably not due to an artifact in the system. One month after 
hypophysectomy, levels of GH found in these areas did not alter or change. 
The pineal gland was also shown to contain substantial amounts of 
immunoreactive growth hormone, 77.45 ± 8.3 ng/mg protein and 41.63 ± 2.7 
pg/mg tissue. Of interest are preliminary studies which appear to show 
that these levels are subject to diurnal variation and that they drop 
significantly after removal of the pituitary. 
TABLE 11 
DISTRIBUTION OF IMMUNOREACTIVE GH 
IN ADULT RAT TISSUES 
(tissues perfused for 10 min. with phosphosaline buffer, pH 7.6) 
(ng/mg protein)** 
n 
Muscle 3 
Kidney 3 
Liver 3 
Pancreas 16 
Small intestine 16 
Large intestine 16 
Pineal 30 
n =number of experiments. 
** Mean ± S. E. M. 
GH (ng/mg protein)** 
0.02 ± .005 
0.40 ± .008 
0.93 ± .02 
1.12 ± .05 
1.23 ± .03 
0.05 ± .02 
77.45 ± 8. 3 
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TABLE 12 
DISTRIBUTION OF IMMUNOREACTIVE GH 
IN ADULT RAT TISSUES 
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(tissues perfused with phosphosaline buffer, pH 7.6, for 10 mins.) 
(pg/mg wet weight tissue)** 
Amygdaloid nucleus 
Muscle 
Kidney 
Liver 
Pancreas 
Small intestine 
Large intestine 
Pineal 
n = number of experiments. 
** Mean ± S. E. M. 
n GH 
13 
3 
3 
3 
16 
16 
16 
30 
(pg/mg wet wt.)** 
284 ± 10.0 
3.0 ± 0.5 
4.5 ± 2.1 
21.0 ± 5.2 
30.2 ± 7.6 
42.6 ± 3.5 
3.2 ± 0.35 
41.63 ± 2. 7 
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b. Thyroid Stimulating Hormone Immunoreactivity 
Tables 13 and 14 demonstrate the amounts of immunoreactive TSH found 
in extrapituitary, non-brain tissues of the rat. As with immunoreactive 
GH, substantial amounts of TSH-like material were detected in GI tract 
tissues, especially in the pancreas, 77.0 ± 5.21 ng/mg protein, 12.42 ± 
ng/mg tissue, and in the small intestine, 23.8 ± 7.62 ng/mg protein and 
12.42 ± 2.54. ng/mg tissue. Similar to the results obtained for GH, the 
enzymes of the GI tract did not appear to interfere with the RIA for TSH, 
as good recoveries of added pure TSH to intestinal extracts were obtained 
in recovery studies. Hypophysectomy did not cause any appreciable fall 
in levels of immunore·active TSH in these tissues 30 days after pituitary 
removal. 
The pineal gland also demonstrated high levels of immunoreactive 
TSH, 388 ng/mg protein, 1.49 ± 0.43 ng/mg tissue, which appears to be 
subject to diurnal variation being significantly higher in the afternoon 
than in the morning. 
D. GROWTH HORMONE AND THYROID STIMULATING HORMONE IMMUNOREACTIVITY IN 
MEDIUM FROM CULTURES OF MONOLAYERED NERVOUS TISSUE 
a. Growth Hormone Immunoreactivity Detected in Tissue Culture Medium 
When the media from actively growing tissue cultures of amygdaloid 
tissue was examined for immunoreactive growth hormone-like material, the 
results, expressed as cumulative hormone present over a 30-day growth 
period, were determined and are shown in Fig. 23 
TABLE 1.3-
DISTRIBUTION OF IMMUNOREACTIVE TSH 
IN ADULT RAT TISSUES 
(tissues perfused for 10 min. with phosphosaline buffer, pH 7 .6) 
(ng/mg protein)** 
Muscle 
Kidney 
Liver 
Pancreas: 
Small intestine 
Pineal 
n 
3 
3 
3 
16 
16 
30 
n = number of experiments. 
** Mean ± S. E. M. 
ng TSH/mg protein** 
5.2 ± 0.30 
4.3 ± 0.25 
4.8 ± 0.32 
77.0 ± 5.21 
23.8 ± 7.62 
388 ± 25.1 
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TABLE 14 
DISTRIBUTION OF IMMUNOREACTIVE TSH 
IN ADULT RAT TISSUES 
(ng/mg wet weight tissue)** 
n ng TSH/mg wet wt. ** 
Hypothalamus 50 
Muscle 3 
Kidney 3 
Liver 3 
Pancreas 16 
Small intestine 16 
Large intestine 16 
Stomach 16 
Pineal u 
n ~number of experiments. 
** Mean ± S. E. M. 
5.433 ± 0.560 
0.010 ± 0.002 
0.040 ± 0.01 
0.063 ± 0.03 
U.42 ± 2.54 
10.78 ± 3.26 
0.18 ± 0.02 
0.18 ± 0.02 
1.49 ± 0. 43 
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Figure 23. 
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DAYS IN CULTURE 
Cumulative immunoreactive growth hormonerele~ed 
from cells of the adult ra; amygdaloid nucleus 
grown in tissue culture. In thes~ five different 
experiments, medium was changed at 5, 10, 20, 
25 and 30 days. Each symbol represents the 
average growth hormone released from approxi-
mately 2 x 106 viable cells plated in each of 
5 Falcon culture flasks containing 3ml. media. 
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From a total of five experiments, in which the medium was changed 
every five days, approximately 2 x 106 viable amygdaloid cells released 
47-65 ng of a growth hormone-like material into the tissue culture medium 
over the 30-day period of the study. Each symbol in Fig. 23 represents 
one experiment, and individual points, the mean levels of immunoreactive 
growth hormone present in the medium of five culture flasks obtained when 
a complete exchange of growth medium was carried out approximately every 
five days. 
When brain tissue was obtained from 21-day post-hypophysectomized 
rats and plated out in monolayer cultures, the cumulative amount of im-
munoreactive growth hormone found in the media, over a 30-day period, was 
determined by RIA and is shown graphically in Fig. 24 Four different 
brain areas are represented and each symbol shows the mean and standard 
error of the mean level of immunoreactive growth hormone released from a 
total of 15 plates from three different experiments. Medium was changed 
every five days and, in these studies using brain tissue from hypophysec-
tomized rats, it was shown that substantial amounts of immunoreactive 
growth hormone were released from all brain tissues into the medium over 
30 days of study. Little diffeiEnce was observed between the amounts ob-
tained from hypophysectomized amygdaloid tissue (Fig. 24 ) and amygdaloid 
tissue from normal intact animals (Fig. 23 ). The cumulative amounts of 
immunoreactive growth hormone released into the tissue culture medium 
from hypophysectomized brain tissue ranged from a mean of 20 ng in the 
cortex to 55 ng in amygdaloid cell cultures over three different experi-
ments. Viability checks throughout all tissue culture experiments showed 
IMMUNOREATIVE G H 
(ng) 
60 
50 
40 
30 
20 
10 
5 
182 
10 15 20 25 30 
DAYS IN CULTURE 
Figure 24. Cumulative immunoreactive growth hormone 
released from cells of the 21 day post-
hypophysectomised, adult, rat brain regions 
grown in tissue culture. Each symbol represents 
the mean and S.E.M. of hormone releasgd in 3 
experiments from approximately 2 x 10 cells 
plated in 5 culture flasks containing 3 ml. 
media. In these experiments, medium was changed 
at 5, 10, 15, 20, 25 and 30 days. 
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between 95%-98% viable cells present at each sampling date. 
b. Thyroid Stimulating Hormone Immunoreactivity Detected in Tissue 
Culture Medium 
Studies of brain tissue monolayers? in wh~ch the measurement 
of TSH-like activity present in the growth medium was determined after a 
certain time period, are plotted in Fig. 25 • Here cumulative TC medium-
immunoreactive TSH is plotted against days grown in tissue culture of dis-
persed cells obtained from specific brain parts from normal adult rat 
brain and from anterior pituitaries. All tissues tested were shown to 
release a TSH-like material into the medium over the 30-day period of 
study, ranging from a total of 2,200 ng for the pituitary to 350 ng for 
thalamus cells. Each symbol in Fig. 25 represents tissue from a different 
brain area or ante~ior pituitary and the individual points, the mean and 
standard error of the mean, cumulative value for immunoreactive TSH re-
leased from suchmonolayered cells. When cells were taken from 21-day 
post-hypophysectomized adult rats and plated in tissue culture medium, 
the amount of cumulative immunoreactive TSH released over a 30-day period 
was also determined. The results are shown in Fig. 26 and ranged from a 
total of 750 ng of TSH from hippocampal tissue to 550 ng of TSH from amyg-
daloid tissue after 30 days in culture. This demonstrates that even after 
hypophysectomy, brain tissue possessed the ability to release immunoreac-
tive TSH into the medium, as long as the viability of the cultured cells 
was maintained. Viability throughout these experiments was maintained 
between 93%-98% of the original cell number. 
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Figure 25. Cumulative immunoreactive thyroid stimulating 
hormone released from cells of the adult rat 
brain regions and pituitary grown in tissue 
culture. Each symbol represents the mean and 
S.E.M. of hormone released in 5 experiments, 
from approximately 2.5 x 106 cells plated in 
5 culture flasks containing 3 ml media. In 
these experiments, medium was changed at 5, 
10, 20 and 28 days. 
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Figure 26. Cumulative, immunoreactive thyroid stimulating 
hormone released from cells of the 21 day post-
hypophysectomised, adult, rat, brain regions 
in tissue culture. Each symbol represents the 
mean and S.E.M, of hormone released in 3 expe-
riments from approximately 2 x 107 cells plated 
in 5 culture flasks containing 3 ml media. In 
these experiments, medium was changed at 5, 10, 
15, 22 and 30 days. 
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E. THE EFFECT OF KNOWN HORMONAL REGULATORS ON THE RELEASE OF IMMUNOREAC-
TIVE GH AND TSH FROM TISSUE CULTURED CELLS OF THE BRAIN AND ANTERIOR 
PITUITARY 
a. Somatostatin Added to Tissue Cultured Brain and Pituitary Cells 
Somatostatin, a known inhibitor of growth hormone release from in-
tact pituitaries (Brazeau, 1973) was shown to be effective at a concentra-
tion of 1 ~g/ml medium in significantly suppressing the release of immuno-
reactive GH from both pituitary and various brain tissues grown in culture. 
In Fig. 27 , the levels of growth hormone present in the medium of control 
and somatostatin-spiked tissue cultures are shown after a 24-hour period 
of incubation. The results delineated in Fig. 27 represent the mean, and 
standard error of the mean, of immunoreactive growth hormone levels from 
three different experiments each containing five separate tissue culture 
flasks, each containing approximately 6 x 106 viable cells. 
b. Thyroxine (T4) Added to Tissue Cultured Brain and Pituitary Cells 
Levels of thyroid stimulating hormone-like activity in actively 
7 growing cultures of brain tissue (10 cells), incubated for 24 hours with 
and without 10-9M L-thyroxine are shown in Fig. 28 • Although this con-
centration of thyroxine (T4) was able to significantly suppress the release 
of TSH from cultured pituitary cells from a mean of 1,700 ng/24 hours to 
a mean of 1,400 ng/24 hours, it was not, however, able to prevent the re-
lease of immunoreactive TSH from any part of the brain grown in monolayers 
under similar conditions. Results in all cases were expressed as the mean, 
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PITUITARY AMYGDALA HIPPOCAMPUS HYPOTHALAMUS 
~ SOMATOSTATIN 
0 NO SOMATOSTAnN 
Figure 27. Immunoreactive growth hormone released from 
6 x 106 cells of the adult rat brain and 
pituitary grown in tissue culture for 24 hrs 
with or without somatostatin (1 ~g/ml). 
Results represent the mean and S.E,M. from 
3 experiments. 
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Figure 28. Immunoreactive thyroid stimulating hormone 
released from 107 cells of the adult rat 
brain and pituitary grown in tissue culture 
for 24 hrs with or without 1-thyroxine, 
(T 4 10'"9 M) • 
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and standard error of the mean, levels of immunoreactive TSH detectable 
after 24 hours from at least five plates in three different experiments 
as shown in Fig. 28 • 
F. IMMUNOREACTIVE THYROID STIMULATING HORMONE LEVELS DETECTED IN A 
CULTURED NEUROBLASTOMA CELL LINE N4TGI 
Over a ten-day growth period, in which media was changed at days 
1, 4, and 9, the levels of immunoreactive TSH released into the growth 
medium from actively growing cultures of the neuroblastoma cell line 
N4TGI were determined by RIA and are shown in Fig. 29 • The mean and 
standard error of the mean values for cumulative hormonal levels from 
5 - 8 individual flasks in three different experimental runs are repre-
sented by each point. A total mean of 760 ng of immunoreactive TSH was 
found in the medium after 10 days growth of this cell line. Throughout 
the experiment, viability was checked by the trypan blue exclusion method 
and found to remain between 95% - 98% of the original number of viable 
cells plated at day one. 
It was apparent that cells of this neuroblastoma cell line are 
capable of releasing a TSH-like immunoreactive material indefinitely, if 
one extrapolates, into the growth medium. 
G. FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION 
Assay of three pellets and three supernatants obtained by differen-
tial ultracentrifugation of brain extracts (as described in Materials and 
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Cumulative immunoreactive thyroid stimulating 
hormone TSH released from 5 x 106 cells of 
the neuroblastoma cell line N4 TG1. Each point 
represents the mean and S.E.M. of hormone 
released from cells in 3 experiments. The media 
was changed at 1, 4 and 9 days. 
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Methods) for their content of either immunoreactive growth hormone or 
thyroid stimulating hormone, gave the data shown in Tables 15 and 16, 
respectively. 
a. Growth Hormone: Distribution in Ultracentrifuged Homogenate 
Fractions 
In Table 15, the quantity of GH is expressed either as ng/fraction, 
taking into account the volume of the fraction or as ng/mg ~rotein, ac-
counting for the amount of protein present. For amygdala and thalamic 
homogenates, the greatest concentration of immunoassayable growth hormone 
was clearly detectable in the second pellet P2 , i.e., P1 = 6.119, Pz = 
17.879, P3 = 0.906, s1 = 18.346, s2 = 8.242, and s3 = 5.477 ng GH/frac-
tion. This second pellet is known to represent the synaptosomal-mite-
chondrial fraction of the brain homogenate after ultracentrifugation. 
For the hypothalamic homogenate, however, there appeared to be an equal 
distribution of immunoreactive GH between the P2 pellet and the final 
supernatant. This would suggest, that in the hypothalamus there is a 
fraction of immunoreactive growth hormone that is not associated with a 
specific structural entity, such as the synaptosomes or mitochondria but 
present instead in some free state, whereas a second fraction which sedi-
ments out is presumably associated with a specific entity present in the 
P2 pellet preparation. 
·-----., -
192' 
TABLE 15 
FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION: 
GROWTH HORMONE 
(Content of fractions ng/fraction and ng/mg protein) 
ng GH/fraction 
AMYGDALA pl 6.119 sl 18.346 
P2 17.879 s2 8.242 
p3 0.906 s3 5.477 
THALAMUS pl 13.100 sl 30.296 
P2 21.602 s2 6.663 
p3 1.626 s3 7.166 
HYPOTHALAMUS pl 10.168 sl 70.762 
P2 36.661 s2 41.237 
p3 2. 775 s3 36.718 
ng/mg protein/fraction 
AMYGDALA pl 2. 769 sl 4.504 
P2 4.659 s2 2.601 
p3 1.839 s3 3.649 
THALAMUS pl 1.160 sl 4.483 
P2 3.673 s2 2.134 
p3 0. 797 s3 2.020 . 
HYPOTHALAMUS pl 0.664 sl 24.824 
P2 6.886 sz 11.034 
p3 4.462 s3 5.669 
P = pellet; S = supernatant 
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b. Thyroid Stimulating Hormone: Distribution in Ultracentrifuged 
Homogenate Fractions 
Similar ultracentrifugal fractionation studies of brain homogenate 
for the detection of TSH-like material, by radioimmunoassay, gave the 
data shown in Table 16. 
Here again, as shown for the amygdaloid homogenate, the greatest 
quantity of immunoreactive TSH was associated with the P 2 pellet whereas 
the hypothalamic fractionation pattern seemed to show two, rather than 
one, distinct pool of immunoreactive material--one associated with the 
P2 pellet and the other with the final supernatant preparation. 
Because of this heterogenous distribution of both immunoreactive GH 
and TSH in the hypothalamic homogenate, further fractionation of the P2 
pellet by sucrose density gradients might allow better discrimination of 
whether the two hormones are actually associated with a particular 
cellular entity such as the synaptosomes. 
H. IMMUNOPEROXIDASE STAINING OF BRAIN TISSUE FOR PITUITARY-LIKE HORMONE 
DISTRIBUTION 
a. Thyroid Stimulating Hormone 
To further pinpoint the location of thyroid stimulating-like hor-
mone in rat brain tissue, immunohistochemical staining of paraformalde-
hyde-fixed tissue was attempted. The conditions noted in the "Materials 
and Methods" section revealed a dense uptake of peroxidase-stained 
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TABLE 16 
FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION: 
THYROID STIMULATING HORMONE 
(Content of fractions ng/fraction and ng/mg protein) 
ng ISH/fraction 
AMYGDALA pl 79.360 sl 251.071 
p2 225.632 sz 52. 768 
p3 49.354 s3 6.811 
HYPOTHALAMUS pl 9 7. 385 sl 347.631 
p2 126. 783 s2 210.295 
p3 108.127 s3 116.534 
ng TSH/mg protein 
AMYGDALA pl 7.638 sl 13.364 
Pz 9.999 s2 4. 713 
p3 3.172 s3 2.008 
HYPOTHALAMUS pl 5. 705 sl 96.730 
Pz 48.630 s2 52.119 
p3 10.714 s3 42.588 
P = pellet; S - supernatant 
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immunocomplex in cells of the pituitary, indicating the presence of TSH. 
Shown under low-power (X 100) in Fig. 30 , and at higher magnification 
(X 400) in Fig. 31 , are representative sections of pituitary with the 
thyrotrophs staining a dark brown against a nonhormonal containing, un-
stained, cell background. All controls revealed a similar appearance to 
Fig. 32 , that is, no uptake of PAP complex by any cell due to the condi-
tions set by the experiment. For the pituitary, therefore, it was demon-
strated that the incubation times and concentrations of antibodies and 
other substituents in this immunohistochemical staining experiment to 
detect TSH activity were sufficient and satisfactory. 
When amygdaloid tissue was treated in a similar manner and examined 
under a high magnification (X 1000), Figs. 33 and 34 , or at a lower mag-
nification CX 400), Fig. 35 , certain cell bodies were seen to stain dark 
brown, indicating the presence of TSH-like immunoreactive material. Con-
trols again provide evidence that this finding was not an artifactual ob-
servation. Pre-treatment with colchicine would perhaps have shown a more 
detailed picture of the involvement of the type of cell, neurone, or glia 
which was being stained. Cell bodies staining for TSH were also detected 
in the hypothalamus and hippocampal regions of the brain, with a few iso-
lated bodies being also distinguished in the cerebral cortex and thalamic 
areas. In the amygdaloid area, all of the individual nuclei appeared to 
contain TSH-like hormone. Those which were more densely stained included 
the nucleus amygdaloides corticalis, amygdaloides basilis, Ra~s·mediales, 
and par:_s 1ateralis. In the hypothalamus, areas in which stained cell 
bodies were prominent were the dorsomedial and ventromedial nuclei. 
Figure 30. Immunohistochemical staining of pituitary 
thyrotrophs by the PAP technique. 
(Blue filter, x 100). 
~6 
Figure 31. Immunohistochemical staining of pituitary 
thyrotrophs by the PAP technique (x400). 
~7 
Figure 32. Control pituitary stained by the PAP technique 
using absorbed TSH antiserum ( x 400). 
Cell bodies containing 
TSH 
Control immunoabsorbed 
ls t. Ab. 
F igure 33. Imm~nohistochemical staining by the PAP 
technique of amygdaloid tissue for TSH 
( X 1000) 
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Figure 34. Immunohistochemical staining of amygdaloid 
t issue for TSH by the PAP technique. Controls (x 1000). 
A. Immunoabsorbed first antibody. B. First antibody 
r eplaced by normal rabbit serum. 
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A 
B 
F i gure 35. A. Immunohistochemical staining for TSH in 
amygdaloid tissue (x400). 
B. Control. First antibody replaced by normal 
rabbit serum. 
200 
A 
B 
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Similar studies with GH, not deta~led in this thesis, have also 
detected GH-like material in cells of the amygdaloid nucleus by an indir-
ect immunoperoxidase technique. Thus, confirming the association of hor-
mone-like material with a particulate fraction of nervous tissue, these 
histochemical studies provide further evidence of a brain source for 
pituitary-like hormones. 
I. CHARACTERIZATION OF "BRAIN HORMONES" BY GEL CHROMATOGRAPHY 
a. IRGH-like Material in the Rat Brain 
The elution pattern obtained when a sample of amygdaloid extract, 
containing immunoreactive GH-like material was placed on a Sephadex G-100 
125 
column together with a trace amount of I labeled rat pituitary GH, is 
shown in Fig. 36 . The ordinates are given as the concentration of im-
munoreactive GH and cpm of radiolabeled pituitary growth hormone. On 
the abcissa, the tube number of the fractions collected is noted. 
The peak of GH immunoreactivity coeluted with the trace amount of 
radiolabeled pituitary growth hormone, indicating molecular identity 
between the hormonal material found in the brain homogenate with that 
isolated from the pituitary. A molecular weight of approximately 46,000 D 
can therefore be assigned to the brain GH-like material. 
b. IRTSH Material in the Rat Brain-
Fig. 37 illustrates a similar experiment in which the amygdaloid 
extract was fractionated on a Sephadex G-100 column, together with 125r 
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Figure 36. Elution pattern of lyophilised and 
reconstituted amygdala extract IRGH 
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Elution pattern of lyophilized and reconstituted 
amygdala extract IRTSH and 125r rat pituitary TSH 
on a Sephadex ~100 column eluted with 0.01 M 
P04 buffer pH 7.6. 
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rat pituitary TSH. Again, coelution of immunoreactive and labeled pitui-
tary TSH material was observed, indicating molecular similarity between 
the hormones isolated from these two distinct sources. A probable mole-
cular weight of 28,000 D can therefore be assigned to the brain TSH-like 
hormone. Similar results for both GH and TSH hormones were demonstrated 
for all brain regions examined. The existence of a prohormone or break-
down product of pituitary hormones in the brain thus seems unlikely. 
c. IR Pituitary-Like Hormones from a Cloned Mouse Neuroblastoma Line 
When a concentrated sample of neuroblastoma N4TGI cell extract was 
similarly fractionated with a trace amount of radiolabeled pituitary TSH, 
coelution of immunoreactive and tracer hormone was shown, as in Fig. 38 • 
Similar results were obtained when non-cell line tissue extracts 
from amygdaloid tissue cell cultures and pituitary cell cultures were 
fractionated and compared. This would indicate that the immunoreactive 
hormonal activity detected in the in vitro experiments were also molecu-
larly similar, in terms of molecular weight, to their pituitary counter-
parts in vivo. 
J. IMMUNOLOGICAL CHARACTERIZATION OF BRAIN PITUITARY-LIKE HORMONES AND 
FURTHER IMMUNOASSAY VALIDATION 
Logit log plots demonstrating parallel displacement for serial di-
lutions of pituitary and CNS extracts are shown in Figs. 39 and 40 for 
GH and TSH, respectively. Although values actually fell along the same 
line, the hippocampal data is displaced for visual emp~asis of the 
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Figure 38. Elution pattern of lyophilised, 
reconstituted N4TG1 cell extract IRTSH and 125r rat pituitary TSH on a Sephadex G-100 
column eluted with 0.01 M P0 4buffer pH 7.6 
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Figure 39. Logit log plot demonstrates parallel 
displacement for serial dilutions of 
pituitary and CNS growth hormone extracts. 
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displacement for serial dilutions of 
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data's linearity. Such linearity between pituitary and brain hormones 
demonstrated probable immunological identity. 
K. BIOLOGICAL ACTIVITY OF BRAIN PITUITARY-LIKE HORMONES AS COMPARED TO 
PITUITARY HORMONES 
a. Growth Hormone Bioassay 
When adult, 14-day post-hypophysectomized male and female rats re-
ceived intraperitoneally injected doses of pituitary, amygdaloid extract 
or saline over a 5-day period, their body weights and width of the tibia 
epiphyseal cartilage were examined as indicators of biological activities 
usually attributable to growth hormone. 
Table 17 shows the changes in body weights recorded over the 5-day 
injection period before sacrifice from two individual experiments. It is 
apparent that, whereas the extract from rat pituitary was able to produce 
an increase in body weight response, neither the amygdaloid extract nor 
saline-treated animals showed a rise in total body weight over the same 
time period. It was,however, apparent that the weight loss was substan-
tially less in aiilygdaloid-treated animals when compared to that experienced 
by saline-treated, hypophysectomized controls. These data were not al-
together surprising because, as noted before, a 100 ~g growth hormone 
dose is usually required before a weight gain is observable. In neither 
experiment was sufficient immunoassayable GH given in the brain extract 
to the test animals. 
---~---- ~--
-----
~--·-·--- ----
Treatment 
Exp 1 ~ 
Treatment 
Exp 2 ~ 
TABLE 17 
BODY WEIGHT CHANGES OVER 5-DAY 
BIOLOGICAL EXPERIMENT PERIOD (gms) 
Total Quantity of IR GH (~g) Injected Over 5 Days 
Saline (0) RAM (73) RAP (113) 
- 5.26 ± 0.10 - 2.3 ± 0.21 + 3.02 ± 0.25 
Saline (0) RAM (90) RAP (95) 
- 6.17 ± 1.35 - 2.3 ± 0.95 + 3.17 ± 0. 79 
209 
The mean and SEM of the difference in body weight between Day 1 of 
the biological experiment and Day 5. Each point represents 5 adult 
animals, 14 days after hypophysectomy. 
RAP = rat anterior pituitary extract 
RAM = rat amygdaloid nucleus extract 
2W 
However, a much lower amount of growth hormone is required to elicit 
a response in the tibia epiphyseal cartilage bioassay, and this was re~ 
fleeted in the results obtained in Table 18a. In both male and female 
groups of hypophysectomized animals from all four experiments, a statis-
tically significant increase in the epiphyseal cartilage width of amyg-
daloid extract-treated animals over those of saline-treated controls was 
observable. This ability to induce cartilage growth was equivalent to 
the effect produced by the pituitary extract on hypophysectomized animals 
under similar conditions. Thus, this experiment revealed that the GH-like 
material present in the brain extracts was capable of eliciting a response 
normally attributable to, and characteristic of, pituitary growth hormone. 
b. Gonadotrophic Bioactivity in Brain Extracts 
From the data examining the overall weights of testes and ovaries in 
all three groups of treated hypophysectomized animals,Tables 18 band c, 
it was apparent that the brain extracts also contained gonadotrophic bio-
activity. This observation has subsequently been substantiated by our 
laboratory (Emanuele et al, 1980) where significant amounts of immuno-
reactive luteinizing hormone have been found in certain areas of the rat 
brain. 
c. Thyroid Stimulating Hormone Bioactivity in Brain Extracts 
The thyroids of hypophysectomized animals treated with either sal-
ine, a high or low dose of rat pituitary extract, or amygdaloid tissue 
extract were examined biologically for structural changes. 
a. 
b. 
c. 
TABLE 18 
BIOASSA~ OF PITUITAR~ AND AMYGDALA EXTRACTS 
DOSE/RAT SEX 
J.18 RGH 
Saline-0 M 
RAP-113 M 
RAM-73 M 
Salin e-O F 
RAP-95 F 
RAM-90 F 
DOSE/RAT SEX 
J.18 RGH 
Salin e-O M 
RAP-113 M 
RAM-73 M 
DOSE/RAT SEX 
J.lg RGH 
Salin e-O F 
RAP-95 F 
RAM-90 F 
m.u. = 0.005 mm 
* p = < 0.05 
RAP = rat anterior pituitary 
RAM = rat amygdaloid nucleus 
TIBIA EPIPH. 
Width m. u. 
8.3 ± 0.5 
10.7 ± 0.4** 
10.3 ± 0.2** 
11.1 ± 2.0 
13.6 ± 3.2 
15.1 ± 3.2** 
TESTIS 
mg 
154 ± o. 7 
193 ± 4.0** 
204 ± 6 .2** 
OVARIES 
mg 
15.2 ± 3.2 
19.1 ± 4.9* 
29.7 ± 4.5** 
** p = < 0.01 
n = 4-5 
extract 
extract 
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Mean and standard deviations derived from bioassay of anterior pituitary 
and amygdaloid nucleus extracts in adult, 14-day, post-hypophysectomized 
male and female rats. Four to five animals were included in each group, 
and experimental animals received comparable amounts of immunoreactive 
growth hormone in four daily divided doses administered intraperitoneally. 
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Details of the results observed are shown in the composite photo-
graph, Fig. 41 . 
Sections of thyroid from saline-treated animals revealed the typical 
follicular characteristics of hypothyroidism, that is, low cuboidal epi-
theleal cells with flattened muclei and a shrunken colloidal mass in the 
follicular lumen. One of the characteristics of TSH activity~ as already 
discussed, is to maintain thyroid function. In both groups receiving pi~ 
tuitary extracts, thyroids revealed this response as demonstrated by the 
appearance of tall, ··cti.}:,.g;J.lial epitheleal follicle cells; large, round 
nuclei filling the cells, and well-maintained follicular collagen and 
vacuolization of colloid. 
The thyroid tissue dissected from amygdaloid extract-treated, hypo-
physectomized animals_also showed these characteristics, indicating, on 
the basis of biological activity, the presence of a TSH-like material. 
Evaluation of this TSH-like effectiveness was also attempted using 
131 
the parameter of I uptake into the thyroid as an activity indicator. 
Table 19 shows the data obtained in terms of 131I uptake into various 
tissues as well as the T4 levels of circulating serum after five different 
treatments. It was apparent that only the high dose of pituitary extract, 
100 lJg/hypophysectomized animal, was sufficient to produce an effect com-
parable to that demonstrated in the intact saline-treated control. In 
this short, four-day study, neither 2 lJg of pituitary TSH nor 4.3 lJg of 
amygdaloid extract TSH, were sufficient to increase the labeled iodide 
uptake into the thyroid or to raise circulating T4 levels, an indirect 
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SALINE (0) * LOH DOSE RAP (5) 
HIGH. DOSE RAP (100} RAM (_4. 5) 
Figure 41. Histology of the thyroid gland of 14 day 
hypophysectomised animals treated with 
brain and pituitary extracts (x 400). 
*( ).= ~g immunoreactive TSH administered over 
a 4 day period to adult rats, 14 days 
after hypophysectomy. Note the low cuboidal 
epithelium lining of the thyroid follicles 
of saline treated animals, and the increased 
height of epithelium of pituitary and amygdala 
treated animals. 
TABLE 19 
EVALUATION OF TSH EFFECTIVENESS TO CHANGE THE 
PATTERN OF lJlI UPTAKE INTO THE THYROID 
T tal 0 ( cpm · 1?II1 Tissue 
Dose 
TSH µg n Thyroid Muscle 
·+ Hypophysectomized Saline 5 4,447 ± 206 273 ± 20 
Hypophysectomized + 100 µg 5 57 ,453 ± 129 237 ± 30 
RAP TSH 
+ Hypophysectomized 2 µg 5 3,000 ± 198 254 ± 16 
RAP TSH 
Hypophysectomized + 4.3 µg 5 2 '795 ± 216 212 ± 22 
RAM TSH 
-
Intact + Saline 5 61,145 ± 598 189 ± 27 
214 
Serum 
I µimi dl 
T '-
0.8 ± 0.1 
2.2 ± 0.3 
0.9 ± 0 .1. 
0.9 ± 0.2 
4.7 ± 0.3 
Four groups of adult, 14-day, post-hypophysectomized rats received either 
saline, 100 µg pituitary extract TSH, 2 µg pituitary extract TSH, or 4.3 
µg amygdaloid nucleus extract TSH over a four-day period, intraperiton-
eally. Eighteen hours before sacrifice, each animal received 1.5 µ cu-
ries of radioactive iodine IP. 
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indicator of a well-maintained thyroid. On reviewing the literature, 
this result was not surprising, as it was found that at least 100 µg of 
pituitary TSH is necessary to show an increased 131I uptake into the 
thyroid of hypophysectomized rats (Cons et al, 1975). 
L. TESTING THE INTACTNESS OF THE BLOOD-BRAIN BARRIER IN BOTH ADULT AND 
YOUNG ANIMALS 
When 125r labeled pituitary hormones were injected IV into the tail 
veins of adult rats and 30 minutes allowed to pass before sacrifice, levels 
of labeled hormone were measured in various body tissues and brain in · 
order to observe if radiolabeled growth and thyroid stimulating hormone 
were capable of passing through the blood brain barrier. Results of 
these experiments are given in Tables 20 and 21 for GH and TSH, respect-
ively, as cpm/mg of wet tissue. The immunoreactive hormone content of 
saline-injected control rat tissue was also determined, in order to com-
pare the sites of receptor-boi.md circulating hormone with sites of immune-
logically active, extractable growth and thyroid stimulating hormones. 
As shown in Table 20, the large organs of the body readily bound 
circulating, labeled pituitary grow:t:h"hormone. The pi,_tuitary itself had a 
fairly high level of 125r hormone/mg tissue, 11.64 ± 2.5 cpm/mg, whereas 
little or no labeled hormone was detected in areas of the CNS, 0 .00 + 
O. 90 cpm/mg. By comparison, levels of immunoreactive growth hormone, as 
measured in tissue extracts by RIA, was highest in the CNS tissues such 
as amygdala, 212 ± 5.4 pg/mg tissue, and lowest in the large organs such 
as the kidney, 2.9 ± 0.2 pg/mg tissue. 
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TABLE 20 
TISSUE DISTRIBUTION OF 125I-RAT GROWTH HORMONE 
INJECTED IV INTO ADULT RATS AND IR GH CONTENT 
OF TISSUES (pg/mg wet weight) 
GH 
n cpm/mg* pg/mg wet wt.* 
Kidney 5 433.84 ± 104.6 2.9 ± 0.2 
Uver 5 55.56 ± 10 .9 17.3 ± 2.6 
Muscle 5 1.45 ± 1.0 2 .2. ± 0.5 
Pituitary 5 11.64 ± 2.5 1.9 
5 
x 10 ± 0. 7 
Amygdala 5 0.90 ± 0.1 212 ± 5 .4 
Thalamus 5 0 .89 ± 0.1 89 ± 3.6 
Cortex 5 o.oo 52 ± 5.2 
n = number of experiments. 
* Mean ± S. E. M. 
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A similar picture was shown for the effectiveness of the blood brain 
barrier in preventing 125 I labeled TSH from entering the brain via the 
peripheral circulation, as demonstrated in Table 21, where no radio-
labeled hormone was shown to be detected in the CNS structures. 
In studies with fetal material, there has been some discussion of 
possible leakages in the immature brain blood barrier. In order to 
determine whether or not this was the case, 21-day-old fetuses were 
given radiolabeled GH or TSH by an intraperitoneal route and the distri-
bution of label was detected in various body tissues and brain 30 minutes 
after administration. Although results are only given for GH in Table 
22b, similar data were obtained for TSH, revealing the total effective-
ness of the 21-day-old fetal blood brain barrier to prevent the entry of 
circulating pituitary hormones into the brain. 
Shown in Table 22a are the results of a similar experiment involv-
ing another such barrier, the fetal-placental barrier. This was also 
examined by injecting females in their 21st day of pregnancy with radio-
labeled hormone. Dissection of the fetuses after a 30-minute delay re-
vealed no label in any part of the fetus, demonstrating an inability of 
GH and TSH to cross the placental barrier. 
M. THE EFFECT OF HYPOPHYSECTOMY ON LEVELS OF BRAIN PITUITARY-LIKE 
HORMONES 
Animals which had been hypophysectomized for varying lengths of 
time were sacrificed and the levels of immunoreactive hormone present in 
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TABLE 21 
TISSUE DISTRIBUTION OF 125I RAT THYROID STIMULATING HORMONE 
INJECTED IV INTO ADULT RATS AND IR TSH CONTENT 
OF TISSUE (ng/mg wet weight) 
IR 
TSH 
n cpm/mg* ng/mg wet wt.* 
Kidney 5 678. 71 ± 10.5 0.040 ± 0.01 
Liver 5 72.65 ± 12.3 0 .075 ± 0 .02 
Muscle 5 18.64 ± 5.6 0.002 ± 0.01 
5 17.33 2.7 5 ± 0 .42 Pituitary ± 1.8 x 10 
Amygdala 5 o.oo 1.521 ± 0 .36 
Thalamus 5 0.00 0. 795 ± 0.27 
Cortex 5 o.oo 0.651 ± 0.43 
* Mean ± S. E. M. 
TABLE 22 
125 
DISTRIBUTION OF I RAT GROWTH HORMONE IN FETAL AND NEONATAL BRAIN AND OTHER TISSUES 
AFTER INJECTION OF RADIOLABELED HORMONE EITHER INTRAPERITONEALLY INTO PREGNANT RATS (A) 
INTO 21-DAY-OLD FETUSES (B) 
OR INTO NEONATAL RATS (C) 
125 I GH, cpm/gm Tissue 
Kidney Pituitary Hypothalamus Amygdala 
Rat Fetal Age (days): 
A. 21 
(IP mother) 0 0 0 0 
B. 21 
(IP fetus) 3000 2 0 0 
Rat Neonatal Age (days): 
c. 1 6676 318 0 0 
4 8759 378 0 0 
10 3764 183 0 0 
N 
t:; 
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the different brain regions compared to intact controls. 
a. Growth Hormone: Effects of Hypophysectomy 
Table 23 depicts the combined results from three separate experi-
ments, in terms of mean hormone levels, ng/mg protein, per group of 20 
animals, for the various brain regions extracted. Animals, hypophysec-
tomized for periods of 7, 14, 28, and 48 days, were compared to intact, 
similar aged controls. An analysis of the data revealed that in some 
brain regions, namely the amygdala, hypothalamus, and thalamus, an ini-
tial fall was observed in hormonal tissue levels after one week of hypo-
physectomy, e.g., amygdala, 6.25 ± 0.46 ~ 1.25 ± 0.50 ng/mg protein. 
However, after 28 days of hypophysectomy, these regions were found to 
contain more hormone than was found in comparable intact controls, e.g. 
amygdala, 5.75 ± 0.50 + 15.00 ± 3.10 ng/mg protein. This is illustrated 
in Fig. 42 for mean and standard errors of the mean levels of growth 
hormone, ng/mg protein, fot.md in amygdaloid tissue. Other areas of the 
brain, such as the caudate, hippo campus, and cortex, showed no fall in 
growth hormone levels throughout the entire 48 days of hypophysectomy 
examined. This kind of pattern is illustrated in Fig. 43 , showing 
mean and standard error of the mean levels of hormone, ng/mg protein, 
assayed in caudate tissue from hypophysectomized and from caudate tissue 
of intact rats. 
b. Thyroid Stimulating Hormone: Effect of Hypophysectomy 
Similar experiments were developed to determine changes in levels 
of immt.moassayable TSH in brain tissue. Combined results are given in 
Table 24 for hormonal levels in hypophysectomized and intact animals, 
pays, Post-
Hypophys. 
AM'YGDALA 
HYPOTHAL-
AMUS 
THALAMUS 
CAUDATE 
IDPPO·· 
CAMPUS 
CORTEX 
CEREBELLUM 
TABLE 23 
IMMUNOREACTIVE GROWTH HORMONE (ng/mg protein)* 
IN EXTRACTS FROM DISCRETE BRAIN PARTS 
HYPOPHYSECTOMIZED ANIMALS INTACT CONTROLS 
7 14 28 48 
A B c D A B c 
1.25 :!: 0.50 
,. 
3.25 ! 0.50 15.0 ! 3.10 13.25!1.56 6.25 !0.46 5.75 !0.88 5.75 !0.50 
0.57 !0.20 1.73 ! 0.20 7.24 !0.50 6.53 !0.90 1.99 !0.30 2.89 !0.15 3.13 !0.40 
0.95 ! 0.10 1.84 !0.02 2.07 !0.60 2.01::!:0.50 1.94 ::!:0.50 1.58 ::!: 0.10 1.86 !0.10 
1.45 ! 0.12 1.81 !0.15 1.75 ::!:0.09 1.91!0.12 1.50 ::!:0.15 1.75 ! 0.24 1.66 ::!:0.27 
1.36 ! 0.04 1.42 ::!:0.05 1.29 ::!:0.20 1.28 ::!: 0.40 1.40 ::!:0.20 1.48 ::!:0.10 1.39 ::!:0.94 
0.95 ::!:0.03 0.72 ::!: 0.04 0.99 ::!: 0.10 1.24 ::!:0.06 1.32 ::!:0.40 1.26 ::!:0.05 0.90 ::!:0.08 
0.05 ::!: 0.02 0.20 ::!:0.04 0.03 !0.10 0.00 0.05 ::!:0.01 0.00 0.04 ::!:0.01 
*Mean ! S.E.M. of 3 experiments, 20 animals/group of hypophysectomized or intact controls. 
D 
6.25 !0.75 
2.96 !0.25 
1.75 ::!: 0.04 
2.00 ::!:0.12 
1.25 ::!:0.01 
1.18 !0.02 
0.03 !0.01 
N 
N 
"""' 
AMYGDALA 
(GH] ng/mg PROTEIN 
OtNTACT 
20 
~ HYPOPHYSECTOM ISED 
~ p-=<0.01-
* 
10 
1 14 28 
DAYS POST HYPOPHYSECTOMY 
Figure 42. Immunoreactive growth hormone present in 
amygdaloid nucleus extracts of intact and 
hypophysectomised rats. 
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CAUDATE 
[GH] ng/mg PROTEIN 
0 INTACT 
3.00 ~ HYPOPHYSECTOMISED 
NS NS 
2..00 NS 
NS 
1.00 
7 14 28 48 
DAYS POST HYPOPHYSECTOMY 
Figure 43. Immunoreactive growth hormone present in 
caudate extracts of intact and hypophysecto-
mised rats. 
NS = not significant. 
Days Post-
Hypo phys. 
AMYGDALA 
HYPOTHALA-
MUS 
THALAMUS 
CAUDATE 
IIlPPO-
CAMPUS 
CORTEX 
CEREBELLUM 
TABLE 24 
IMMUNOREACTIVE THYROID STIMULATING HORMONE (ng/mg protein)* 
IN EXTRACTS FROM DISCRETE BRAIN PARTS 
HYPOPHYSECTOMIZED ANIMALS INTACT CONTROLS 
. -
7 14 28 48 
A B c D A B c 
18.95 :!: 2.10 27.58 :!:0.30 26.79 :!:2.70 24.64:!:1.50 21.50 :!:2.10 25.95 :!:0.50 25.79 :!: 3.31 
38.52 !0.20 31.43 :!:0.70 23.33 :!:3.40 25.95 :!:0.60 125.60!1.50 143.50 :!: 2.70 193.33 ! 1.66 
16.55 :!:0.50 19.24:!:1.50 17.32 :!: 2.10 15.95+1.00 17.21 :!:0.40 19.36 :!:0.80 18.80 :!: 2.11 
- I 
14.71 :!:0.80 12.92 :!:0.90 15.63 :!:0.90 14.99 !0.80 12.95 :!:0.20 14.83 !0.40 14.79 :!:0.60 
12.69 :!:0.80 9.76 :!: 0.20 10.30 !l.20 11.51 :!:0.70 12.58:!:1.10 11.63 :!:0.70 9.62 :!:0.91 
9.51 :!:0.40 11.18 :!:0.50 10.62 :!:3.20 10.98:!:1.20 8.79 :!:0.90 10.51 :!:0.50 11.66:!:1.60 
13.95 :!:0.30 12.69 :!:2.20 14.95 :q.20 15.63:!:1.10 14.23:!:1.50 13.65 :!: 0.80 16.35 :!:0.90 
* Mean :!: S.E.M. of 3 experiments, 20 animals/group of hypophysectomized or intact controls. 
D 
26.32 :!: 2.90 
139.60 :!: 5.90 
16.20:!:1.10 
15.60 :!:0.32 
10.60:!:1.30 
12.68 :!:0.63 
17.26 :!:0.50 
N 
N 
;i:.. 
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over different time periods, post-operatively. 
All tissue extracts analyzed for TSH, except hypothalamic tissue, 
were found to show no change in innnunoreactive hormone levels over the 
entire experimental period. However, a significant, p • < 0.02, fall 
in hypothalamic levels of TSH was noted from 7 - 28 days post-hypophy-
sectomy. These results are illustrated for 28-day post-hypophysectom-
ized and intact rats in Fig. 44 • The data are expressed as the mean 
and standard error of the mean IR hormone level per group of 20 animals 
for three different long-term hypophysectomy experiments. 
c. Validation of Hypophysectomy Procedure 
The efficiency of hypophysectomy was verified not only by micro-
scopic examination of the sella turcica, but by determination of levels 
of circulating TSH, T4 , GH, and% T3 resin uptake, in intact and hypo-
physectomized rats. Results of these assays are given in Tables 25 and 
26, and demonstrate that hypophysectomy could be considered complete 
for the animals used in these experiments, as levels of circulating 
pituitary hormones and thyroid hormones all fell to levels indicating 
complete loss of the pituitary. 
N. TARGET ORGAN REMOVAL: EFFECT ON LEVELS OF BRAIN HORMONES 
a. Growth Hormone: Effect of Removal of Target Organs 
Removal of a target organ may or may not have an effect on levels 
of pituitary growth hormone. Lacking any one specific target organ, it 
[TSH) n9/m9 PROTEIN 
200 
190 
30 
20 
10 
NS 
HYPOTHALAMUS AMYGDALA THALAMUS 
0 INTACT 
~ HYPOPHYSECTOMISEO 
NS 
NS 
CORTEX HIPPOCAMPUS 
28 DAYS POST HYPOPHYSECTOMY 
Figure 44. Immunoreactive TSH present in extracts from 
various brain regions of intact and 28 day 
hypophysectomised rats. 
NS = not significant. 
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TABLE 25 
IMMUNOREACTIVE GH AND TSH LEVELS IN SERUM OF ADULT RATS 
(ng/ml)* 
GROWTH HORMONE 
Intact 
(n • 200) 
2 49 • 86 ± 35 • 32 
30 days 
Hypophysectomized 
(n '"' 125) 
20 .28 ± 5. 80 
THYROID STIMULATING HORMONE 
Intact 
(n = 390) 
489.67 ± 52.59 
30 days 
Hypophysectomized 
(n = 120) 
59. 79 ± 3 .13 
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TABLE 26 
CIRCULATING THYROID HORMONE LEVELS IN SERUM OF ADULT RATS 
Intact 
(n = 40) 
64.02 ± 0.4 
30-day 
Hypophysectomized 
(n = 40) ·· 
47. 600 ± 2 .1 
% RES IN UPTAKE T 3?---
30-day 
Intact Hypophysectomized 
(n = 40) (n = 40) 
4.5 ± 0.3 0.63 ± 0.01 
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becomes more difficult to assess the possible effect of organ removal on 
GH levels. However, the main objective in this series of experiments was 
to reveal possible differences between brain and pituitary hormonal levels 
after one or four weeks of target organ removal with respect to any ef-
fects in sham-operated controls. The four-week data proved the most 
consistent throughout all three separate experiments, and results for 
both TSH and GH are given as the mean obtained from three experiments of 
20 animals/group/experiment. 
(i) Adrenalectomy 
As shown in Fig. 45 , the effect of removal of the adrenal gland 
on levels of immtmoreactive GH in serum, pituitary, hypothalamus, and 
amygdala was demonstrated to have no significant effect when compared to 
sham-operated controls. Levels of GH in other brain areas showed a 
similar lack of change, as given in Table 27, in terms of ng/mg protein. 
(ii) Oophorectomy 
When the ovaries of female adult rats were removed for four weeks, 
a significant drop (P = < 0.01) was observed in circulating GH, whereas 
pituitary levels of hormone remained unchanged (Table 28 and Fig. 46 ) • 
Contrary to this observation was that shown for the amygdala and hypo-
thalamus, which in all three experiments demonstrated a significant rise 
(P = < 0 .01) in GH levels present in brain tissue as compared to sham-
operated controls (Fig. 46 ) . Other brain areas did not show this rise 
in GH following the removal of ovaries but remained tmchanged four weeks 
postsurgery (Table 28). 
ng/ml 
200 
100 
GH LEVELS 4 WEEKS AFTER ADRENALECTOMY 
SERUM 
NS 
PITUITARY HYPOTHALAMUS 
ng/mg ng/mo Ag/mg 
PROTEIN NS PROTEIN PROTEIN 
NS 
800 4.0 5.0 
0SHAM 
AMYGOALA 
NS 
230 
~ ADRENALECTOMISED 
Figure 45. Effects of adrenalectomy on growth hormone 
levels in serum, pituitary, and brain. 
NS = not significant. 
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TABLE 27 
EFFECT OF ADRENALECTOMY (4 WEEKS) ON BRAIN GH LEVELS 
n 
AMYGDALA 60 
HYPOTHALAMUS 60 
CAUDATE 60 
THALAMUS 60 
HIPPOCAMPUS 60 
CORTEX 60 
CEREBELLUM 60 
ANTERIOR 
PITUITARY 60 
SERUM 60 
n = total animals 
** = mean ± S. E. M. 
(ng/mg protein)** 
Sham 
5.1 ± 0.26 
3.2 ± 1.50 
0.95 ± 0.26 
1.32 ± 0.37 
1.29 ± 0.08 
1.110 ± 0.24 
0.04 ± 0.01 
1.0 x io6 ± 0 .51. 
GH ng/ml 
183 ± 33.0 
of 3 experiments 
Statistical 
Adrenalectomized Significance 
5.4 ± 1.23 NS 
4.0 ± 0.50 NS 
1.10 ± 0.51 NS 
1.51 ± 0.76 NS 
1.24 ± 0.10 NS 
0 .94 ± 0.08 NS 
0.01 ± 0.006 NS 
0.98 x 6 10 ± o. 32 NS 
** 
179 ± 27.0 NS 
ngAnl 
200 
100 
GH LEVELS 4 WEEKS AFTER OOPHORECTOMY 
SERUM PITUITARY HYPOTHALAMUS AMYGOALA 
µg/mg 
PROTEIN 
800 
8.0 
ng/mg 
NS PROTEIN 
4.0 
* 
10.0 
ng/mg 
PROTEIN 
OsHAM 
~ OOPHORECTOMISEO 
Figure 46. Effects of oophorectomy on growth hormone 
levels in serum, pituitary and brain. 
NS = not significant. 
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TABLE 28 
EFFECT OF OOPHORECTOMY (4 WEEKS) ON BRAIN GH LEVELS 
(ng/mg protein) ** 
Statistical 
n Sham Adrenalectomized Significance 
AMYGDALA 60 4.32 ± 1.21 9.21 ± 0 .64 p = < 0.01 
HYPOTHALAMUS 60 2.81 ± 0.63 5.42 ± 1.21 p = < 0 .01 
CAUDATE 60 2.09 ± 0.31 1.49 ± 0 .52 NS 
THALAMUS 60 1.31 ± 0.26 0 .94 ± 0.20 NS 
HIPPOCAMPUS 60 1. 86 ± 0.30 1.44 ± 0 .15 NS 
CORTEX 60 o. 81 ± 0 .03 0.95 ± 0 .11 NS 
CEREBELLUM 60 0.11 ± 0.06 0.3 ± 0.01 NS 
ANTERIOR 
105 ± 0 .3 5 PITUITARY 60 8.1 x 8.6 x 10 ± 0 .25 NS 
GH ng/ml** 
SERUM 60 267 ± 22.6 68.90 ± 10.5 p = < 0 .01 
n = total animals 
** = mean ± S. E. M. of 3 experiments 
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(iii) Orchidectomy 
Unlike oophorectomy, removal of the testes did not produce any sig-
nificant change in immunoreactive GH levels in serum, pituitary, or in 
other brain tissues (Fig. 47 , table 29). 
(iv) Thyroidectomy 
Four weeks after removal of the thyroid, a significant drop (P = 
< 0 .01) was observed in both serum and pituitary immunoreactive GH levels. 
Levels of immunoreacti ve hormone in the·" hypothalamic and amygdaloid 
regions showed an opposite effect, that of a significant (P = < 0.01) 
increase in GH levels in operated animals, as compared to sham controls. 
This data is illustrated in Fig. 48 . All other brain areas showed no 
significant change in immunoreactive GH content when compared to sham 
controls four weeks after thyroidectomy, as shown in table 30. 
b. Thyroid Stimulating Hormone: Effect of Removal of Target Organs 
(i) Adrenalectomy 
As shown in Fig. 49 , four weeks after adrenalectomy, levels of 
circulating immunoreacti ve TSH remained constant, whereas a significant 
fall in pituitary TSH levels was observed (P = < 0 .05). Assay of hormone 
levels in various brain regions showed that only in the hypothalamus was 
any significant change brought about by removal of the adrenal glands 
(Table 31). 
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G H LEVELS 4 WEEKS AFTER ORCHIDECTOMY 
SERUM PITUITARY HYPOTHALAMUS AMYGDALA 
200 
µg/mg ng/mg 
NS PROTEIN NS PROTEIN 
---- ----
....__ 
no/ml 
4.0 NS 
no/mg 
PROTEIN 
5.0 
OsHAM 
~CASTRATED 
Figure 47. Effects of orchidectomy on growth hormone 
levels in serum, pituitary, and brain. 
NS = not significant. 
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TABLE 29 
EFFECT OF ORCH!DECTOMY (4 WEEKS) ON BRAIN GH LEVELS 
(ng/mg protein)** 
Statistical 
n Sham Castrated Significance 
AMYGDALA 60 6.12 :t 0. 35 5 .80 :t 0 .10 NS 
HYPOTHALAMUS 60 3.60 :t 1.20 3.95 :t 0.37 NS 
CAUDATE 60 1.29 :t 0 .51 1.02 ± o. 81 NS 
THALAMUS 60 2.10 :t 0. 39 1.95 ± 0.26 NS 
HIPPOCAMPUS 60 1.13 :t 0. 04 1.42 ± 0.31 NS 
CORTEX 60 1. 72 ± 0.33 1. 75 :t 0.62 NS 
CEREBELLUM 60 0.04 :t 0.02 0.06 ± 0.01 NS 
ANTERIOR 
x 105 :t 0. 40 PITUITARY 60 1.86 1. 72 :t 0. 31 NS 
GH ng/ml** 
SERUM 60 185 .o ± 22.0 177 :t 33.0 NS 
n = total animals 
**=mean± S. E. M. of 3 experiments. 
ng/ml 
200 
100 
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GH LEVELS 4 WEEKS AFTER THYROIDECTOMY 
SERUM 
** 
,ug/mg 
PROTEIN 
800 
PITUITARY HYPOTHALAMUS AMYGDALA 
** 
ng/mg 
PROTEIN 
3.0 
•• 
0SHAM 
~ THYROIDECTOMISED 
Figure 48. Effect of thyroidectomy on growth hormone 
levels in serum, pituitary, and brain. 
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TABLE 3a 
EFFECTS OF THYROIDECTOMY (4 WEEKS) ON BRAIN GH LEVELS 
(ng/mg protein)** 
AMYGDALA 
HYPOTHALAMUS 
CAUDATE 
THALAMUS 
HIPPO CAMPUS 
CORTEX 
CEREBELLUM 
ANTERIOR 
PITUITARY 
SERUM 
n = total animals 
n 
60 
60 
6a 
6a 
6a 
6a 
60 
6a 
6a 
Sham 
4.52 ± 0.63 
2. 75 ± a.25 
1.35 ± o.as 
1.45 ± a .12 
1. 87 ± a.31 
1.63 ± a.2a 
a.16 ± a.as 
5 
9.5 x 10 ± a. 7 
GH ng/ml** 
212 ± 25.a 
** = mean ± S. E ~··. M. of 3 experiments 
Thyroidectomized 
8.21 ± a.96 
4.82 ± a.65 
1.39 ± a.10 
a.95 ± a.31 
2.la ± a.26 
1.24 ± a.41 
a.a5 ±a.al 
5 
1.1 x la ± 0.4 
93.a ± 10 .6 
Statistical 
Significance 
p = < o.al 
p = < a.al 
NS 
NS 
NS 
NS 
NS 
p = < a .al 
p = < a .01 
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TSH LEVELS 4 WEEKS AFTER ADRENALECTOMY 
SERUM 
ng/ml ;.tg/mg 
2000 
1000 
PROTEIN 
300 
NS 
•p=<O.~ 
** p=< 0.02 
PITUITARY 
* 
AMYGDALA HYPOTHALAMUS 
ng/mg ng/mg 
** PROTEIN PROTEIN 
200 
NS 
30 
100 
0SHAM 
~ ADRENALECTOMISED 
Figure 49. Effect of adrenalectomy on TSH levels in serum, 
pituitary and brain. 
NS = not significant. 
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TABLE 31 
EFFECT OF ADRENALECTOMY (4 WEEKS) ON BRAIN TSH LEVELS 
(ng/mg protein)** 
Statistical 
n Sham Adrenalectomized Significance 
HYPOTHAW\MUS 60 176.25 ± 5.31 225.65 ± 6. 73 p = < .02 
AMYGDALA 60 27.52 ± 2.63 32.5 2-3.79 NS 
CEREBELLUM 60 22.26 ± 6.33 20.09 ± 2.10 NS 
THAW\MUS 60 16.53 ± 0.59 16. 75 ± 0.26 NS 
CAUDATE 60 11.96 ± 0.73 12.13 ± 0.98 NS 
CORTEX 60 14.25 ± 1. 76 12. 75 ± 0.52 NS 
HIPPO CAMPUS 60 10. 76 ± 0.92 9.83 ± 1. 79 NS 
ANTERIOR 
x 105 ± 0.26 2.5 x 105 ± 0.50 PITUITARY 60 3.6 p = < .05 
TSH ng/ml** 
SERUM 60 826.91 ±~50.75 750.26 ± 75 .63 NS 
n = total animals 
** = me.an ± S. E. M. of 3 experiments 
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As shown in Fig. 49. , a significant (P = < 0 .02) rise in inum.moreactive 
TSH levels occurred in adrenalectomized animals' hypothalamic tissue, as 
compared to sham-operated controls. 
(ii) Oophorectomy 
Removal of the ovaries did not produce any significant change in 
TSH immt.moreactive hormone levels in serum, pituitary, or brain tissue,. 
as illustrated by the data obtained in Fig. 50 and Table 32. 
(iii) Orchidectomy 
Whereas removal of the testes caused a significant fall (P = < 0.05) 
in immt.moreactive TSH levels in serum and pituitary, a significant rise 
(P = < 0.02) was shown for hypothalamic tissue four weeks postoperatively, 
(Fig. 51 ) • Other brain regions showed no significant change in TSH 
levels (Table 33). 
(iv) Thyroidectomy 
When immt.moreactive TSH was measured four weeks after thyroidectomy, 
it was shown that serum levels of the immunoreactivehormone rose dramati-
cally (P = < 0.001) as compared to controls, whereas a significant fall 
in pituitary levels (P = < 0.02) was observed (Fig. 52 ) • This fall in 
pituitary levels was shown in all three experiments and is contrary to 
what would be expected after loss of T4 production by thyroidectomy. 
However, as noted from the literature previously, it is believed that the 
turnover of TSH is so great in the pituitary, under these conditions, as 
to result in measured low basal levels •• Although the hypothalamus showed 
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TSH LEVELS 4 WEEKS AFTER OOPHORECTOMY 
SERUM PITUITARY AMYGOALA 
no/ml ..uo/mo no/mq 
PROTEIN PROTEIN 
NS 
1000 300 30 
NS 
NS 
0SHAM 
~ OOPHORECTOMISED 
Figure 50. Effect of oophorectomy on TSH levels in serum, 
pituitary and brain. 
NS = not significant. 
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TABLE 32 
EFFECTS OF OOPHORECTOMY (4 WEEKS) ON BRAIN TSH LEVELS 
(ng/mg protein)** 
Statistical 
n Sham Oophorectomized Significance 
HYPOTHALAMUS 60 209.63 ± 5 .11 212.90 ± 6. 73 NS 
AMYGDALA 60 33.96 ± 2.59 35.05 ± 3. 72 NS 
CEREBELLUM 60 16.22 ± o. 79 17.69 ± 0.95 NS 
THALAMUS 60 18.13 ± 2.11 17.98 ± 0.63 NS 
CAUDATE 60 12.93 ± o. 89 14.60 ± o. 84 NS 
CORTEX 60 12. 75 ± 2.30 11.98 ± 0.68 NS 
HIPPOCAMPUS 60 11.38 ± 1.62 12 .95 ± 0 .98 NS 
ANTERIOR 5 
x 105 ± 0 .5 PITUITARY 60 2.4 x 10 ± 0.9 2.2 NS 
TSH ng/ml ** 
SERUM 60 640 ± 120 .o 602 ± 35 .0 NS 
n = total animals 
** = mean ± S. E. M. of 3 experiments 
TS H LEVELS 4 WEEKS AFTER CASTRATION 
SERUM PITUITARY HYPOTHALAMUS 
ng/ml ,ug/mg ng·/mg 
1000 
.. p =< 0.05 
•• p =< 0.02 
PROTEIN PROTEIN 
300 
** 
200 
OsHAM 
~CASTRATED 
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Figure 51. Effect of orchidectomy on TSH levels in serum, 
pituitary and brain. 
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TABLE 33 
EFFECTS OF ORCHIDECTOMY (4 WEEKS) ON BRAIN TSH LEVELS 
(ng/mg protein)** 
Statistical 
n Sham Castration Significance 
HYPOTHALAMUS 60 205 .61 ± 7.39 280 .00 ± 11.65 p = < 0 .02 . 
AMYGDALA 60 26.32 ± 4.61 35 .92 ± 1.95 NS 
CEREBELLUM 60 13.40 ± 0.16 14.24 ± 1.36 NS 
THALAMUS 60 12.46 ± 2.51 15 .36 ± 0.95 NS 
CAUDATE 60 16. 39 ± 1.55 13.97 ± 2.60 NS 
CORTEX 60 14.61 ± o. 78 12. 65 ± 1.20 NS 
HIPPOCAMPUS 60 12.59 ± 0 .90 12.78 ± 1.10 NS 
ANTERIOR 5 5 
PITUITARY 60 2.4 x 10 ± 0 .51 1.2 x 10 ± 0 .42 p = < 0 .0-5 
TSH ng/ml** 
SERUM 60 640 .00 ± 79 .6 405.00 ± 59. 70 p = < 0.05 
n = total animals 
** = mean ± S. E. M. of 3 experiments 
TS H LEVELS 4 WEEKS AFTER THYROIDECTOMY 
SERUM 
no/ml µo/mo 
* PROTEIN 
1000 
•P=(0.001 
** p=( 0.02 
300 
PITUITARY 
no/mo 
PROTEIN 
30 
AMYGOALA 
NS 
D INTACT, SHAM 
~ THYROIOECTOMISEO 
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Figure 52. Effect of thyroidectomy on TSH levels in serum, 
pituitary and brain. 
NS = not significant. 
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TABLE 34 
EFFECTS OF THYROIDECTOMY (4 WEEKS) ON BRAIN TSH LEVELS 
(ng/mg protein)** 
Statistical 
n Sham 
-
Thyroidectomized Significance 
HYPOTHALAMUS 60 158. 36 ± 10 .63 207 .00 ± 21.35 NS 
AMYGDALA 60 33.39 ± 1.65 36. 89 ± 2.71 NS 
CEREBELLUM 60 15.96 ± 1.30 14.63 ± 2.50 NS 
THALAMUS 60 18.15 ± 0 .45 17.10 ± 2. 73 NS 
CAUDATE 60 16. 72 ± 0.87 15.96 ± 0.55 NS 
CORTEX 60 14.10 ± 2.61 16.59 ± 0. 71 NS 
HIPPO CAMPUS 60 13. 78 ± 0.60 12.11 ± 1.24 NS 
ANTERIOR 
3.5 x 105 x 105 PITUITARY 60 ± o. 80 1.9 ± 0 .52 p = < 0.02 
TSH ng/ml** 
SERUM 60 462.00 ± 59.60 2226.00 ± 102.3 p = 0 .001 
n • total animals 
** = mean ± S. E. M. of 3 experiments 
TABLE 35 
SIGNIFICANCE OF CHANGES IN BRAIN GH AFTER HYPOPHYSECTOMY AND TARGET ORGAN REMOVAL (4 WEEKS) 
PROCEDURE Other Brain 
Pituita!l_ Serum Hypo thalamus Amygdala Regions 
HYPOPHYSECTOMY -- p = < 0.001 p = < 0.01 p = < 0 .01 Thalamus: 
p = < 0.05 
Others: NS 
ADRENALECTOMY NS NS NS NS NS 
OOPHORECTOMY NS p = < 0.01 p = < 0.01 p = < 0 .01 NS 
ORCHIDECTOMY NS NS NS NS NS 
THYROIDECTOMY p = < 0 .01 p = < 0.01 p = < 0.01 p = < 0.01 NS 
N 
.g; 
TABLE 36 
SIGNIFICANCE OF CHANGES IN BRAIN TSH AFTER HYPOPHYSECTOMY AND TARGET ORGAN REMOVAL (4 WEEKS) 
PROCEDURE 
HYPOPHYSECTOMY 
ADRENALECTOMY 
OOPHORECTOMY 
ORCHIDECTOMY 
THYROIDECTOMY 
T 4 ·· · AD:t-jINIS-TRAT:(ON 
Pituitary 
p = <; 0 .05 
NS 
p = <; 0 .05 
p = < 0.02 
p ·.= < 0.002 
Serum 
p = <; 0 .01 
NS 
NS 
p = <; 0.05 
p = < 0.001 
p = <; 0.002 
Other Brain 
Hypothalamus Amygdala Regions 
p = < 0.02 NS NS 
p = < 0.02 NS NS 
NS NS NS 
p = < 0.02 NS NS 
NS NS NS 
NS NS NS 
N 
fO 
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a slight rise in TSH levels, it was not statistically significant, as 
was the case for all other brain areas, as shown in Table 34. Levels of 
circulating T4 fell from 3.42 to 0.02 µg/dl, while the % T3 resin uptake 
remained constant in thyroidectomized animals. 
The significance of the changes discussed in GH and TSH after hypo-
physectomy and target organ removal are shown in Tables 35 and 36, res-
pectively. 
0. THYROXINE LEVELS: EFFECT OF AN INCREASE IN CIRCULATING T ON SERUM 
AND TISSUE LEVELS OF TSH AND T4 
The effect of injecting IM, 0.4 µg T4/gm body weight, daily for 
7 days into intact adult rats on TSH levels in serum, pituitary, and 
amygdaloid tissue, is illustrated in Fig. 53 • Whereas approximately 
200 µgm T4 caused a dramatic, significant (P = < 0.002) fall in circu-
lating TSH (400 + 58 ng/ml) and pituitary TSH (300 + 50 µg/mg protein), 
presumably by a "negative feedback." effect, no significant change in TSH 
levels was seen in amygdaloid or other brain tissues, including the hypo-
thalamus. Circulating T4
1 s were increased from 4.70 + 17.42 µg/dl in 
treated animals, whereas the % T3 resin uptake remained constant. In 
hypophysectomized animals, however, the effect of a similar dose of T 4 
on brain levels of TSH was to cause a statistically significant (P = 
< 0.05) rise in the levels of IRTSH in the hypothalamus as compared to 
saline-injected hypophysectomized animals. T 4 levels in such animals 
rose from 0.8 + 24 µgm/dl, and similarly % T3 uptake also rose from 48.5 
+ 70.229. Other brain regions showed no change in immtmoreactive TSH 
levels after thyroxine treatment. 
SERUM PITUITARY AMYGDALA 
TSH ,ug/mg ng/mg 
ng/ml PROTEIN PROTEIN 
400 
NS 
00 * 30 300 
200 
100 
* p=<0.002 0 SALINE 
~ 200)lgmT4 
Figure 53, The effect of injecting IM. 0.4µg T4 /gm body 
weight daily for·7 days into intact adult rats, 
on TSH levels in serum, pituitary and amygdala. 
NS = not significant. 
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P. ONTOGENY OF PITUITARY AND BRAIN PITUITARY-LIKE HORMONES 
In order to examine the levels of hormone at various stages of de-
velopment, rat fetuses from ten days to birth and pups from birth to 
30-day-old adults were sacrificed and brain homogenates analyzed for 
pituitary hormonal content by RIA. 
a. Growth Hormone 
(i) Growth hormone in brain and pituitary tissues 
In Fig. 54 , levels of immunoreactive growth hormone, expressed as 
ng hormone/mg protein, in terms of fetal and neonatal age of the animal, 
are shown. This data demonstrated the appearance of immunoreactive hor-
mone at fetal day 10 and a remarkable rise in the level of detectable 
hormone extracted from the hypothalamus and amygdala just prior to birth, 
or day 21 of gestation in the rat. Postpartum, hormone concentration in 
these brain regions fell abruptly and then rose, gradually attaining adult 
levels at around 30 days of age, essentially at the time of puberty. All 
other brain parts--thalamus, caudate, and cortex--showed a similar, al-
though not so pronounced, preparturitional rise over adult levels of growth 
hormone. The hippocampus showed the most dramatic preparturitional in-
crease of all brain regions compared to adult levels. 
Levels of pituitary growth hormone were also measured over the same 
age span, as shown in Fig. 55 • Contrasting to the finding of pituitary-
like hormones in the rodent brain as early as fetal day 10, growth hor-
mone was not detectable until day 12 of fetal life in the pituitary anlage 
GROWTH HORMONE 
ng/mg PROTEIN 
50 
30 
10 
IOF BIRTH 
o-----0 HYPOTHALAMUS 
• • AMYGDALA 
10 
DAYS 
20 30 
253 
Figure 54. The ontogenetic development of growth hormone 
levels in the CNS from fetal to adulthood in 
the rat. 
GROWTH HORMONE 
ng/mg PROTEIN 
106 
104 
10 F BIRTH 
---·-------- ---~--------·-·--------------··- ·- - ----
PITUITARY 
10 
DAYS 
20 30 
Figure 55. The ontogeneric development of growth hormone 
in the pituitary from fetal to adulthood in 
the rat. 
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AMYGDALA PITUITARY 
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Figure 56. The ontogenetic development of growth hormone 
levels in the pituitary and CNS from f~tal to 
adulthood in the rat. 
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and showed no preparturitional surge, but rather a gradual rise toward 
adult levels between 10 and 20 days after birth. These two sets of data 
can be superimposed, as shown in Fig. 56 , to show the relationship which 
exists between the hormonal levels in brain versus pituitary tissue. 
(ii) Growth hormone in fetal and matemal sera and amniot-ic fluid 
Levels of GH, in terms of ng of hormone/ml, of a,mn:;lOLiC fluid, fetal 
sera, and matemal sera were also measured at day 17, 19 and 21 days 
gestation, and for several days postpartum in the case of sera. As 
shown in Fig. 57 , amniotic fluid levels continued to rise steadily tmtil 
parturition, and levels of fetal serum growth hormone also rose slowly 
tmtil the first day after delivery and then fell to adult levels. At 
day 21, immtmoreactive growth hormone levels were substantially higher 
in fetal serum than in maternal serum, which essentially showed no change 
throughout pregnancy and after delivery. Levels of extracted placental 
immtmoreactive growth hormone were also measured and remained constant 
and at levels approximating those of matemal serum. 
b. Thyroid Stimulating Hormone 
(i) Thyroid stimulating hormone in brain and pituitary tissue 
A similar pattem, in terms of development, was observed when 
brain TSH was measured in 10-day fetal and up to 30-day old adult rat 
brain tissue. All brain regions containing this material showed a dra-
matic preparturitional rise and abrupt fall just after birth. Fig. 58 
shows this phenomenon for the hypothalamus and amygdala, in terms of ng 
immtmoreactive TSH/mg protein. When pituitary, immtmoreactive TSH levels, 
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Figure 57. Levels of growth hormone (ng/ml) in amniotic 
fluid, fetal serum, and maternal serum from 
17 days fetal to 2 days postnatal in the rat, 
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determined over the same time period, are superimposed on this data, as 
in Fig. 59.. , the relationship between the development of hormonal levels 
in these two distinct tissues can be seen. Here again, TSH could be 
measured by day 10 of fetal life in the brain tissue extracts, whereas 
immunoassay able TSH was detectable by day 15-17 in the fetal pituitary. 
(ii) Thyroid stimulating hormone in fetal and matemal sera and 
amniotic fluid 
Unlike growth hormone, TSH amniotic fluid levels showed a fall 
before birth, whereas fetal serum levels remained constant and then 
dropped quickly after delivery. No change in maternal TSH serum levels 
was noted during the entire study period as shown in Fig. 60 • Placental 
TSH levels remained constant throughout gestation, levels of hormone cor-
responding to those found in matemal sera. 
c. Summary of Fetal Brain Levels of Immunoreactive GH and TSH Data 
In Table 37, GH and TSH levels in various regions of the 21-day 
fetal CNS were compared in terms of the percent rise above levels nor-
mally found in the adult rat brain. The hippocampus, hypothalamus, and 
amygdaloid regions showed the greatest preparturitional surge in pitui-
tary-like hormones. 
d. Immunological Characterization of Fetal Brain Hormones 
When the immunological characteristics of fetal brain growth hor-
mone were compared with those from fetal pituitary homogenates, parallel 
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Figure 58. The ontogenetic development of TSH levels in 
the CNS from fetal to adulthood in the rat. 
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Figure 59. The ontogeneric development of TSH levels in 
the pituitary and CNS from fetal to adulthood 
in the rat 
100 
500 
400 
200 
400 
AMNIOTIC FLUID 
FETAL SERUM 
r 
MATERNAL SERUM 
17 
261 
(TSH] ng/ml 
r f 1 
19 21 BIRTH 2 
FETAL AGE POSTNATAL AGE 
DAYS DA'l'S 
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TABLE 37 
GH- AND TSH-LIKE IMMUNOREACTIVE PEPTIDES 
IN THE 21-DA~ FETAL CNS 
% ABOVE ADULT LEVELS 
GH TSH 
Hippocampus 2000 1000 
Hypothalamus 300 1000 
Amygdala 600 600 
Cerebellum 10 300 
Cortex 800 100 
Caudate 15 10 
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dose-response displacement curves were obtained as shown in Fig. 61 • 
Fetal TSH from brain tissue showed similar parallelism with pitui-
tary TSH. This indicated immunological similarity between the hormones 
from the two different sources. Although the brain curve was in fact 
superimposable on the pituitary curve, it had been displaced downward 
for visual effect. 
e. Molecular Weight Determinations of Fetal Brain Hormones 
The possibility of heterogenous forms of these brain peptides oc-
curring in brain and pituitary tissue of fetuses and adult rats was also 
examined. As shown in Fig. 62 , using a G-100 Sephadex column, 22-day-
. 125 
old fetal brain extracts were co-chromatographed with I labeled adult 
-· 
rat pituitary GH. It can be seen that the peak of immunoreactive GH-like 
material co-eluted with the radioactive marker. 
In Fig. 63 , a similar column chromatography experiment demonstrated 
the co-elution of immunoreactive TSH-like material from fetal CNS extracts 
with 125I TSH from adult pituitaries, suggesting molecular similarity be-
tween fetal and adult brain pituitary-like hormones. 
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Figure 63. Elution pattern ~~ 5 lyophilised 21 day old fetal brain and I adult rat pituitary TSH 
on a Sephadex G-100 column eluted with O.OlM 
P0 4buffer pH 7.6. 
6. DISCUSSION OF DATA 
Initially prompted by the observation of the presence of immuno-
reactive growth hormone-like material in the media of cultured rat ner-
vous tissue reported by Pacold et al (1976), this study has attempted to 
characterize, in various ways, this growth hormone-like material. In 
addition, we have sought to characterize a TSH-like material, also found 
in the tissue culture medium of cultured rat nervous tissue, and discov-
ered in the course of ~hese original studies. The relevance of the data 
obtained from these investigations will be discussed in the light of other 
recent observations also dealing with the discovery of diverse peptides 
in the central nervous system, a phenomenon only recently appreciated. 
Previously, monoaminergic substances were considered the only chemical 
neurotransmitters, whereas it now seems abundantly likely that peptides 
of neuronal origin from cells within the CNS also have neurotransmitter 
roles. In addition, new and unusual roles may be assigned which could 
include effects on brain development and growth, perception of pain, 
normal and disturbed behavior, and even effects on intelligence to mention 
but a few possible roles for these recently discovered brain peptides. 
The finding of such peptides and the speculation that they may play 
a physiological role in neural function is a relatively recent sugges-
tion by de Wied (1980) and is now supported by several lines of evidence, 
such as the induction of lordosis by intracerebral injection of lutein-
izing-releasing hormone in female rats (Foreman, 1977). Observations 
such as these have led to the concept that many peptides, whatever 
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their traditional tissue of origin, exert effects upon the brain which 
lead to behavioral consequences apart from their classical endocrine 
effects. 
The main objectives of this particular study concerning the pre-
sence of two such peptides, GH and TSH, traditionally of pituitary origin, 
in rodent and also in primate brain tissue, is to show that these hor-
mones are probably of CNS origin rather than diffusion contaminants from 
the pituitary, that their presence is largely independent of pituitary 
function, and finally to speculate on the possible reasons for their 
presence in the brain. 
Initial experiments were concerned with the systematic extraction 
and mapping of different areas of the rodent and primate brain. Both a 
growth hormone-like and thyroid stimulating-like material were found, by 
radioimmunoassay, to be unevenly distributed throughout the central ner-
vous system of both rat and primate. These data immediately suggested a 
CNS origin rather than a pituitary origin for such extractable hormone-
like materials, as an overall uniform distribution of hormone concentra-
tion throughout the CNS would have been indicative of contamination from 
circulating pituitary hormones. 
Innnunoreactive growth hormone-like material was found in greatest 
concentrations, in terms of ng hormone/mg protein in the amygdaloid nu-
clear region of the rat CNS by tissue extraction experiments. The rat 
hypothalamus was also found to contain substantial amounts of such im-
munoreactive material. 
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Extractable immunoreactive TSH-like hormone was also detectable in 
both rodent and primate bra~n tissue. The rodent hypothalamic region was 
found to contain the largest amount of detectable materiai and a TSH-like 
substance was also present in the amygdaloid nucleus and other brain re-
gions to a lesser extent. Large differences between pituitary and brain 
levels of both hormones were observed, even though these two tissues un-
derwent similar extraction procedures. Several explanations for such 
wide variations can be envisaged, such as the possibility of differences 
in the rates of peptide synthesis in each tissue, and the biological 
half-lives of hormones of pituitary and brain origin. Another possibil-
ity for widely variant concentrations could be that differences in tis-
sue extractable levels of hormone are due to the types of precursors 
present and the subsequent post-translational processing of such precur-
sors. De Wied (1980), for example, when discussing the two apparent 
pools of hypothalamic and pituitary ACTH, suggests that such processing 
of brain peptides may give rise to fragments of hormone which, although 
having biologically significant effects on the surrounding CNS milieu, 
are not recognizable by either immunological or biological assays .. Simi-
lar arguments could be made to speculate on the apparent differences in 
the magnitude found between growth hormone and thyroid stimulating hor-
mone-like concentrations in brain and pituitary pools. 
Preliminary studies showed that, in the case of both immunoreactive 
GR- and TSH-like material in primate brains, the hypothalamus exhibited 
the highest concentrations of these particular CNS peptides. Although 
growth hormone was found in most other areas of the primate brain, the 
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distribution of TSH was such that large areas of the primate CNS appeared 
to contain non-measurable quantities. 
Further speculation on this data from primate CNS will have to 
await further in-depth investigation. Its measured presence, however, 
does indicate that certain pituitary-like peptides apparently are not 
restricted to the rodent brain. 
Mapping locations of GH- and TSH-like peptides in the rodent central 
nervous system, using immunohistochemical techniques, demonstrated the 
pres~nce of TSH in various areas of the central nervous system. In the 
hypothalamus, TSH was distinguishable in cell bodies of the dorsomedial 
and ventromedial nuclei, and most of the nuclei of the amygdala showed 
positive staining for the presence of TSH. Other areas of the CNS shown 
to have extractable hormone, but which did not show positive staining by 
the immunohistochemical technique, are known to be innervated by fibres 
originating from cell bodies found in the hypothalamus and the amygdaloid 
nuclei. Axon collaterals of hypothalamic tuberinfundibular neurons ex-
tend to brain sites quite distant from the hypothalamus, such as the 
thalamus, the limbic system, other than the amygdala, and the cortex 
(Martin et al, 1975), and therefore represent the means whereby hormone, 
possibly produced in the cell bodies of the hypothalamus, might be axon-
ally transported to other brain regions. In preliminary studies, the 
amygdala and hypothalamus also showed the largest number of positively 
staining cell bodies for immunoreactive GH-like material. 
At this level of investigation, it is difficult to associate any 
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particular cell type, either glial or neuronal, with a higher than aver-
age hormonal content, although from the immunohistochemistry data, neurons 
were more likely involved. However, in tissue culture studies with the 
neuroblastoma cell line N4TGI, TSH-like material was found in neuronal-
type cells. Despite this, the tumor origin of such cell lines cautions 
its use as a positive indication that normal, non-tumor neuronal cells, 
rather than glial or interstitial cells, are involved in hormone synthesis 
or storage in the CNS. It can only be concluded from our tissue culture 
studies, therefore, that primary mixed cell cultures of rat nervous tis-
sue appear to release both growth hormone and thyroid stimulating hormone-
like peptides into the growth media over a 30-day time period. Further 
studies utilizing techniques to propagate pure neuronal or glial primary 
cell cultures are needed to further this study. 
In order to pinpoint the association of these peptides with a parti-
cular cell fraction, our ultra-centrifugation studies showed that both 
TSH- and GH-like immunoreactive material were isolated together with the 
synaptosomal-rich fraction of CNS tissue homogenates, suggesting the possi-
bility that, like other peptides such as somatostatin, TRH and VIP, these 
pituitary-like hormones may be associated with pre- or post-synaptic 
membranes in vivo. 
There exists the possibility, as shown by these same ultra-centrifu-
gation studies, that part of the extractable pool of GH- and TSH-like 
material fotmd in the hypothalamus, may be present unassociated with any 
specific cellular fraction. Whether the origin of this free pool of 
hormone is the brain or pituitary is open to speculation. 
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The studies which were undertaken to characterize these extractable 
immunoassayable peptides from rat brain tissue in a chemical, immunologi-
cal, and biological manner revealed that hormones of brain origin were 
indistinguishable from those found in the pituitary, in terms of mole-
cular weight, as shown by column chromatography, and in terms of immune-
logical identity, as shown by parallelism studies. Their biological 
activity also demonstrated a similarity to their respective pituitary 
counterparts in terms of possessing the capability of eliciting a simple 
TSH-like response on the histology of the thyroid or, for growth hormone-
like material, to increase the width of epiphyseal cartilage in the 
tibias of hypophysectomized animals. 
Such immune- and biological similarities between pituitary and brain 
hormones would suggest, without further evidence, the possibility that 
the presence of pituitary-like hormones in the brain is merely due to 
pituitary hormone contamination of these CNS tissues by circulating 
pituitary hormone. 
Experiments designed to test this concept were carried out in this 
study using radioactively-labeled pituitary hormone in order to test the 
e~fectiveness of the blood-brain barrier. They show that it seems un-
likely that significant quantities of pituitary TSH or GH are transported 
to the brain either by the general circulation or portal vessel routes. 
3 
Similarly, Mezey et al (1979), showed that whole brain uptake of H ACTH, 
given intravenously to adult rats, was less than 0.07% of the initial 
radioactive hormone dose given. In the experiments reported here, no 
radioactivity was found in brain tissue of either young or adult rats 
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after systemic injection of 125I-labeled pituitary GH or TSH. This indi-
cates that, in the particular rodent model system which was used through-
out this study, the blood-brain barrier was apparently intact throughout 
life, eliminating any possibility of cross-contamination of brain tissue 
by pituitary hormones. Other indications of the bidirectional intactness 
of this barrier were that no increase or decrease in circulating hormone 
levels after experimental manipulations, such as hypophysectomy and target 
organ removal, produced any subsequent rise in the hormonal levels found 
in brain tissue. Similarly, no increase or decrease in brain tissue levels 
produced a concomitant increase or decrease in the concentration of circu-
lating pituitary hormone. Experiments by Weiss et al (1975) substantiate 
this data in that pituitary cells implanted in the rat brain ventricles 
of hypophysectomized rats did not produce normalization of circulating 
pituitary hormone levels, even though it could be demonstrated that such 
implants continued to produce growth hormone and thyroid stimulating hor-
mone. Whatever the role of the pool of brain hormones, it is unlikely to 
be as a reserve pool which can be drawn on in times of pituitary deficiency. 
Besides the demonstration of blood-brain barrier intactness to cir-
culating pituitary hormone, evidence of a CNS origin of brain peptides, 
other than GH and TSH, comes from similar experiments comparing brain 
tissue levels of hormone-like material before and after removal of the 
pituitary gland. That the concentration of ACTH,°'- MSH, f3 endorphin, 
and prolactin, as reported previously by Liotta et al (19 78), Kobayashi 
et al (1978), and Toubeau et al (1979), are essentially unchanged in most 
274 
of the brain areas examined after such treatment, is consistent with the 
possibility of synthesis of these peptides by the brain tissue itself.· 
Such variations in hormonal level that do occur after hypophysec-
tomy in the data obtained in this study for TSH could be the result of 
several factors, such as changes brought about in the levels of a known 
regulatory factor to pituitary hormone, e.g., dopamine, by hypophysectomy. 
The slight decrease in TSH levels seen 28 days after hypophysectomy are 
most probably too late an event to be the re.sult of tissue damage in-
curred by surgical intervention but could be a reflection of falling 
dopamine levels, which have been ovserved in the hypothalamus after long-
term pituitary removal (Nagatsu et al, 1964). A fall in dopamine levels 
would have an adverse effect on the content of TSH in a nonnal pituitary; 
however, whether similar effects can be induced on all or part of the 
hypothalamic pool of TSH-like peptide can only be speculated upon at this 
time. 
Another controlling factor, in terms of hypothalamic levels of TSH 
after hypophysectomy, could be the effect of falling TRH levels, reported 
by Nemeroff et al (1979) to occur in the hypothalamus, but not in other 
brain regions, after pituitary removal. These levels were shown by 
Nemeroff to be restorable by T4 therapy. In a study for this disserta-
tion using long-term hypophysectomized animals which received T4 substi-
tution treatment, levels of extractable immunoreactive TSH in the hypo-
thalamic region were shown to be restored by such therapy. The possi-
bility, therefore, exists of a TRH-influenced control over part of the 
hypothalamic TSH pool and would provide an explanation for the fall seen 
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in hypothalamic TSH levels and not other CNS pools of TSH after long-
term hypophysectomy. 
Examination of the data concerning iIIllilunoreactive GH levels in brain 
tissue after hypophysectomy show no change in hormonal levels for most 
of the brain areas examined. Exceptions were the levels of growth hor-
mone in hypothalamic and amygdaloid tissues,which demonstrated an initial 
fall in hormone levels after 7 days of hypophysectomy, followed by a re-
markable rise in hormone content after 28 or more days without a pitui-
tary. 
The lack of such an early fall in GH measured from tissue-cultured 
amygdaloid and hypothalamic tissue derived from long-term hypophysectom-
ized animals indicates the possibility that after a certain time period 
of hypophysectomy, such as 7 days, a growth hormone inhibitory factor, 
e.g., somatostatin, may be present in sufficiently lowered amounts as to 
be unable to cause a normal depression of growth hormone levels in vivo. 
This theory is substantiated by experiments, previously quoted by Baker 
et al (1976), showing that somatostatin levels do fall in the hypothala-
mus about 10 days after hypophysectomy. The ability of somatostatin to 
suppress "brain" growth hormone has been shown in our study using tissue 
cultured normal CNS tissue. Perhaps this initial decrease in amygdaloid 
and hypothalamic tissue levels of growth hormone is-: due to somatostatin, 
and the increased levels after 10-14 days hypophysectomy are due to the 
disappearance of this inhibitory factor from the CNS milieu because of 
pituitary ablation. Certainly the implication that animals in such ex-
periments were incompletely hypophysectomized (Moldow et al, 1978a'b) has 
not been substantiated either by microscopic inspection of the empty 
sella turcica, by levels of circulating T4 , TSH, and GH, which were 
measured in the serum of operated animals, or by gross examination of 
atrophied target glands such as the thyroid, adrenals, and gonads in 
hypophysectomized rats. 
Enhancement of levels of ACTH-like material in rat hypothalamus, 
but not in other brain areas, 12 days after hypophysectomy has been 
demonstrated by Krieger and Liotta (1979), which tends to support our 
data for GR-like levels in the CNS after pituitary removal. These ex-
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periments add further evidence to the possibility that these pituitary-
like peptides in the CNS are not of pituitary origin. 
Other data, also corroborated by Krieger and Liotta's group, are 
those obtained from the tissue culture of cells from rat central nervous 
system tissues, demonstrating the presence of immunoreactive GH and TSH 
in the growth medium for up to 30 days of cell culture. The ability of 
cells derived from the arcuate nucleus of the hypothalamus to release 
ACTH into tissue culture media for up to 17 days, has similarly been 
reported (Liotta et al, 1979a). Using this model system of dispersed 
3 hypothalamic cells, it has been possible to demonstrate that H-labeled 
amino acids can be incorporated into material with the characteristics of 
the pituitary precursor of ACTH, giving credence to a CNS origin for this 
traditionally thought of pituitary hormone (Liotta et al, 1979b). Evi-
dence also exists that an ACTH-like pituitary peptide other than GH and 
TSH persists after long-term hypophysectomy in CNS tissues and that it 
is most likely synthesized in situ within the brain. 
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Other experiments have sought to investigate the mechanisms of 
regulation of these'pituitary-like peptides, compared to those regulating 
pituitary hormones. Such experiments have shown, for example, that con-
centrations of hypothalamic immunoreactive ACTH-like material are not 
significantly altered 24 hours or 2 weeks after adrenalectomy, after 
dexamethasone or corticosteroid administration, or by the stress of 
ether administration (Liotta et al, 1978). All of these procedures are 
normally associated with alteration in the levels of ACTH in the pitui-
tary gland and serum. Alterations of levels of ACTH in the pituitary 
and serum due to adrenalectomy are the result of feedback mechanisms. 
The secretory functions of the anterior pituitary appear to be 
modulated by hormonal signals originating in such peripheral target 
glands as the adrenals, thyroid, and gonads, and in the pituitary itself, 
through complicated networks of feedback mechanisms called, respectively, 
"long" and "short." Within each category of feedback systems, "negative" 
as well as "positive" mechanisms have been described. A feedback system 
in which the input, represented by a hormone originating in a peripheral 
target gland, reduces the output of pituitary hormone is called "negative" 
and where a feedback system, in which increased secretion of a peripheral 
hormone stimulates anterior pituitary function, it is generally called 
"positive." The unaltered hypothalamic levels of ACTH after adrenalectomy, 
in contrast to increased levels found in the pituitary due to a lack of 
negative feedback of circulating adrenal cortisone, reflect a difference 
in the control mechanisms of brain-situated hormone compared to pituitary 
hormones. Similarly, Rossier et al (1977a) have observed no change in 
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the concentrations of immunoreactive S-endorphin-like material in the 
. brains of adrenalectomized animals. Animals subjected to the stress of 
foot shock showed some decrease in S-endorphin-like immunoreactivity in 
b the hypothalamus, but not in other brain areas (Rossier et al, 1979 ) • 
Other studies by Havrankova et al (19 79) have demonstrated that ''brain 
insulin" concentrations are also unaffected by extreme changes in cir-
culating hormone concentrations. 
Removal of such target organs as the adrenals and testes, in our 
experiments, appeared to have no effect on the levels of growth hormone 
in either serum, pituitary, or other brain areas analyzed. Obviously, 
no feedback mechanisms occur in vivo involving these peripheral organs 
and pituitary or brain growth hormone. Oophorectomy induced a signifi-
cant fall in the levels of circulating GH, but no significant difference 
in pituitary levels of controls or in operated animals. A significant 
rise in the levels of hypothalamic and amygdaloid immunoassayable GH 
concentrations was seen, however, after the removal of the ovaries. 
Other brain areas appeared unaffected by such ovarian ablation. 
Thyroidectomy produced a similar picture of a fall in serum and 
pituitary levels of immunoassayable growth hormone and a rise in the 
hypothalamic and amygdaloid levels of this immunoreactive peptide. As 
with the gonadectomized GH content, brain regions other than hypothalamus 
and amygdala appeared unaffected by removal of the thyroid. What seems 
most striking from data derived from these experiments is the demonstra-
tion of an apparent independence between the levels of, e.g., growth 
hormone found in the pituitary and in serum, compared to levels found 
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in specific areas of the brain. 
The possibility of the existence of a short loop feedback regula-
tory system of some kind between the hypothalamus and the anterior pitui-
tary would be a possible explanation of the data we have described from 
the present studies. It is disturbing, however, that GH and TSH levels, 
in areas other than the hypothalamus and amygdala, are unaffected by 
specific target organ removal and/or trophic hormone treatments, especial-
ly if we hypothesize from the immunohistochemical data, that extractable 
hormone levels in one region may be derived from cell bodies in the hypo-
thalamus and amygdaloid nuclei. The possibility, therefore, exists that 
in situ synthesis of peptides in these brain areas exists at a level un-
detectable by the immunohistochemical technique performed in these 
studies. Further investigations should therefore aim at improving the 
sensitivity of this particular technique for detecting GH and TSH in 
brain areas other than the hypothalamus and amygdala. 
Adrenalectomy and orchidectomy in adult male rats produced similar 
divergent results between pituitary and serum TSH levels and those 
measured in the hypothalamus. Thyroidectomy resulted in a significant 
rise in circulating TSH and a lowering of pituitary TSH levels. No ef-
fect on brain levels of TSH-like peptides was observed after removal of 
the thyroid. 
Immunoreactive GH and TSH of the brain, like ACTH and 13 endorphin, 
appear, therefore, to be unaffected in any particular way by the positive 
and negative hormonal feedback signals normally affecting the concentra-
tion of these peptides in the anterior pituitary gland and in the 
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circulation. This apparent dissociation was also reflected in the tissue 
culture studies described in this study, where r 4 added to the growth 
media of growing anterior pituitary or brain tissue monolayers had little 
or no effect on levels of immunoreactive TSH f otmd in the culture medium 
of normal brain cells. TSH levels from medium of anterior pituitary cells, 
so treated, reflected the anticipated decline in TSH production due to a 
negative long feedback loop operating on pituitary TSH secretion in the 
presence of high levels of the thyroid hormone, T 4 • 
Speculation on the presence of a short loop feedback between pitui-_ 
tary and hypothalamic pools, similar to that postulated between pituitary 
and pituitary stalk TSH pools by Baak.e et al (1967), was not substantiated 
by data from these studies. Our data confirms, rather, the findings of 
others who have attempted direct implantations of TSH into the hypothala-
mus in order to demonstrate a feedback control mechanism on the pituitary. 
Levels of TSH, so implanted, apparently fail to affect the concentration 
of pituitary TSH by a negative short feedback loop, making TSH unique in 
this regard among the anterior pituitary hormones. 
Further evidence for the independence of pools or in situ synthesis 
of brain and pituitary growth and thyroid stimulating hormones comes from 
the results of the ontogenetic studies reported in this dissertation, where 
brain, serum, and pituitary levels of GH and TSH were examined during 
gestation, in the neonatal period, and into adulthood. 
In such ontogenetic studies, it was apparent from the data that a 
striking preparturitional surge of immunoreactive GH and TSH occurs in 
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the 24 hours immediately before delivery, and is followed by a fall in 
the first day of extrauterine life. These peptides were found to possess 
similar molecular amd immunological characteristics to their pituitary 
counterparts. The abrupt rise of a substance within the developing fetal 
CNS and serum just before birth is not an unusual finding. Several re-
ports from other investigators have noted comparable patterns to those 
described here for GH and TSH. Some of these are shown in Table 38 , and 
include such identifiable substances as glycogen (Kohle et al, 1977), 
histamine (Pearce et al, 1969), estrogen (Dohler et al, 1975), prosta-
glandins (Vale et al, 1972), and receptors for serotonin and estrogen 
(McClusky et al, 1979), as well as angiotensin II (Baxter et al, 1980). 
Other data show that the levels of other substances such as somatostatin 
(Blasquez et al, 1974), T4 and T3 (Rabie et al, 1979), and TRH (Schaeffer 
et al, 1980) rise in the CNS in the first few days after birth, as shown 
in Table 39 • 
Changes in hormone concentrations of TSH or GH in the fetal brain 
did not appear to reflect pituitary secretions as the patterns of acquisi-
tion were quite different. Growth hormone and TSH were first detected in 
the fetal brain at 10 days of fetal age and could not be detected in the 
fetal pituitary until 12-15 days of age. Furthermore, pituitary hormone 
concentrations did not show the dramatic preparturitional surge noted in 
the brain. 
Radiolabeled GH and TSH given intraperitoneally to either the fetus, 
or pregnant rat, did not reach the fetal rat brain tissue in either case, 
indicating the intactness of both the fetal blood-brain barrier as well as 
TABLE 38 
SUBSTANCES WHOSE LEVELS RISE JUST PRIOR TO BIRTH 
IN THE CNS 
RECEPTORS FOR: 
Angiotensin 11 
Renin 
Estrogen 
Glycogen 
Spermidine 
Histamine 
Substance P 
TRH in telencephalon 
Estrogen 
Vasotocin 
PGF 2 a. , PGE, PGE2 
Ketone Bodies 
Membrane Phospholipids/ 
Baxter et al, 1980 
Baxter et al, 1980 
McClusky et al, 1979 
Kohle et al, 1977 
Pearce et al, 1969 
Pearce fil...a.l. 1969 
Gilbert et al, 1979 
Schaeffer et al, 1980 
Dahler et al, 1975 
Pavel et al, 1976 
Vale et al, 1972 
Liggins et al, 1973 
Haymond et al, 1979 
Cholesterol Kapitulnik et al, 1979 
ENZYMES: 
Gfucose ··6-·PO 4 tase 
Dehydrogenase 
Monoamine Oxidase 
Fructose 1-6 
Di phosphatase 
Pyruvate Carboxylase 
UDP-glucose--glycogen ) 
Transglucosylase ) 
Phosphogli.Jcomutase 
Oliver et al, 1963 
Andres et al, 1980 
Snyder et al, 1979 
Haymond et al, 1979 
Haymond et al, 1979 
Kohle et al, 1977 
IN THE FETAL SERUM 
Testosterone 
ACTH 
Corticoids 
Growth Hormone 
LH 
FSH 
TSH 
Prolactin 
Estrogen 
Weisz et al, 1980 
Rose et al, 1978 
Rose et al, 1978 
Bassett et al, 1970 
Courbier et al, 1978 
Riddick et al, 1979 
Dehler et al, 1975 
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TABLE 39 
SUBSTANCES WHOSE LEVELS RISE JUST AFTER BIRTH 
. DAY FIRST 
C N S DETECTABLE SOURCE 
Mono amines 1 - 2 Coyle et al, 1973 
Somatostatin 5 Blasquez et al, 1974 
TRH in hypothalamus 6 Schaeffer et al, 1980 
Androgen receptors 5 Vito et al, 1979 
T4 and T3 2 & 12 Rabie et al, 1979 
Glycogen phosphorylase 10 min. Jacquot et al, 1964 
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the fetal-maternal-placental barrier, to circulating pituitary hormones 
at the time of the preparturitional brain surge. It is also known that 
the pituitary portal vessel-hypothalamic-link is not fully developed in 
the rat until Day 5 of life (Glydon, 1957), another indication that fetal 
brain hormone is not of fetal pituitary origin. 
The gradual rise of levels of growth hormone and TSH in the fetal 
serum and their fall after birth is thought by some authors to be due to 
this innnaturity of the pituitary-hypothalamic regulatory system. Somato-
statin, for example, has failed to be, detected before the fifth day of 
post-uterine life. The significant fall in serum levels of pituitary 
hormones after birth has also been postulated to be mediated by adrenergic 
mechanisms (Basset et al, 1970), as infusion of catecholamine and isopren-
aline into fetal lambs was shown to decrease serum GH concentrations. 
The dramatic rise in fetal brain levels of TSH and GH does not, 
however, reflect the same pattern displaced by serum and amniotic fluid 
and, ~s p~evtously concluded with reference to pituitary levels of these 
hormones, the CNS concentrations are probably independent of such extra 
CNS pools of hormone. Any speculation on the role of this precipitous 
rise in fetal brain levels of immunoassayable GH and TSH should be dis-
cussed in the light of fetal morphology and physiology. 
During the transition from intrauterine to extrauterine life, a 
number of metabolic changes and adaptions occur in fuel homeostasis. 
These adaptions allow the fetus to convert from a state in which it is 
totally dependent on maternal fuel sources, to a state in which it relies 
on endogenous substrate for the maintenance of normal cellular growth. 
In order to maintain normal cellular metabolism and anabolic growth, the 
newborn must have at least three requirements: an adequate store of 
hepatic and brain glycogen, muscle protein and fat, the enzymatic capacity 
to release and utilize these substrates, and thirdly, to be able to 
regulate such enzyme induction, substrate mobilization, and peripheral 
utilization of metabolic fuels. 
Unlike glycogen in the liver, the functional significance of glyco-
gen in the brain is poorly understood, although its potential as an energy 
source may explain the greater resistance of young animals to hypoxia. 
Glycogen levels in the brain are shown by Kahle et al (1977) to rise 
abruptly at day 20-21 of gestation and then to decrease rapidly after 
birth until, 7 days postnatally, very low levels are observed. An in-
crease in glycogen-synthesizing enzymes has also been observed to follow 
a similar developmental trend. Although glycogen breakdown appears to 
commence the day of birth, 26% of the total fetal brain glycogen store is 
utilized within 10 minutes of birth. This glycogenolysis is in response to 
accelerated cerebral glycolysis resulting from the cerebral hypoxia of 
vaginal delivery. 
A role for fetal brain growth hormone in such adaptions to neonatal 
life could possibly be one in which the fetal hormone exhibits 11 insulin-
like11 properties by increasing the permeability of cells in order to feed 
the rapid rise in glycogenolysis. Growth-promoting hormones, in particu-
lar GH and r 4 , have been shown by Levi-Montalcini et al (1968) to have 
complementary and synergistic effects on cell growth and the regulation of 
somatic development. In the developing CNS, many more neurons are pro-
duced in fetal life than survive; in fact, cell death of up to 50% of 
original neurons before birth is a common feature. McClusky et al (1979) 
have speculated that the rapid increase in estrogen receptors and estrogen 
levels, reported two days prior to parturition, and their rapid disappear-
ance after birth, could be linked to a role for estrogen in preventing 
cell death and stabilizing surviving neurons at this critical period of 
development. Perhaps a similar argument could be made for the preparturi-
tional rise in brain growth hormone. Furthermore, it is thought that 
nerve cells die when they fail to contact other cells during brain devel-
opment, and it is possible that growth hormone and perhaps TSH may in-
crease nerve cell contacts by causing enlargement of cells and cell-to-
cell surface contacts. 
If indeed these brain hormones possess the same effects on cell 
metabolic activities as do their pituitary counterparts, other hormone-
promoted activities, such as increased protein synthesis and m.RNA content 
for GH, increased mitochondrial respiration, and the increased uptake of 
precursors of phosphol~pids for possible cell wall synthesis by TSH, could 
perhaps contribute to the general maintenance of neuronal tissues in fetal 
and adult tissues. 
However, in any effort to assess the functional significance of 
pituitary-like hormones such as GH and TSH in the brain, the possibility 
that the role of the hormones within the CNS differs from their currently 
assigned physiological role within the pituitary, should not be overlooked. 
For example, it is known that TRH-like activity is present in the neural 
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tissue of certain invertebrates, even though evidence of a role for it in 
the regulation of pituitary.TSH has only been found in animals higher in 
the evolutionary scale (Scharrer, 1978). 
Another line of approach to the question of function of neuronal 
peptides has been the concept that "peptidergic neurons" refer not only 
to the neurosecretory cells of the hypothalamus producing vasopressin and 
hypophysiotropic hormones, but also to those neurons containing additional 
peptides such as Substance P, neurotensin, angiotensinogen, gastrointest-
inal peptides, and now more recently the hormones of the anterior pituitary 
such as ACTH, GH, TSH, LH, and S-lipotrophin. There is the possibility 
that, in the case of hypothalamic ACTH, GH, and TSH, extractable levels 
of hormone could be derived from two different sources. Those of CNS 
origin could be part of a peptidergic neural system present in addition 
to the classically described motor, sensory, and autonomic nervous sys-
tems, but which interrelates with such systems. Such peptides are specu-
lated to be secreted at peptidergic terminals, and may act on a variety 
of effector cells, including neurons, functioning either as neurotrans-
1l)itters or neuromodulators, rather than within the normal definition of 
a "hormone." It has been hypothesized by Barker (1977) that whereas 
neurotransmitters are involved in the momentary mediation of single cell-
to-cell interaction, the neurohormones may be important in the sustained 
modulation of specific sets of target neurons. Neuromodulation implies 
an action of the secreted peptide in altering the effect of the classical 
neurotransmitter on its receptors. Possible examples of such interactions 
have been shown by the reported presence by Hokfelt et al (1979) of 
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neurons containing both peptides and classic monoaminergic neurotransmit-
ters, and by the effects which other peptides 1 such as ACTH and vasopressin, 
have on acetylcholine, norepinephrine, and serotonin content or turnover in 
various brain regions (Gispen and de Wied et al, 1977). De Wied has also 
shown that these peptides, vasopressin and ACTH, can enhance the dephos-
phorylation of membrane proteins leading to a change in membrane permea-
bility. 
The reports of opioid-peptide effects on pain perception, addictive 
states, and psychiatric disorders have previously been reviewed, as have 
those reports concerning the effects which ACTH and MSH, given intraven-
tricularly, appear to have on rat behavior. Behavioral studies suggesting 
a role for vasopressin in learning and memory (De Wied and Versteeg, 1979) 
showed that impaired learning behavior in Brattleboro rats, which lack 
vasopressin-synthesizing mechanisms, can be reversed by intraventricular 
injections of yasopressin. In normal rats, peripheral vasopressin injec-
tions appear to influence learning and memory, and in clinical trials, 
vasopressin may improve memory in brain-damaged human subjects. Studies 
with TRH demonstrate that this hypothalamic hormone can elicit behavioral 
excitation and anorexia in animals and may cause mood enhancement in 
humans (A. J. Prange et al, 1975). 
In addition to such postulated behavioral effects assigned to pep-
tide hormones in the brain, such hormones may also have an effect on en-
docrine regulatory processes. Experiments with intrahypothalamically 
injected ACTH have been reported to demonstrate inhibitory effects on 
pituitary ACTH release, although unphysiological doses and long periods 
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of treatment tend to dispute this data of Yates et al (1974). However, 
the possibility of such short-loop feedback mechanisms has also been 
alluded to in this discussion as a possible role for hypothalamic GH. It 
remains to be determined if such observations reflect a dual effect of 
these compounds on releasing factors or on the neurotransmitters that 
regulate such releasing factors. 
The finding of GH- and TSH-like hormones in both the CNS and in the 
gastrointestinal tract in this study is not terribly surprising, consid-
ering the number of other peptides recently reported in such dual loca-
tions. Such peptides as somatostatin (Arimura, 1975), glucagon (Conlon 
et al, 1979), and VIP (Said et al, 1972) are found in the GI tract and, 
from this study, immunoreactive GH- and TSH-like material in extrapitui-
tary sites such as the pancreas and small intestine. These data give 
further credence to one of the objectives of this dissertation, i.e., that 
of determining whether "brain" hormones are of CNS origin rather than the 
result of retrograde transport via the portal vessels from the pituitary 
to hypothalamus. 
The finding of immunologically active, pituitary-like hormones in 
such extrapituitary, extra-CNS sites as the GI tract and pineal gland, 
leads to speculation that these peptide-containing cells can be classified 
as belonging to the amine-precursor uptake and decarboxylation series of 
cells, a concept originally developed and outlined by Anthony Pearse in 
1977. 
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Other lines of approach to explain this apparent multisite distri-
bution of pituitary-like peptides would be that the presence of such 
peptides is due primarily to incomplete gene suppression in those parti-
cular tissues, or that the detectable levels merely represent bound, 
circulating, pituitary peptide to tissues with appropriate hormone recep-
tors. Removal of the pituitary as a source of circulating hormone for 
up to 28 days did not appreciably lower the levels of extractable hormone 
in those extrapituitary sites studied. The possibility that the observed 
immunoreactive material was merely receptor-bound is therefore unlikely 
in the light of the in vivo hypophysectomy experiments reported here. 
In conclusion, results obtained in this study appear to add yet two 
more peptides, formerly thought to have been of non-neural origin, to the 
ever-growing list of brain peptides. Many of these, such as Substance P, 
have been speculated to be potential neurotransmitter or neuromodulator 
candidates, and represent an active field of research at the present time 
seeking to unravel the parameters involved in the development and func-
tioning of the CNS. 
Brain growth hormone and TSH await further investigation before 
specific functions can be assigned to their presence in rodent and primate 
brain. However, their apparent independence from patterns of pituitary 
hormone secretion, and their probable synthesis within the CNS tissues 
are tantalizing observations that await further conceptual organization, 
CONCLUSIONS 
The following conclusions can be drawn from the data obtained in 
this dissertation. 
1. Innnunoreactive growth hormone (GH)- and thyroid stimulating hormone 
(TSH)-like peptides were fotmd to be unevenly distributed throughout the 
rodent and primate central nervous system (CNS) and gastrointestinal tract. 
2. Highest levels of extractable GR-like material were obtained from 
rodent amygdaloid tissue, whereas the hypothalamus contained the largest 
concentration of a TSH-like peptide. 
3. Both brain peptides showed a similarity to their pituitary counter-
parts in terms of molecular weight, innnunological affinity, and biological· 
activity. 
4. Histochemical mapping of the CNS for the TSH-like peptide using a 
peroxidase anti-peroxidase technique showed hormonal material concentrated 
in neuronal cell bodies of the rodent amygdaloid nucleus and hypothalamus. 
5. Ultra-centrifuged homogenates of amygdaloid and thalamic tissues 
showed an association between GH- and TSH-like immunoreactivity and the 
synaptosomal-mitochondrial pellet (SMP). In ultra-centrifuged hypothala-
mic tissue, the immunoreactivity was distributed evenly between the SMP 
and the final supernatant. 
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5. Tissue cultured CNS cells from intact and hypophysectomized animals 
released both GH- and TSH-like material into the growth medium over a·30-
day period. This would indicate the CNS, rather than the pituitary, as 
the source of both brain hormones. 
6. Contamination of CNS tissues by pituitary GH and TSH was shown to 
be tmlikely by a demonstration of blood-brain barrier intactness through-
out life, and a lack of change in brain hormone levels after hypophysec-
tomy. 
7. Target organ ablation studies showed an apparent independence between 
regulatory mechanisms controlling pituitary and brain hormone levels. 
8. The appearance of detectable hormone in the fetus and the subsequent 
pattern of development differed between brain and pituitary hormone pools. 
A preparturitional rise in brain hormone levels was detected, followed by 
a fall to normal levels in the CNS after birth. 
9. In conclusion, this study verified the presence in the rodent and 
primate brain of GH- and TSH-like materials which appear to be of CNS 
rather than of pituitary origin. 
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